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Abstract 
  Breast cancer is one of top three diagnosed cancers in Australia and other countries.  
Approximately 64% of human breast cancers are oestrogen receptor positive (ER+) and express the 
MYB oncogene. The MYB oncogene encodes a transcription factor (MYB) that regulates many 
cellular genes such as genes that are associated with cell proliferation, differentiation and apoptosis. 
To date, most MYB target genes have been identified and characterized in hematopoietic cells; 
MYB and its target genes are still understudied in human ER+ breast cancer cells. 
  Previous studies from our laboratory found that MYB expression is necessary for proliferation of 
human ER+ breast cancer cells and for tumour development in vivo. Furthermore, overexpression of 
MYB prevented chemically-induced differentiation of human ER+ breast cancer. Moreover, 
shRNA-mediated MYB knockdown initiated differentiation of human ER+ breast cancer cells, and 
greatly sensitised them to chemically-induced apoptosis.  
  There were three main aims of this thesis that focused on identification of MYB target genes, the 
function of MYB in DNA damage response and the role of MYB in breast cancer stem cells. The 
first aim of this thesis was to identify and validate MYB target genes in human ER+ breast cancer 
cells by using doxycycline (Dox)-inducible MYB shRNA to knockdown MYB and using RNA-Seq 
gene expression profiling. Chapter 3 of this thesis showed cells expressing MYB shRNA showed 
80% MYB knockdown and 40% inhibition of cell proliferation, compared to nonsilencing control. 
These cells were used to identify MYB target genes using RNA-Seq gene expression profiling. 
Approximately 500 genes showed differential expression between two MYB shRNA groups, 
compared to nonsilencing control. After integration with published chromatin immunoprecipitation 
data, 145 potentially direct MYB target genes including several DNA damage response genes were 
identified. 
  There is very little information on the role of MYB in the DNA damage response of ER+ breast 
cancer cells. However, two studies showed that silencing MYB increased radiation-induced DNA 
damage in nasopharyngeal carcinoma and DNA damage-induced cell death in castration resistant 
prostate cancer cells. Therefore, the second aim of this thesis was to investigate the role of MYB 
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and its target genes in DNA damage responses in human ER+ breast cancer cells. Chapter 5 of this 
thesis showed that MYB knock down sensitized ER+ breast cancer cells to DNA damaging reagents. 
This may result from downregulation of BCL2, increasing DNA damage, an effect on DNA damage 
response such as RAD51 foci formation or a combination of effects. 
  From RNA-Seq results, there was a cancer stem cell-related gene (ALDH1A3) that was identified 
as a potentially direct MYB target gene. A previous study showed that a cancer stem cell-related 
gene (NANOG) was identified as a MYB target genes in human ER+ breast cancer MCF-7 cells. The 
cancer stem cell theory proposes that tumours may arise from a small population of cancer cells 
with stem cell properties. Mammosphere culture is an in vitro surrogate assay to culture cancer stem 
cells in an undifferentiated state and to examine cancer stem cell properties such as self-renew. 
Although MYB has been studied in breast cancer in vitro and tumour formation in vivo, there is very 
little information on the roles of MYB in ER+ breast cancer stem cells. Therefore, the third aim of 
this thesis was to examine the potential role of MYB in human ER+ breast cancer stem cells. Chapter 
6 of this thesis showed that MYB expression was increased during serial passage of 
mammosphere-derived cells, compared to the first generation. However, silencing MYB may not 
affect mammosphere-forming ability of MCF-7 cells.  
   This thesis makes contributions of significance as follows: (1) further understanding of how 
MYB and its target genes contribute to control cell proliferation and DNA damage response in 
human ER+ breast cancer; (2) these genes may be potential targets for the development of specific 
therapeutics; (3) understanding the role of MYB in cancer stem cells derived from human ER+ 
breast cancer. 
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Chapter 1- Introduction                                        
1. Introduction to cancer 
Cancer is a serious public health problem in Australia and other countries. Approximately 1 in 2 
Australians will suffer from cancer and 1 in 5 of those cases will die before the age of 85. 
According to a joint report by the Australian Institute of Health and Welfare (AIHW) in 2012, more 
than 120,700 individuals would be detected with cancer. The top three diagnosed cancers among 
these cases are predicted to be prostate cancer, bowel cancer and breast cancer (AIHW, 2012). 
1.1 Human carcinogenesis  
Cancers are a wide range of diseases that are characterised by uncontrolled cell proliferation. 
This uncontrolled cell division results in malignant tumours that can invade nearby tissues and 
move into different organs of the body by penetrating the wall of the lymph node or blood vessels. 
This process is referred to as metastasis. Cancers may result from the influences of genetics and 
environment factors. Hanahan and Weinberg (2000) proposed that cancer development is a 
multistep process of genetic changes that carry on oncogenic and tumour suppressor mutation and 
drive normal cells to transform to malignant cells (Hanahan and Weinberg, 2000, Hanahan and 
Weinberg, 2011). This process of cancer development is also called tumourigenesis or 
carcinogenesis. Cancer development has been proposed to require 10 essential alterations: genome 
instability and mutation, self-sufficiency in growth signals (e.g. oncogene H-Ras activation), 
avoiding programmed cell death (apoptosis), evading growth suppressors (e.g. loss of 
retinoblastoma suppressor), avoiding immune destruction, deregulating cellular energetics, 
limitless replicative potential (e.g. turning on telomerase), tumour-promoting inflammation, 
sustained angiogenesis, and activating tissue invasion and metastasis (Hanahan and Weinberg, 
2011).  
1.2 Proto-oncogenes, oncogenes and tumour suppressor genes 
Proto-oncogenes are a group of normal genes that encode proteins including growth factors, 
growth factor receptors with tyrosine kinase activity, nuclear regulatory proteins, intracellular 
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serine/threonine kinases, and transcription factors. These proteins stimulate cell growth and 
differentiation in the body. When proto-oncogenes are mutated by point mutations, deletions, or 
insertions in the promoter region of the proto-oncogenes or DNA rearrangements (translocation and 
gene amplification), these genes become oncogenes which encode proteins that start to induce 
normal cells to transform into tumour cells. For example, the mutation of Ras induces various 
carcinoma including colon adenoma, lung adenocarcinoma, pancreatic carcinoma and bladder 
carcinoma (Wang et al., 2012, Ogura et al., 2013, Trigka et al., 2013, Zenonos and Kyprianou, 
2013). 
Oncogenes can stimulate cell division, inhibit cell differentiation and suppress cell death. In 
cancer cells, most oncogenes arise from proto-oncogene mutation that leads to increased 
transcription and oncoprotein synthesis. Some cancers are caused by oncogenic viral infection 
(Rous, 1910). For example, two v-myb genes were originally isolated from avian myeloblastosis 
virus and avian leukaemia virus E26 that can transform immature hematopoietic cells in vitro and 
induce acute leukaemia in chickens (Roussel et al., 1979, Beug et al., 1979). The first human 
tumour virus, called Epstein Barr virus (EBV), was discovered from Burkitt’s lymphoma (Epstein 
et al., 1964). Virus-mediated oncogenesis may result from direct and/or indirect transformation 
[reviewed in (Morales-Sanchez and Fuentes-Panana, 2014)]. In direct mechanism, viruses express 
viral oncoproteins that can directly transform infected cells. For example, EBV encodes its 
oncoprotein that can inactivate two of the major regulators of genome stability, cell cycle and cell 
viability; namely, the p53 and retinoblastoma proteins (pRB) (Levine, 2009). Inactivation of p53 or 
pRB leads to promotion of cellular transformation (Hansen et al., 1995, Munroe et al., 1990). In 
addition to direct transformation through expression of viral genes, virus infection can also lead to 
cancer through two indirect mechanisms: (i) triggering chronic inflammation and oxidative stress 
that persistently damage local tissues; and (ii) by producing immunosuppression that reduces or 
eliminates anti-tumour immune surveillance mechanisms (Tsai and Chung, 2010, Mason et al., 
2010, Chadburn et al., 2013). In addition, gene amplification can activate oncogene and lead to 
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cancer (Alt et al., 1978, Keung et al., 1997). For example, amplification of c-myc or erbB-2 
(HER2/neu) was found in breast cancer and ovarian cancer (Brison, 1993, Eccles, 2001).  
The other contributors to neoplastic transformation are tumour suppressor genes. Tumour 
suppressor genes are normal genes that, for example, slow down cell division, repair DNA damage 
and regulate programmed cell death. When tumour suppressor genes – for example TP53, BRCA1, 
BRCA2, APC and RB1 – are mutated, it leads to the loss of normal function and contributes to 
cancer development (Senda et al., 2007, Lee and Muller, 2010, Muller and Vousden, 2013, Ciavarra 
and Zacksenhaus, 2011).  
1.3 Origins of cancer: The cancer stem cell hypothesis  
Once a cancer has been diagnosed, several treatments are applied to remove or kill rapidly 
dividing cancer cells in terms of cancer type and severity. These treatments include surgery, 
radiation therapy, and systemic chemotherapy or hormonal therapy. However, these approaches 
have limitations in cancer therapy. For example, all the cancer cells may not be removed by surgery 
due to cancer metastasis. Previous research has revealed that a tumour consists of various types of 
tissue components, including phenotypically heterogeneous cancer cells, stromal cells, and 
vasculature (Bergers and Benjamin, 2003). Several models have been proposed to explain cancer 
development in terms of the heterogeneity of cancer cells (Figure 1.1) (Visvader, 2011). For 
example, the cancer stem cell (CSC) hypothesis suggests that heterogeneous cells in new tumours 
may only arise from a tiny population of undifferentiated cells, transit amplifying cells or the 
maturation arrest of immature stem cells (Figure 1.1) (Bonnet and Dick, 1997, Al-Hajj and Clarke, 
2004, Clarke, 2005). Evidence for the CSC hypothesis was first reported in haematological 
malignancies in which only a small population of cancer cells was able to form new tumours 
(Lapidot et al., 1994, Bonnet and Dick, 1997, Sutherland et al., 1996). In in vivo studies with human 
acute myeloid leukaemia (Kononen et al.), cells were transplanted into nonobese diabetic/severe 
combined immunodeficiency (NOD/SCID) mice. Leukaemia-initiating cells expressing 
CD34+/CD38– were identified. These cells have differentiation and self-renewal capacities – that 
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are stem cell properties – by serial transplantation (Bonnet and Dick, 1997). Putative CSC 
populations have been identified in multiple epithelial cancers: the breast (Al-Hajj et al., 2003), 
prostate (Collins et al., 2005), pancreas (Li et al., 2007), colon (O'Brien et al., 2007), ovaries (Gao 
et al., 2010) and brain (Singh et al., 2004). These cells have stem-like properties that enable the 
regeneration of new tumours with all cell types. Cancer stem cells have been considered to be 
potential candidates in anti-cancer drug resistance and cancer recurrence, which may explain why 
cancer often cannot be eradicated by vigorous therapy (Maitland et al., 2007, Dittmar et al., 2009, 
Gottschling et al., 2012). Thus, understanding the molecular mechanisms of CSC development may 
provide potential new targets for cancer therapy.  
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Figure 1.1: Two models of cancer development (adapted from Visvader, 2011). a, In the genetic 
mutation model, different genetic or epigenetic mutations occurring within the same target cell 
result in different tumour morphology. b, In the cell-of-origin model ( also called cancer stem cell 
model), different tumour cells in new tumours may only arise from a small population of 
undifferentiated cells (blue), transit amplifying cells (yellow) or the maturation arrest of immature 
stem cells (organ).  
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1.4 Cancer stem cells and cancer recurrence  
Several studies have shown that cancer stem cells may survive radiation and/or chemotherapy 
(Zhang et al., 2007, Printz, 2012, Liu et al., 2010, Richard et al., 2013). For example, cancer stem 
cells contributed to cisplatin resistance in Brac1/p53-mediated mouse mammary tumours (Shafee et 
al., 2008). That study showed that tumour cells relapsed after 2 to 3 months of drug treatment. The 
relapsed tumour cells contained a higher proportion of CD29hi CD24med cells; interestingly, these 
are normal mammary stem cell markers (Shafee et al., 2008). CD29hi CD24hi cells isolated from 
p53 null mice were able to generate tumours and were likely to represent an enriched subpopulation 
of cancer stem cells (Zhang et al., 2008). These data may suggest that CD29hi CD24+ cells may play 
a role in mouse breast cancer recurrence.  
 
2. Biology of breast cancer 
The mammary gland goes through dramatic changes in composition and architecture during the 
lifetime. During that time, the epithelium will undergo several cycles of proliferation and cell death. 
The aberrant growth of the mammary epithelial cells will result in tumours during the development 
of the mammary gland (Lanigan et al., 2007). Mammary tumours occur in humans and many 
mammals (Hamilton, 1974, Cassali et al., 2007). The morphology and function of the mammary 
gland in the human and mouse are similar, but they are potentially significant differences (Cardiff 
and Wellings, 1999). The mouse mammary gland has emerged as the primary biological model for 
the study of human breast cancer (Russo et al., 1990).  
2.1 Normal mammary gland 
2.1.1 Structure/cell types 
2.1.1.1 Mouse mammary gland 
The mouse mammary gland is a complex organ. It is comprised of a network of ducts. These 
ducts are formed from a variety of cell types, which are collectively called the mammary epithelium. 
The mammary epithelium is embedded in the mammary fat pad – called the stroma (Schedin and 
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Hovey, 2010). The mouse mammary stroma is comprised of adipocytes, fibroblasts and cells of the 
vasculature and immune systems. 
The mammary epithelium can be broadly categorised into two groups: the luminal (ductal or 
alveolar) epithelium and the myo-epithelium (Dairkee et al., 1986, Nagle et al., 1986). The ductal 
epithelial cells line the lumen of the ducts, and alveolar epithelial cells in the terminal end bud 
synthesise milk proteins during pregnancy. The contractile myo-epithelium surrounds the ducts and 
offers the delivery of milk during lactation (Hennighausen and Robinson, 2005). These two 
epithelial cell layers are surrounded by a sheath of basement membrane, which in turn is surrounded 
by a layer of extracellular matrix (ECM) (Figure 1.2). Signalling from the ECM is required for the 
development of the mammary epithelium and breast cancer (Schedin and Keely, 2011, Muschler 
and Streuli, 2010, Talhouk, 2012).  
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Figure 1.2: Structure of a terminal end bud and the cell lineages of the mammary gland 
(adapted from Smalley and Ashworth, 2003). The ducts of the mammary gland are comprised of 
inner luminal epithelial cell (purple) layers and outer myoepithelial cell (orange) layers. These two 
layers are surrounded by a sheet of basement membrane, which in turn is surrounded by a fibrous 
layer of extracellular matrix in a bed of connective tissue. The terminal end bud of the extending 
ducts is comprised of an outer layer of undifferentiated cap cells (blue) and inner layers of highly 
proliferative luminal epithelial cells (green). The undifferentiated cap cells contribute to the 
formation of the myoepithelium. The body cells in the centre of the extending ducts undergo 
apoptosis to generate lumen.  
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2.2 Stem cells and breast cancer 
Mouse and human mammary glands are composed of ductal epithelial cells, alveolar 
epithelial cells and myoepithelial cells. Electron microscopic studies have observed a number of 
undifferentiated mammary cells (Visvader and Smith, 2011). In studies with the serial 
transplantation of retroviral-tagged mammary fragments into an epithelium-free mammary fat pad, 
the entire mammary gland was regenerated (Kordon and Smith, 1998, Shackleton et al., 2006). 
Another study in mice combining long-term in vivo BrdU labelling with immunosorting and 
transplantation showed that the mammary cells which expressed stem cell antigen 1 (SCA-1) were 
able to regenerate the mammary gland (Welm et al., 2002). Previous studies have proposed that 
cells forming the epithelial compartment of the mammary gland are derived from mammary stem 
cells (Smalley and Ashworth, 2003, Visvader and Stingl, 2014). These mammary stem cells have 
the capacity to self-renew and give rise to committed luminal progenitor cells and myoepithelial 
progenitor cells (Figure 1.3) (Visvader and Stingl, 2014). These progenitor cells differentiate into 
luminal cells and myoepithelial cells (Visvader and Stingl, 2014).  
A mammary stem cell-enriched population was identified on the basis of the high expression of 
specific cell surface markers including CD29 (β1-integrin), CD49f (α6-integrin) and moderate 
levels of CD24 (heat stable antigen) (Shackleton et al., 2006, Sleeman et al., 2006, Stingl et al., 
2006). Several studies have proposed that mammary stem cells may contribute to oncogenesis in 
terms of analysis of the hyperplastic but premalignant mammary tissue of MMTV-wnt-1 mice, 
which was found to harbour a significantly increased number of Lin-CD29hiCD24+ mammary stem 
cells (Shackleton et al. 2006; Vaillant et al. 2008).   
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Figure 1.3: Cells lineages in mammary epithelium (adapted from Visvader and Stingl, 2014). In 
this model, it is proposed that the luminal progenitor cells and myoepithelial progenitor cells are 
derived from mammary stem cells (MSCs). The luminal progenitor cells develop into the ductal 
progenitor cells (DPs) during puberty. The DPs possibly comprise both ER+ and ER- cells. DPs 
differentiate to form mature ductal cells. During pregnancy, the alveolar precursors (APs) give rise 
to alveoli. The APs are likely to be ER- cells derived from common luminal progenitors. The 
myoepithelial progenitor cells differentiate into myoepithelial cells.  
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2.3 Classification of human breast cancer 
Human breast cancer is a heterogeneous group of diseases with substantial variation in their 
genetic and clinical characteristics (Stingl and Caldas, 2007). To understand the heterogeneity of 
breast cancer, breast cancer classification systems have been developed based on histological and 
molecular subtypes (Malhotra et al., 2010). Based on architectural patterns and cytological features, 
60-70% of all breast carcinomas are ultimately described as invasive ductal carcinomas not 
otherwise specified (IDC-NOS), also called breast carcinoma of no special type (breast carcinoma 
NST) (Stingl and Caldas, 2007). Unlike the detailed classification of the haematopoietic tumours 
based on the cell origin and cell morphology, the cellular hierarchy in breast cancer is still only 
partially understood (Stingl and Caldas, 2007). This issue may result from the similar morphology 
of breast cancer with different response to the same drug therapy (Dawson et al., 2013).  
Gene expression profiling (GEP) by microarray analysis has offered a strategy to define human 
breast cancer (Perou et al., 2000, Sorlie et al., 2001, Sotiriou et al., 2003). This molecular 
classification is based on gene expression profiles and a similarity to normal mammary cells. GEP 
has classified five main sub-types of breast carcinoma: luminal A, luminal B, Her2 positive, 
basal-like carcinoma and normal-like carcinoma (Perou et al., 2000, Sorlie et al., 2001). Table 1.1 
presents a summary of the six sub-types of breast cancer (Prat and Perou, 2011). 
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Table 1.1: Molecular classification of human breast cancer (adapted from Prat and Perou, 
2011). 
Prevalence (%) 
 
Luminal 
A 
Luminal 
B 
HER2+ Basal-like Normal-like Claudin-low 
DNA 
microarray  
29±2 21±2 17±5 16±6 6±4 11±4 
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2.4 Breast cancer stem cells  
Several studies have attempted to demonstrate the existence of human breast cancer stem cells 
based on cell surface markers. CD44+CD24-/low cells have been isolated from patients with breast 
cancer (Al-Hajj et al., 2003, Ponti et al., 2005). Transplantation of these cells into the mammary fat 
pads of nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice can regenerate the 
original tumours (Al-Hajj et al., 2003, Mani et al., 2008). CD44+/CD24-/low cells in human breast 
cancer also expressed the putative stem cell marker Oct-4 (Ponti et al., 2005).  
An additional marker, CD133, was used for the isolation of breast cancer stem cells from 
Brca1-exon11/p53+/- mouse mammary tumours (Wright et al., 2008). This marker is a known marker 
of cancer stem cells in several organs: the brain, blood, liver and prostate (Hwang-Verslues et al., 
2009). Another study reported that aldehyde dehydrogenase was increased in a sub-population of 
both human normal mammary epithelial cells and cancer stem cells (Ginestier et al., 2007). This 
sub-population of human mammary cells was able to generate tumours in contrast to aldehyde 
dehydrogenase (ALDH) negative cells (Ginestier et al., 2007). Other surface markers, such as 
CXCR4 and ABCG2, may be also associated with stem cell properties (Miki et al., 2007, Hang et 
al., 2012). CXCR4 is a G-protein coupled heptahelical receptor that contributes to metastasis in 
human breast cancers (Kang et al., 2003). ABCG2, which is one of the ATP-binding cassette 
transporters, is a known stem cell marker in hematopoietic stem cells, nestin-positive islet-derived 
progenitors of Langerhans and neural stem cells (Zhou et al., 2001, Lechner et al., 2002, Cai et al., 
2004). Thus, these markers may be the candidates for the isolation of putative human breast cancer 
stem cells.  
2.4.1 The mammosphere culture system  
  While serial transplantation model in mice has been applied in searching for putative mammary 
cancer stem cells, the identification of putative mammary cancer stem cells has been hindered by 
the absence of suitable in vitro assays for testing key stem cell properties i.e. self-renewal and 
differentiation. Dontu et al. (2003) developed a surrogate assay to test whether human mammary 
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epithelial cells derived from reduction mammoplasties had stem cell properties. This assay allows 
mammary epithelial cells to grow in an undifferentiated state. Dontu et al. (2003) found that 
human mammary epithelial cells formed spherical colonies when cultured on ultralow attachment 
plates in a serum-free culture medium. These non-adherent colonies were defined as 
mammospheres by analogy to neurospheres derived from mammalian central nervous system 
(Reynolds and Weiss, 1996, Dontu et al., 2003, Bez et al., 2003). Dontu et al. (2003) also found 
single cells dissociated from mammospheres were able to generate new spheres when they were 
replated in 96-well plates for seven days. These single cells derived from mammospheres could be 
passaged several times (Dontu et al., 2003).  
Ponti et al. (2005) found that CD44+/CD24−/low cells derived from human primary breast 
carcinoma could form spheres in nonadherent culture conditions. These floating mammospheres can 
adhere and differentiate after the addition of 5% fetal bovine serum (Ponti et al., 2005). In addition, 
mammosphere formation was also reported in cells from metastatic breast cancer from pleural 
effusions (Grimshaw et al., 2008) and breast cancer cell lines (Engelmann et al., 2008, Fillmore and 
Kuperwasser, 2008, Croker et al., 2009, Xie et al., 2012). These spheres contain cells that express 
cancer stem cell markers CD44+/CD24-/low (Grimshaw et al., 2008, Engelmann et al., 2008, Fillmore 
and Kuperwasser, 2008, Croker et al., 2009, Xie et al., 2012). Importantly, CD44+/CD24-/low cells 
derived from mammospheres were able to generate tumours in vivo xenograft assay (Grimshaw et 
al., 2008, Engelmann et al., 2008, Fillmore and Kuperwasser, 2008, Croker et al., 2009, Xie et al., 
2012).  
 
2.5 Oestrogen action and breast cancer    
Approximately 70% of human breast tumours express oestrogen receptors (ERs) (Nagaraj et al., 
2012). ERs mediate the proliferative and many other actions of oestrogens in breast cancer cells 
(Covaleda et al., 2008). ERs are found in both the cytosol and the nucleus. ERs belong to the 
hormone nuclear receptor family of transcription factors and have two isoforms, α and β (Cicatiello 
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et al., 2004). Steroid hormones, such as oestrogen, enter the cell through passive diffusion (Shibata 
et al., 1997). When an oestrogen or oestrogen analogue reaches the cytoplasm or cell nucleus, it 
binds to an ER and a complex set of chaperone proteins, including HSP-90 and cyclophilin 40. This 
binding alters the conformation of the ligand-binding domain of the receptor and allows the 
interaction with co-regulator molecules that act as activators (Edwards, 2000, Pike et al., 2000). 
ERs are ligand-dependent transcription factors that regulate expression of their primary target genes 
via ER dimerization and translocation into the nucleus to bind the oestrogen response elements in 
target genes. It is now known that the ERs can also regulate the expression of genes without directly 
binding to the oestrogen-response element in target genes. For example, oestrogen receptors can 
control the transcriptional activity of transcription factors, such as Jun, Fos, and ATF family 
proteins, and result in the activation of genes containing activator protein 1 (AP-1) elements 
(Kushner et al., 2000). In addition, oestrogen receptor can be activated by other molecules. For 
instance, both epidermal growth factor and insulin-like growth factor-I can stimulate the 
transcription of oestrogen receptor target genes in the absence of oestrogen by increasing 
phosphorylation of ER (Ignartrowbridge et al., 1995, Stoica et al., 2000, Yee and Lee, 2000). 
Previous studies have indicated that oestrogens may be mammary carcinogens (Stephenson, 
2001, Twombly, 2003, Spink et al., 2009). Several clinical and experimental studies have supported 
the idea that oestrogen deprivation (e.g. fulvestrant (Massarweh et al., 2006)) reduces mammary 
tumours and that oestrogen exposure stimulates breast cancer growth (Nicholson and Manning, 
1992; Howell et al., 1997; Spink et al., 2009; Crooke et al., 2011; Weigel et al., 2012). Thus, 
understanding oestrogen action may play an important role in the development of breast cancer.  
 
2.6 Breast cancer and DNA damage  
   Breast cancer is intimately related to accumulation of DNA damage and DNA repair defects 
(Cressman et al., 1999, Cipollini et al., 2004). For example, inherited mutations in BRCA1 and 
BRCA2 (DNA damage repair), ataxia telangiectasia mutated (ATM) (Swift et al., 1987, Gatti et al., 
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1999), CHEK2, and TP53 (cell cycle checkpoint) in families showed high risk of breast cancer 
(Walsh et al., 2006). ATM functions as a mediator of the cell cycle checkpoint pathway in response 
to DNA double-strand breaks (DSBs) (Ding et al., 2004, Shiloh and Ziv, 2013). Following DNA 
DSBs, the MRE11– RAD50–NBS1 (MRN) complex senses and initiates DNA repair and recruits 
ATM to the site of DNA damage before interacting with BRCA1 (Shiloh and Ziv, 2013, Shiloh, 
2014). In addition, the breast cancer susceptibility gene BRCA2 is associated with Fanconi anemia 
complementation group D1 (FA-D1) and has been identified as a FA gene, FANCD1 (Offit et al., 
2003, D'Andrea and Grompe, 2003, Howlett et al., 2002). Fanconi anemia (FA) is a rare autosomal 
recessive disease (Fanconi, 1967, D'Andrea and Grompe, 2003). FA symptoms includes increased 
cancer incidence. FA cells are hypersensitive to DNA crosslinking agents (D'Andrea and Grompe, 
2003). DNA crosslinking is one types of DNA damage (as shown in Figure 1.4) (Hosoya and 
Miyagawa, 2014). DNA damage can result from endogenous insults (such as DNA copying errors), 
environmental insults (such as chemical exposures), or the process of aging (Davis and Lin, 2011). 
Replication errors are a common type of endogenous DNA damage. They can be due to dNTP 
misincorporation, interconversion between DNA bases caused by deamination, loss of DNA bases 
following DNA depurination, and modification of DNA bases by alkylation (Lindahl and Barnes, 
2000).       
   Environmental DNA damage can result from physical (such as ionizing radiation) or chemical 
sources (e.g. oestrogen (Dees et al., 1996, Savage et al., 2014)). Chemotherapeutic agents are 
common chemical sources that can result in a variety of exogenous DNA damage (as shown in 
Figure 1.4) (Hosoya and Miyagawa, 2014). For example, cisplatin can result in DNA crosslinking 
and etoposide can cause DNA double strand breaks (DSBs) (Farrell et al., 2004, Kachnic et al., 
2011).  
   The process of aging is a third source that can cause DNA damage in cells. One result of aging is 
telomere shortening. Telomeres are composed of repetitive DNA sequences that are located at the 
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ends of chromosomes. They can protect the ends of chromosomes from deterioration or fusion with 
other chromosomes during mitosis. Telomere shortening occurs as a consequence of end 
replication. In order to prevent telomere shortening and extend replication cycles, breast cancer 
cells highly express telomerase that can add long repeats of AGGGTT at the end of chromosomes 
(Mokbel, 2000).  
   In order to maintain genomic integrity, each type of DNA damage can be responded by different 
mechanisms of DNA repair (as illustrated in Figures 1.4 and 1.5). Most DNA damage response 
mechanisms are composed of a similar set of coordinated processes: namely recognizing DNA 
damage, accumulating DNA repair factors at the site of DNA damage and finally repairing the 
DNA lesion.  
  Among various types of DNA damage, DSBs are one of the most dangerous (Ciccia and Elledge, 
2010). They can be generated by endogenous sources (Bessho, 2003), exogenous sources (Sinha et 
al., 1988) or aging (Soleimani et al., 2011, Robles and Adami, 1998). DSBs are predominantly 
repaired by either homologous recombination (HR) (Lopez and Coppey, 1987), classical 
non-homologous end joining (C-NHEJ) (Takata et al., 1998, Hefferin and Tomkinson, 2005) or 
alternative NHEJ (A-NHEJ) (Grabarz et al., 2012).  
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Figure 1.4: Overview of different types of DNA damage and DNA repair factors (adapted from 
Hosoya and Miyagawa, 2014). The key proteins in response to different types of DNA damage are 
shown. In homologous recombination, phosphorylated BRCA1 recruits RAD51 to the site of DNA 
double strand break to repair DNA. In non-homologous end joining, the Ku70/80 complex binds to 
the DNA double strand break ends and recruits the other indicated DNA repair factors.    
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  HR is an error-free pathway of DNA repair (Richardson et al., 1998). It requires a non-damaged 
sister chromatid to be a template for DNA repair and usually only occurs in the S and G2 phases of 
the cell cycle (Rothkamm et al., 2003, Saleh-Gohari and Helleday, 2004). HR is not only regulated 
by DNA damage response signalling pathways (Sorensen et al., 2005) but also by the cell cycle 
(Figure 1.5) (Aylon et al., 2004, Jazayeri et al., 2006, Krajewska et al., 2015). DSBs can be repaired 
by HR-mediated pathways (i.e. double-strand break repair (DSBR) pathway, synthesis-dependent 
strand annealing (SDSA) pathway and break-induced replication (BIR) pathway) (Sung and Klein, 
2006, Krejci et al., 2012). In these pathways, repair is initiated by DNA 5’ resection to generate 3’ 
single-stranded DNA ends followed by formation of RAD51 filaments that invade into homologous 
template to form D-loop structures (Sung and Klein, 2006, Krejci et al., 2012). This ‘5 to 3’ end 
resection is initiated by the MRN (MRE11, RAD50, NBS1) complex and CtIP. Then, resected 
DNA-ends are coated by replication protein A (RPA) before RAD51 loading onto DNA to form 
RAD51 filaments (Krajewska et al., 2015). Crucial proteins that are involved in RAD51 loading 
and the formation of RAD51 filament include TOPBP1, the MRN complex, replication protein A 
(RPA), BRCA1, PALB2, RAD51 and BRCA2 (Hartlerode and Scully, 2009). RAD51 filaments can 
invade the DNA double helix and promote the D-loop formation (Lord and Ashworth, 2016). After 
D-loop formation and DNA synthesis, three pathways (DSBR, SDSA and BIR) can be invoked. In 
the DSBR pathway, the second DSB end can be captured to generate a double-Holliday Junction 
(dHJ) intermediate (Szostak et al., 1983, Krejci et al., 2012). After gap-repair DNA synthesis and 
ligation, resolution of dHJs can occur in either generate crossover or non-crossover products. In the 
SDSA pathway, the extended nascent strand is displaced, followed by annealing of the extended 
single-strand end to the single-strand DNA on the other break end, and DNA synthesis completes 
repair (Nassif et al., 1994, Sung and Klein, 2006). In the BIR pathway, when the second DSB end is 
absent, the D-loop intermediate can turn into a replication fork that lead to DNA strand synthesis 
(Malkova et al., 1996). Many proteins that are involved in HR-mediated DNA repair are now 
recognized to also contribute to hereditary breast cancer risk including ATM (Renwick et al., 2006), 
 20 
CHEK2 (Consortium, 2004), BARD1 (De Brakeleer et al., 2010), BRIP1 (Seal et al., 2006), 
MRE11, RAD50, NBS1 (Steffen et al., 2006, Damiola et al., 2014), RAD51C (Meindl et al., 2010) 
and PALB2 (Rahman et al., 2007). 
      NHEJ is an error-prone pathway of DSB repair. It does not require a homologous 
chromosome for DNA repair and can function throughout the cell cycle (Moore and Haber, 1996, 
Sonoda et al., 2006). The general mechanism of NHEJ for repair of DSBs can be broken down into 
four steps (i.e. (I) DNA end recognition at the DSB sites; (II) loading core NHEJ factors onto DNA 
ends; (III) DNA end processing; and (IV) ligation of the broken ends) [reviewed in (Deriano and 
Roth, 2013)]. NHEJ can be divided into two forms: classical NHEJ (C-NHEJ) and alternative NHEJ 
(A-NHEJ) (Grabarz et al., 2012, McVey and Lee, 2008). C-NHEJ pathway can directly join the two 
broken DNA ends with short homology (1–3 nt) or no homology. The first step in C-NHEJ is that 
the Ku70 (also known as XRCC6)/Ku80 (also known as XRCC5) complex binds to the DSB for 
DNA end recognition (Mimori and Hardin, 1986, Mari et al., 2006).  Once the Ku complex is 
bound to the DSB ends, it recruits DNA-dependent protein kinase catalytic subunit (DNS-PKcs) 
onto DNA ends (Yaneva et al., 1997). DNS-PKcs phosphorylates Artemis (5’ to 3’ single-strand 
DNA exonuclease) to process the DNA end (Ma et al., 2002). Finally, the XLF, X-ray repair 
complementing defective repair in Chinese hamster cells 4 (XRCC4), DNA ligase 4 complex ligate 
the DNA ends to complete DNA repair (Hartlerode and Scully, 2009). However, A-NHEJ appears 
to be independent of the above factors. The initial step in A-NHEJ is that poly (ADP-ribose) 
polymerase 1 (PARP1) binds to the DSB for DNA end recognition [reviewed in (Frit et al., 2014)]. 
Next, PARP1 recruits the MRN complex and the exonuclease CtBP-interacting protein (CtIP) to 
process DNA ends [reviewed in (Frit et al., 2014)]. Finally, the DNA ends are rejoined either by 
DNA ligase 1 or 3 [reviews in (Iliakis et al., 2015)]. A-NHEJ often results in a deletion with 
microhomology at the repair junction (Bennardo et al., 2008). To date, five NHEJ factors that are 
associated with breast cancer risk include Ku70, XRCC4, Ligase 4 (Fu et al., 2003), CtIP (Rebbeck 
et al., 2011, Reczek et al., 2016) and PARP1 (Alanazi et al., 2013). 
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Figure 1.5:  Overview of DNA repair pathways (adapted from Bartek and Lukas, 2010). Seven 
DNA repair pathways are involved in response to different types of DNA damage. For example, 
Checkpoint activation, homologous recombination (HR) and non-homologous end joining (NHEJ) 
pathways are associated with repairing DNA double strand breaks (DSBs). The base excision repair 
(BER) pathway is involved in repairing damaged base, single strand break (SSB). The nucleotide 
excision repair (NER) pathway is involved in repairing pyrimidine dimerization. The mismatch 
repair (MMR) pathway is associated with DNA mismatch repair. Fanconi anaemia (FA) pathway is 
involved in response to DNA replication fork stalling and interstrand crosslinks. 
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2.7 Current therapies in breast cancer  
2.7.1 Treatments for ER+ breast cancer 
    To date, there are five main types of breast cancer therapies: surgery, radiation therapy, 
chemotherapy, hormone therapy, and targeted therapy (Sledge et al., 2014). Apart from the primary 
surgical treatment and radiation therapy, patients with ER positive breast cancer typically receive 
endocrine therapy (e.g. aromatase inhibitors that block oestrogen synthesis and selective 
oestrogen-receptor response modulators (SERM; for example tamoxifen) that block the activity of 
ER) to prevent recurrence of the cancer [reviewed in (Rugo et al., 2016)]. Previous studies reported 
that aromatase inhibitors reduce the level of oestrogen by inhibition of the aromatase in plasma and 
breast tissue (Brodie et al., 1981, Lonning and Geisler, 2010) and also lead to ovarian 
hyperstimulation (Pritts, 2010). In postmenopausal women, oestrogen synthesis is relied on 
aromatase (Purohit and Reed, 2002). Aromatase inhibitors are generally divided into two types: 
steroidal or non-steroidal inhibitors (Hamilton and Volm, 2001, Altundag and Ibrahim, 2006). 
Steroidal aromatase inhibitors (e.g. exemestane) bind irreversibly to aromatase (Murphy, 1998, 
Hamilton and Volm, 2001). In contrast, non-steroidal inhibitors (e.g. anastrozole, letrozole and 
vorozole) bind competitively to the heme iron of aromatase (Murphy, 1998, Hamilton and Volm, 
2001). Previous studies have reported aromatase inhibitors with excellent activity in enhancing 
disease-free survival and preventing of recurrence when compared to tamoxifen (Goss et al., 2003, 
Altundag and Ibrahim, 2006, Arimidex et al., 2008, Litton et al., 2012).  
    Tamoxifen is one of the most widely used ER antagonists for ER positive breast cancer 
therapy (Gallo and Kaufman, 1997, Early Breast Cancer Trialists' Collaborative, 2001). Tamoxifen 
competitively binds to the AF-2 region of ERα receptor (Berry et al., 1990) and inhibits the 
proliferative actions of oestrogen in vitro (Wolczynski et al., 2000). However, tamoxifen also 
functions as an agonist through binding of unknown coactivators in other tissues (e.g. bone and 
endometrium) [reviewed in (Riggs and Hartmann, 2003)]. Thus, tamoxifen is usually referred to as 
a selective oestrogen receptor modulator (SERM) [reviewed in (Riggs and Hartmann, 2003)]. 
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Unlike tamoxifen, two oestradiol analogues (ICI 182,780 (Fulvestrant) and ICI 164,384) inhibit the 
transcriptional activation of ERα receptor from both AF1 and AF2 (Wakeling and Bowler, 1988, 
Pike et al., 2001) and are considered as pure ERα antagonists (Howell et al., 1996, Howell et al., 
2000). These pure ERα antagonists are recommended for ER positive breast cancer therapy (Howell 
et al., 1996). However, resistance to ERα antagonists has been reported in cell line model (Brunner 
et al., 1997, Brockdorff et al., 2003, Frogne et al., 2005, Fan et al., 2009). Resistance to ERα 
antagonists could result from genetic and epigenetic changes [reviewed in (Garcia-Becerra et al., 
2012, Hayes and Lewis-Wambi, 2015)].  
 
2.7.2 Treatment for ER negative breast cancer 
2.7.2.1 HER2 overexpressing breast cancer 
    HER2 overexpression usually results from gene amplification (Persons et al., 1997, Riou et al., 
2001, Hojati and Orangi, 2012). HER2 overexpression is associated with poor clinical outcomes 
and aggressive tumour progression (Slamon et al., 1987, Slamon et al., 1989, Olson et al., 2012). 
HER2/neu is a tyrosine kinase receptor that can be targeted to its extracellular domain by 
monoclonal antibodies (e.g. trastuzumab and pertuzumab) (Hudis, 2007, Gianni et al., 2010, 
Baselga et al., 2010), which block the dimerization of HER2/neu receptor and cell proliferation of 
HER2-overexpressing breast cancer (Brockhoff et al., 2007). Patients with HER-2/neu 
overexpressing breast cancer usually treated with anti-HER2 monoclonal antibodies (e.g. 
trastuzumab and pertuzumab) in combination with cytotoxic chemotherapeutic agents [reviewed in 
(Tinoco et al., 2013)]. However, resistance to trastuzumab and pertuzumab in HER2-amplified 
breast cancer has been reported [reviewed in (Valabrega et al., 2007, Luque-Cabal et al., 2016)]. To 
date, potential pathways that are involved in trastuzumab resistance include the phosphatidylinositol 
3'-kinase/protein kinase B/mammalian target of rapamycin pathway, cross-talk with oestrogen 
receptors, immune response, cell cycle control mechanisms, and other tyrosine kinase receptors (e.g. 
insulin-like growth factor I receptor) (Luque-Cabal et al., 2016). In addition, the use of HER2 
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tyrosine kinase inhibitors is the second option of HER-2/neu overexpressing breast cancer therapy. 
HER2 tyrosine kinase inhibitors (e.g. lapatinib) can target to the intracellular domain of HER2 
receptors and lead to the inhibition of cell proliferation of HER2-amplified breast cancer (Scaltriti et 
al., 2007, O'Brien et al., 2010). Preclinical and clinical studies show that HER2 tyrosine kinase 
inhibitors (e.g. gefitinib, lapatinib and neratinib) seem to be promising therapeutic agents in the 
treatment of HER2-overexpressing breast tumours [reviewed in (Segovia-Mendoza et al., 2015)].  
 
2.7.2.2 Basal-like breast cancer 
    Basal-like breast cancers are often lack of ER, PR, and HER2 expression in conjunction with 
expression of basal cytokeratins (CK5/6) and/or epidermal growth factor receptor (Cheang et al., 
2008). As a result, basal-like breast cancers are usually associated with a poor outcome (Banerjee et 
al., 2006). Patients with basal-like breast cancer are treated with epidermal growth factor receptor 
inhibitors (e.g. cetuximab that binds to the extracellular ligand-binding domain of epidermal growth 
factor receptors and block the dimerization of epidermal growth factor receptors) (Dong et al., 2010, 
Carey et al., 2012). In addition, it has become clear that the characteristic phenotypes of basal-like 
breast cancer are similar to BRCA1-related tumours (arising in BRCA1 mutation) [reviewed in 
(Turner and Reis-Filho, 2006, Fadare and Tavassoli, 2008)]. BRCA1-regulated DNA repair 
pathway may defect in basal-like breast cancer (Ohta et al., 2009, Hill et al., 2014). Thus, the 
combination of DNA-damaging agents (e.g. etoposide) and epidermal growth factor receptor 
inhibitors may a new strategy for basal-like breast cancer therapy and require further studies.  
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3. The MYB oncogene 
   The word ‘MYB’ is an acronym derived from myeloblastosis – a type of leukaemia. 
3.1. MYB gene family 
3.1.1 Discovery 
The MYB encoded proteins are part of a family of transcription factors with a DNA binding 
domain of approximately 51-52 amino acids (Rosinski and Atchley, 1998). Two v-myb genes were 
the first members of the MYB gene family to be studied and were originally isolated from avian 
myeloblastosis virus (AMV) and avian leukaemia virus E26 (Sotirov, 1981). These viruses can 
transform immature hematopoietic cells in vitro and induce acute leukaemia in chickens (Beug et al., 
1979, Roussel et al., 1979). The v-myb in AMV-transformed leukemic myeloblasts encodes a 
48kDa protein, p48v-myb (AMV). The v-myb in E26 encodes a 135kDa protein that is a 
gag-Myb-Ets-1 fusion protein (Boyle et al., 1983). This protein contributes to the transforming 
properties of E26 (Leprince et al., 1983, Nunn et al., 1983). V-myb corresponds to the central part of 
the cellular myb oncogene (c-myb/MYB) (Klempnauer et al., 1982, Ramsay and Gonda, 2008). The 
human MYB locus has been mapped to a region (6q21-23) of chromosome 6 that is involved in 
chromosomal translocations in both myeloid and lymphoid neoplasms (Harper et al., 1983). These 
chromosomal translocations commonly lead to MYB overexpression in myeloid and lymphoid 
neoplasms and adenoid cystic carcinomas (Harper et al., 1983, Pelicci et al., 1984, West et al., 2011, 
Drier et al., 2016). The MYB gene family contains another two members, namely, MYBL1 (also 
known as A-MYB) and MYBL2 (also known as B-MYB) which have different roles in various tissues 
(Nomura et al., 1988). The following review and the present project focus on c-myb/MYB. 
 
3.2 Structure of the MYB protein 
MYB proteins are composed of three functional domains: an N-terminal DNA binding 
domain, a transactivation (TA) domain and a C-terminal negative regulatory domain. This 
composition of the protein is illustrated in Figure 1.6.  
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Figure 1.6: Structure of MYB (adapted from Gonda, 1998). The MYB protein consists of three 
functional domains: a DNA binding domain, a transactivation (TA) domain and negative regulatory 
domain. The DNA binding domain of MYB comprises three tandem repeats: R1, R2 and R3. L 
points to the leucine zipper motif in MYB. Two phosphorylation sites by casein kinase II 
(N-terminal) are labelled `P'. The EVES motif overlaps a mitogen-activated protein (MAP) kinase 
phosphorylation site. The truncated v-MYB proteins of the avian leukaemia viruses AMV and E26 
are depicted in relation to MYB. The N-terminally truncation of MYB was found in Abelson 
murine myelogenous leukaemia (ABML) and Moloney murine leukaemia virus (M-MuLV) induced 
myelogenous leukaemia (MML). The C-terminally truncated forms of MYB were found in murine 
myeloid leukaemia cell lines (NFS-60 and VFLJ2). 
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3.2.1 N-terminal DNA binding domain 
MYB proteins function as transcription factors that recognize the consensus sequence 
C/T–A–A–C–G/T–G, which is known as the MYB binding site (MBS) (Biedenkapp et al., 1988). 
The DNA binding domain (DBD) of MYB consists of three tandem repeats of approximately 51-52 
amino acids with a helix-turn-helix structure: R1, R2, and R3 (Biedenkapp et al., 1988). As a 
transcription factor, MYB interacts with various co-regulators to regulate the expression of target 
genes both positively and negatively (i.e. activates transcription of certain genes and represses 
transcription of others). The DBD of MYB is known to interact with several co-activators such as 
Mi2α (Saether et al., 2007) and FLASH (Alm-Kristiansen et al., 2008), as well as co-repressors 
including N-CoR and c-Ski (Nomura et al., 2004), which have been shown to influence the MYB 
transcriptional activity. For example, by pull-down assays using GST fusion proteins, Mi2α binds to 
the DBD of MYB and enhances MYB-p300 transactivational activity (Saether et al., 2007). In 
addition, the c-Ski-N-CoR-mSin3A complex was shown to bind to the R2 and R3 repeats of the 
DBD. This co-repressor complex blocks the transactivation ability of MYB (Nomura et al., 2004).  
3.2.2 Transactivation domain 
The transactivation domain of MYB was identified as the region from amino acid residues 
241 to 325 in mice and amino acid residues 275 to 325 in humans (Sakura et al., 1989, Weston and 
Bishop, 1989). The transactivation domain of MYB contains a cluster of acidic residues and has 
been shown to interact with the co-activators including CBP/p300 (Dai et al., 1996, Oelgeschlager 
et al., 1996), and the TIP60 co-repressor (Zhao et al., 2012), both of which have an effect on MYB 
transactivation activity by regulating histone acetylation (Shiama, 1997, Zhao et al., 2012). For 
example, CBP, p300 and TIP60 are histone acetyltransferases that can lead to acetylation of 
histones (Ogryzko et al., 1996, Zhao et al., 2012). CBP binds to both the transcriptional activation 
domain (TAD) and the C-terminal domain of MYB (Dai et al., 1996, Swope et al., 1996). Antisense 
RNA of CBP decreases MYB-induced transcriptional activation (Dai et al., 1996) and dominant 
negative mutants of CBP repress MYB-specific transcription as measured on the MYB target gene 
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mim-1 promoter (Oelgeschlager et al., 1996). In addition, TIP60 (a MYB co-repressor) interacts 
with the transcription activation domain of MYB and lead to inhibition of the transcriptional 
activation ability of MYB in functional reporter assays (Zhao et al., 2012). These results indicate 
that either two MYB coactivators (CBP and p300) or TIP60 are essential to regulate MYB 
transcriptional activity. 
3.2.3 C-terminal negative regulatory domain 
The C-terminal regulatory domain of MYB part of which is deleted in v-Myb was first 
identified in 1989 (Sakura et al., 1989). Early studies indicated that the deletion of the C-terminal 
regulatory domain of MYB increased the transactivational activity (Sakura et al., 1989) of the 
protein and DNA binding activity (Hu et al., 1991). These results suggested that the C-terminal 
regulatory domain of MYB may function as a negative regulator. The C-terminal regulatory domain 
of MYB contains a leucine zipper-like structure (Kaneiishii et al., 1992) and the EVES motif that 
overlaps a MAP kinase phosphorylation site (Aziz et al., 1993, Zhou and Ness, 2011). These two 
motifs can inhibit transcriptional activation independently (Dubendorff et al., 1992). An early study 
found that this leucine zipper-like structure in the C-terminal regulatory domain of MYB resembled 
the leucine zipper region in other DNA binding transcription factors (Landschulz et al., 1988). The 
replacement of leucines by proline residues in the leucine zipper region of the C-terminal regulatory 
domain of MYB promoted the transactivation and transformation activities of MYB (Kanei-Ishii et 
al., 1992). Although the precise signaling pathway is unclear, several studies have suggested that 
the mechanisms of negative regulation in the C-terminal regulatory domain of MYB were involved 
in interactions with intramolecular and other proteins (Favier and Gonda, 1994, Dash et al., 1996, 
Ness, 1996). Interestingly, one form of MYB, p89, lacks the leucine zipper region resulting from 
the insertion of exon 9A. p89-MYB was found to have higher transactivation activities compared to 
the p75 form of MYB (Woo et al., 1998). This result further suggests that the leucine zipper motif 
in the C-terminal regulatory domain may play an important role in the negative regulation of MYB. 
With regard to the MAP kinase phosphorylation site in the C-terminal regulatory domain of MYB, 
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deletion analysis and in vitro kinase assays have shown that the phosphorylation at that site by a 
serine/threonine kinase, p42, may play an important role in MYB regulation (Miglarese et al., 1996). 
The discovery of a highly conserved ‘EVES’ domain in the negative regulatory region of MYB led 
to the hypothesis that MYB may be able to regulate its own activity through the physical interaction 
of the C-terminus with the N-terminus (Dash et al., 1996). Yeast-two hybrid assays and phage 
display experiments indicated that the EVES domain physically interacted with the DNA binding 
domain of MYB. A transcriptional co-activator of the Epstein-Barr virus nuclear protein EBNA2, 
called p100, also contains an ‘EVES’ domain (Tong et al., 1995, Dash et al., 1996). The binding 
assays showed that p100 can interact with MYB proteins through the ‘EVES’ domain to increase 
the ability of the latter to activate transcription of the mim-1 target gene (Dash et al., 1996). This 
supports the conclusion that the C-terminal truncation of MYB leads to the protein activation, as 
truncation would abolish the self-interaction. However, further work is required to investigate the 
significance of the ‘EVES’ domain in MYB regulation.  
 
3.3 MYB interacting proteins 
The MYB mRNA is expressed in immature, proliferating haematopoietic precursors and several 
differentiating epithelia. MYB encoded protein regulates gene expression by cooperation with two 
groups of transcriptional co-regulators: co-activators and co-repressors. Those transcriptional 
co-regulators – that cooperate with MYB and acting as co-activators – include CREB-binding 
protein (CBP) and p300 (CBP/p300) (Dai et al., 1996), p100 and Pim-1 (Tong et al., 1995, 
Leverson et al., 1998), CCAAT/enhancer binding proteins (C/EBPs) such as C/EBP β (also known 
as NF-IL6 and NF-M) (Burk et al., 1993, Mink et al., 1996), Ets family proteins such as Ets-2 
(Dudek et al., 1992), and  PU.1 along with C/EBP-alpha or tetrameric complex GABP 
(Nuchprayoon et al., 1997) and runt homology domain protein RUNX-1/AML-1 (Zaiman and Lenz, 
1996, BritosBray and Friedman, 1997). The other transcription co-regulators (that interact with 
MYB and act as co-repressors) include RARα and c-Maf (Pfitzner et al., 1998, Hegde et al., 1998), 
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p160/p67 (Tavner et al., 1998), TIF1 β and Ski (Nomura et al., 2004) and cyclin D1 or D2 (Ganter 
et al., 1998, Lei et al., 2005).  
 
3.3.1 CREB-binding protein (CBP) and p300 
CBP and p300 belong to a family of ubiquitous coactivators that interact with many 
transcription factors (Arany et al., 1994, Dai et al., 1996). CBP and p300 can control the chromatin 
remodelling and acetylation of other transcription factors such as p53 because of their histone 
acetyltransferase activity (Ogiwara et al., 2011, Kim et al., 2012).  
3.3.2 CCAAT/enhancer binding proteins (C/EBPs) 
C/EBPs are a family of transcription factors that contain a highly conserved leucine zipper 
domain at the C-terminal end (Ramji and Foka, 2002). The leucine zipper domain of C/EBP is 
involved in dimerisation and DNA binding. To date, at least six sub-types of C/EBP proteins have 
been identified (Ramji and Foka, 2002). Previous studies have shown that C/EBP β cooperated 
with MYB or v-Myb in order to activate the mim-1 gene through binding to adjacent sites on the 
mim-1 promoter (Burk et al., 1993, Chayka et al., 2005).  
 
3.4 MYB regulation 
The expression and activity of MYB is regulated by various transcriptional, 
post-transcriptional and post-translational modifications.  
3.4.1 Transcriptional elongation control 
MYB transcription is regulated by elongation control (Bender et al., 1987, Castellano et al., 
1992, Yuan, 2000). Hugo et al. (2006) found MYB transcription attenuation occurred at a region in 
the first intron, approximately 1.7 kb downstream of the promoter. This region of MYB contains two 
motifs which are responsible for a blockade in the elongation of MYB transcription (Castellano et al., 
1992). The first of these motifs is a polyT tract of 19-22 residues (Thompson et al., 1997). This 
polyT tract is preceded by a second sequence that potentially encodes a transcript capable of 
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forming a stable RNA stem loop sequence (Thompson et al., 1997, Hugo et al., 2006). It has been 
proposed that this polyT tract leads to RNA polymerase II stalling and that the generation of an 
RNA stem loop that serves as a docking site for specific RNA binding proteins involved in 
elongation control (Ramsay and Gonda, 2008), such as positive transcription elongation factor b 
(P-TEFb) (Fujita et al., 2008). In colon cancer, the deletion of the polyT tract or RNA stem loop 
region resulted in an increase in transcriptional read-through compared with the wild-type sequence 
(Hugo et al., 2006). In MCF-7 breast cancer cells, oestrogen bound ERα is recruited to the 
transcription pausing site along with P-TEFb (CDK9/CyclinT1) to release transcription attenuation, 
as illustrated in Figure 1.7 (Drabsch et al., 2007, Mitra et al., 2012).  
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Figure 1.7: Model for oestrogen-mediated relief of MYB transcription elongation pausing 
(adapted from Mitra et al., 2012). In the absence of oestrogen, transcription is paused at the SL-dT 
region in MCF-7 cells. In the presence of oestrogen, the ER α/CyclinT1/CDK9 complex is recruited 
to the attenuation (SL-dT) region. Subsequently, this complex phosphorylates the Ser-2 residue of 
RNA Pol II to allow resumption of elongation. 
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3.4.2 MYB regulation by microRNA 
 A microRNA (miRNA) is a single stranded and endogenous ~22nt RNA. It can 
post-transcriptionally regulate gene expression by base-pairing to target mRNAs, leading to their 
cleavage or translational repression (Bartel, 2004). Xiao et al. (2007) found that miR-150 controlled 
B-cell differentiation by targeting MYB-encoded mRNA. Further studies also identified that 
MYB-encoded mRNA was a critical target of miR-150 in the differentiation of 
megakaryocyte-erythrocyte progenitors (Lu et al., 2008). Ectopic expression of miR-150 in breast 
cancer and leukaemia has been found to inhibit endogenous MYB at mRNA and protein levels (Lin 
et al., 2008). MYB is also the target of the dleu2 tumour suppressor locus that encodes two 
microRNAs, miR-15a and miR-16 (Chung et al., 2008).  
3.4.3 Post-translational modification  
The expression and activity of MYB is also regulated by post-translational modification 
including include phosphorylation, acetylation, ubiquitination and sumoylation (Sramko et al., 
2006). MYB has numerous phosphorylation sites and some of these sites seem to be of functional 
importance. For example, serine-11 and serine-12 (at the N-terminus of MYB) have been mapped 
as in vivo phosphorylation sites that can be modified by casein kinase II (CKII) in vitro (Luscher et 
al., 1990). Phosphorylation of these two serine residues was reported to reduce the DNA-binding 
activity of MYB (Luscher et al., 1990). In contrast, a second report showed that phosphorylation of 
serine 11/12 (using a shorter form of MYB that lacks the entire carboxyl terminus) by CKII 
increases DNA-binding activity (Ramsay et al., 1995). It was suggested that CKII potentially 
regulates MYB function through phosphorylation at the N-terminal domain [reviewed in (Ganter 
and Lipsick, 1999)]. However, mutation of the CKII sites did not result in oncogenic transformation 
in vitro or in vivo (Dini and Lipsick, 1993, Jiang et al., 1997). In addition, 8 potential sites of 
phosphorylation by MAP kinases (that are conserved between the avian, murine, and human MYB) 
are clustered in or near the C-terminal negative regulatory domain of MYB (Aziz et al., 1993). For 
example, a p42MAPK phosphorylation site was identified in avian and murine MYB (at serine-528 in 
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the C-terminal negative regulatory domain) (Aziz et al., 1993). Substitution of serine-528 with 
alanine caused a 2- to 7-fold increase in the ability of MYB to transactivate a MYB-responsive 
promoter/reporter gene construct (Aziz et al., 1995). This implied that phosphorylation at 
serine-528 in the C-terminal negative regulatory domain may provide a mechanism to regulate 
MYB function (Aziz et al., 1995).  
    A previous study reported that MYB is also a protein that is functionally regulated by 
acetylation at the C-terminal conserved domain in vitro and in vivo (Tomita et al., 2000). 
Acetylation at the lysine residues of the conserved domain (K438, K44, K471, K480 and K485) by 
CBP/p300 increases in DNA binding activity of MYB (Tomita et al., 2000, Sano and Ishii, 2001). 
Furthermore, CBP-induced acetylation also increases MYB transactivation ability by enhancing its 
association with CBP (Sano and Ishii, 2001).  
    Steady state level of MYB plays an important role in proliferation and differentiation of 
hematopoietic cells [reviewed in (Introna et al., 1994)]. MYB has a short half-life (approximately 
50  minutes), after which is rapidly degraded by the ubiquitin-26S proteasome pathway (Bies and 
Wolff, 1997). An E3 ubiquitin ligase (Fbw7) facilitates ubiquitylation and degradation of MYB in 
vitro (Kanei-Ishii et al., 2008, Kitagawa et al., 2009). The C-terminal truncation mutant of MYB 
(CT3-MYB) results in the increased resistance to ubiquitin-mediated proteolysis (Bies and Wolff, 
1997, Feikova et al., 2000) and enhances cell proliferation of hematopoietic cells (Corradini et al., 
2005).  
    Sumoylation is a reversible process of post-translation modification of proteins with small 
ubiquitin-like modifiers (SUMO) (Matunis et al., 1996, Mahajan et al., 1997). Four SUMO proteins, 
designated SUMO-1 to SUMO-4, were found in mammals [reviewed in (Wilkinson and Henley, 
2010)]. SUMO modification of MYB that can affect its activity has been divided into distinct 
groups. The first group was reported that SUMO modification of MYB by covalent attachment of 
the small ubiquitin-related protein (SUMO-1) enhances its stability and is shown to reduce its 
transactivation function (Bies et al., 2002, Dahle et al., 2003). The second group was reported that 
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conjugation of two other members of the SUMO protein family (SUMO-2 and SUMO-3) to MYB 
also suppresses its transcriptional activity under different cellular stresses (e.g. oxidative stress) 
(Sramko et al., 2006). Two major sites of sumoylation (lysine 499 and lysine 523) were identified in 
the negative regulatory domain of MYB (Bies et al., 2002, Sramko et al., 2006). 
 
3.5 MYB-regulated genes  
   MYB, acting as a transcription factor, can regulate many cellular genes. Genes have MYB 
binding sites within proximal promoter region or other regions of genes that can be activated by 
MYB directly (Zhao et al., 2011). Others are repressed by MYB directly or appear to be regulated 
by indirect mechanisms.  
3.5.1 MYB-activated genes  
MYB is expressed in normal tissue such as bone marrow and mammary glands and in cancer 
cells such as leukaemia and breast cancer (Ramsay and Gonda, 2008). A number of potential MYB 
target genes have been identified by microarray and chromatin immunoprecipitation (ChIP) assays 
(Lorenzo et al., 2011, Lei et al., 2004, Yan et al., 2011, Quintana et al., 2011). The first bona fide 
MYB-activated gene to be disclosed was mim-1, which is directly regulated by MYB in 
combination with C/EBP β (Burk et al., 1993, Chayka et al., 2005). MYB-activated genes can be 
divided into three broad functional groups: housekeeping genes, such as MAT2A (methionine 
adenosyltransferase 2a) and GSTM1 (glutathione S-transferase M1); genes that are involved in the 
specific functions of particular differentiated cell types or lineages, such as ELA2 (neutrophil 
elastase 2), MIM1, CD4 and PTCR α (pre-T-cell receptor-α); and genes that might be associated 
with oncogenicity. This last group can be further distinguished into: genes that are linked to survival, 
including BCL2 (B-cell lymphoma 2), HSPA5 (heat shock protein A5; also known as GRP78) and 
HSP70; and genes that are linked to cell proliferation – such as CCNA1 (cyclin A1), CCNB1, 
CCNE1, MYC and KIT; and genes associated with cell differentiation such as GATA3 (Ramsay and 
Gonda, 2008). A study with human erythroleukemic cell line K562 (a pluripotent precursor that can 
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differentiate towards erythrocytes, megakaryocytes, and macrophages) also found MYB-activated 
genes, including genes encoding haematopoiesis-related transcription factors (STAT5A, GATA2, and 
IKZF1) and genes crucial for myeloid differentiation (LMO2 and MYADM) (Lorenzo et al., 2011). 
A previous report from the Gonda laboratory found 1171 MYB-activated genes including 418 genes 
directly activated by MYB in an engineered ERMYB myeloid progenitor cell line expressing a 
truncated ER-MYB fusion protein (Zhao et al., 2011). These MYB-activated genes include BCL2, 
CXCR4, PDCD4 and IFNGR1 which are responsible for cell survival during oncogenesis, and GFI1, 
MPO and MYC which play important role in cell differentiation (Zhao et al., 2011).  
3.5.2 Indirect mechanisms of gene regulation by MYB 
MYB can influence gene regulation via indirect mechanisms. For example, MYB can 
transactivate AP-1 of the Epstein-Barr virus (EBV) BMRF1 promoter by cooperating with an EBV 
gene product (BZLF1) even though no MYB binding site was identified (Kenney et al., 1992). 
Another study also found that MYB was able to activate the human HSP70 gene promoter even 
though no MYB binding sites were identified (Kanei-Ishii et al., 1994). A further study reported 
that MYB could activate VEGF without binding with its promoter (Lutwyche et al., 2006). This was 
suggested to occur via Sp1 binding elements in the VEGF promoter.  
 
3.5.3 MYB-repressed genes 
MYB can also function as a transcriptional repressor. For example, MYB expression is able 
to repress transcription from the c-erbB-2 promoter (Mizuguchi et al., 1995). MYB can also result 
in the repression of c-fms expression via binding to a site upstream of the c-fms promoter, but not 
depend on transcription competition (Reddy et al., 1994). In addition, MYB can repress the 
promoter of the plasma membrane Ca2+/ATPase-1 (pmca1) promoter in rat and mouse vascular 
smooth muscle cells (Afroze and Husain, 2000). Zhao et al. (2011) identified approximately 1197 
MYB repressed genes including 375 genes directly repressed by MYB. These direct MYB 
repressed genes include CEBPB, JUNB, RUNX1, GATA3 and SFPI1 that are positive regulators of 
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haematopoietic differentiation (Zhao et al., 2011). A recent study also reported that MYB could 
directly repress DRAK2 expression – which encoded a pro-apoptotic death receptor-associated 
protein kinase (DRAK2) – in acute myeloid leukaemia cells (Ye et al., 2013).  
 
3.6 Cellular functions of MYB  
3.6.1 Regulation of cellular proliferation 
To investigate the role of MYB in cellular proliferation, anti-sense oligonucleotides have been 
employed. The anti-sense inhibition of MYB expression in normal human bone marrow cells 
(Gewirtz and Calabretta, 1988b, Luger et al., 2002) and leukaemia cells (Opalinska et al., 2005) 
decreased both colony size and number. Furthermore, MYB anti-sense oligonucleotides inhibited T 
cell and colorectal cancer proliferation and led to cell cycle arrest at the late G1 or early S phase 
(Gewirtz and Calabretta, 1988a, Abaza et al., 2003). This evidence supports the proposition that the 
MYB oncogene is required to regulate the cell proliferation and cell cycle progression of 
haematopoietic and colorectal cancer cells.  
3.6.2 Suppression of cellular differentiation 
As haematopoietic cells differentiate, MYB expression is downregulated (Westin et al., 1982, 
Gonda and Metcalf, 1984). Overexpression of MYB blocks the differentiation of immature myeloid 
and erythroid cell lines (Weston, 1998). It is unlikely that MYB simply functions as a proliferative 
stimulus, regulating a switch between proliferation and differentiation, as these two processes are 
not mutually exclusive (e.g. see (Kastan et al., 1989)). The role of MYB in terminal differentiation, 
which results cells in staying in the G0 phase and no longer proliferating, has been intensely studied. 
Several studies have shown that the expression of MYB is predominant in immature haematopoietic 
cells and is downregulated during the terminal differentiation of these cells (Westin et al., 1982, 
Golay et al., 1996, Jieping et al., 2007). Furthermore, the down-regulation of MYB is also found in 
cytokine or chemically-induced differentiation of myeloid cells or erythroid leukaemia cells (Gonda 
and Metcalf, 1984, Schmidt et al., 2001, Kuehl et al., 1988), and in the retinoic acid-induced 
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differentiation in human neuroblastoma cell lines (Thiele et al., 1988).  
From the above studies, it is clear that MYB expression induces cell proliferation and blocks the 
differentiation of haematopoietic cells. Several studies have tried to clarify the signals required for 
terminal differentiation that is caused by the down-regulation of MYB. In one study, when the M1 
myeloid cells were exposed to differentiation inducers (IL-6 or leukaemia inhibitory factor) to 
induce terminal differentiation, only the decreased MYB expression occurred. This suggests that the 
down-regulation of MYB is required for terminal differentiation (Hoffmanliebermann and 
Liebermann, 1991).  
Gene knockout in transgenic mice is another strategy to determine MYB function. In MYB 
knockout mice, the disruption of the MYB locus resulted in embryonic lethality (Mucenski et al., 
1991). The homozygous mutant mice appeared normal at day 13 of gestation, but those mice were 
severely anemic and resulted in death by day 15. This suggests that MYB is not required for early 
development. Further analysis of different stages of in utero development found that embryonic 
erythropoiesis – which occurs in the yolk sac – was not diminished by the MYB abrogation. 
However, the adult-type erythropoiesis – that first occurs in the fetal liver – was greatly impaired in 
MYB mutant mice. Other haematopoietic lineages were found to be similarly affected except for no 
change in megakaryocyte cell number. 
3.6.3 Apoptosis 
Cell numbers are controlled by a balance between proliferation, growth arrest, and programmed 
cell death (apoptosis). The above-mentioned studies showed that MYB could regulate cell 
proliferation and differentiation in blood cells. In one study with M1 myeloid leukaemia cells, the 
deregulated expression of MYB inhibited growth arrest and accelerated TGF β1-induced apoptosis 
that was correlated with the level of MyD118 expression (Selvakumaran et al., 1994). In another 
study, the inhibition of MYB resulted in a significant proportion of the cell population undergoing 
apoptosis, but had no apparent effect of cell-cycle progression in the murine thymoma cell line EL4. 
This inhibition of MYB was correlated with the down-regulation of BCL2 (Taylor et al., 1996, Yi et 
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al., 2002). Further analysis of the BCL2 promoter by run-on transcription, band shifting, and 
transient expression assays indicated that it was a direct target of MYB (Taylor et al., 1996, Yi et al., 
2002). An MYB binding protein, called c-Maf, interacted with MYB to reduce BCL2 expression 
and increase apoptosis in CD4 T cells (Peng et al., 2007).  
 
3.7 MYB in cancer 
  Early studies with murine myeloid tumours that were caused by leukaemogenic retroviruses 
have indicated that MYB expression is involved with the development of myeloid tumours. For 
instance, the Abelson leukaemia virus-induced plasmacytoid lymphosarcomas (ABPL tumours) 
were generated in BALB/c mice following the injection of pristane and a mixture of Abelson 
leukaemia virus and Moloney murine leukaemia virus (Mo-MuLV). These ABPL tumours 
contained a rearranged MYB locus (Mushinski et al., 1983, Shen-Ong and Wolff, 1987, Shenong et 
al., 1984), resulting from the integration of the Mo-MuLV genome into a 1.5 kb stretch of cellular 
DNA in the third exon of the MYB, which in turn resulted in the synthesis of aberrant mRNA 
transcripts lacking the 5’ MYB-coding sequences. MYB rearrangements were also found in human 
melanoma with a translocation in the chromosome 6q22 region (Dasgupta et al., 1989) and in 
human T cell acute lymphocytic leukaemia with a translocation in the chromosome 6q23 region 
(Jacobs et al., 1994, Clappier et al., 2007, Murati et al., 2009). MYB rearrangements play essential 
role in leukaemia (Zuber et al., 2011, Pattabiraman and Gonda, 2013).  
In colon cancers, robust mRNA expression accompanying MYB gene amplification was found 
in two cell lines derived from metastatic colon carcinomas (Alitalo et al., 1984, Winqvist et al., 
1985). Mutations in the MYB intron 1 regulatory sequence have also been shown to increase 
transcription in colorectal cancers (Hugo et al., 2006). With the advent of mRNA profiling, it has 
become clearer that MYB is over-expressed in colorectal cancer (>80% of cases) (Su et al 2001) 
and is associated with poor prognosis for patients (Biroccio et al., 2001).  
3.7.1 MYB and breast cancer 
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An early study showed that 64% of breast tumours expressed MYB and that MYB expression 
correlated strongly with the presence of ER (Guerin et al., 1988, Guerin et al., 1990). Subsequent 
studies have been conducted to investigate the role of MYB expression in sporadic breast cancers 
(Drabsch et al., 2007, Fang et al., 2009, Iddawela et al., 2012). Oestrogen can promote cell 
proliferation and regulate MYB expression through ER α in human ER+ breast cancer (Anderson et 
al., 2002, Frasor et al., 2003, Drabsch et al., 2007). When ER+ breast cancer cells were treated with 
MYB anti-sense oligonucleotide or MYB shRNA, cell proliferation was inhibited (Drabsch et al., 
2007). These data imply that MYB is involved in cell proliferation in human ER+ breast cancer cells.  
A previous study from the Gonda laboratory found that the down-regulation of MYB expression 
promotes the chemically-induced differentiation and apoptosis in the human breast cancer cell line 
MCF-7, as well as the hormonally-induced differentiation of a non-tumourigenic murine mammary 
epithelial cell line, HC11 (Drabsch et al., 2010). In addition, overexpression of MYB up-regulates 
BCL-2 expression and protects mammary carcinoma cell lines from chemically-induced apoptosis 
(Drabsch et al., 2010). 
 In a mouse xenograft model, MYB knockdown by inducible RNA interference suppressed 
tumour growth (Miao et al., 2011). Mammary specific MYB deletion by gene targeting abolished 
tumour formation in mouse mammary tumour virus (MMTV)-NEU transgenic mice (Miao et al., 
2011). These data suggested that MYB is required for mammary tumour development (Miao et al., 
2011). However, another study found that MYB knockdown using RNA interference in ER+ breast 
cancer cell line (MCF-7) increased tamoxifen resistance and colony formation (Thorner et al., 2010). 
This was also found in an animal study, where MYB-depleted MCF-7 cells injected into nude mice 
grew significantly faster than MCF-7 controls (Thorner et al., 2010). These data are contradictory to 
the Gonda laboratory’s findings (Drabsch et al., 2007, Miao et al., 2011). Thus, the role of the MYB 
oncogene in human breast cancer requires further study.  
Several studies have identified the presence of ER expression in metastatic tumours (Zheng et al., 
2001, Harrell et al., 2006). ER regulates the promoter of metastasis tumour antigen (MTA) 3 that 
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represses Snail – a gene implicated as a regulator of epithelial to mesenchymal transitions (Fujita et 
al., 2003). Expression of Slug (SNAI2, Snail2) – one of the Snail family of transcription factors – is 
required for tumour invasion (Tanno et al., 2010). Slug expression is controlled by MYB (Tanno et 
al., 2010). Furthermore, the TGFβ-mediated MYB expression controls the expression of 
EMT-associated genes and promotes the invasion of ER+ breast cancer cells (Cesi et al., 2011, 
Hugo et al., 2013). Moreover, MYB up-regulates cathepsin D to contribute to cell migration and 
invasion in human breast cancer cell line MDA-MB-231 (Knopfova et al., 2012). This evidence 
shows MYB may be involved in breast cancer metastasis.  
In addition, several MYB target genes, including BRCA1 (a DNA damage response gene), 
NANOG (a cancer stem cell-related gene), CCNB1 (which is involved in cell cycle), CXCR4, JUN, 
KLF4, MYC (which are associated with oncogenicity) (Quintana et al., 2011), BCL2 (which is 
involved in cell survival) (Drabsch et al., 2010) and CXCL12 (which is involved in metastasis and 
angiogenesis) (Chen et al., 2010), were identified in human breast cancer MCF-7 cells. However, 
the role of MYB target genes in breast cancer stem cells is still understudied.  
3.7.2 MYB and DNA damage responses 
   There is very little information on MYB function in the DNA damage response of ER+ breast 
cancer cells. However, several DNA damage response genes including ATM, TOPBP1, RAD51, 
RAD50, XRCC6, XRCC1, FANCD2, FANCJ were identified as MYB target genes (Quintana et al., 
2011). In addition, an early study showed that overexpression of MYB and MYC was found on 
ataxia-telangiectasia lymphoblastoid cell lines (Fiorilli et al., 1985). Ataxia-telangiectasia 
lymphoblastoid cell lines were derived from two patients with ataxia-telangiectasia (Le 
Francois-Chabas and Montagnier, 1983). Ataxia-telangiectasia was resulted from ATM mutation. 
ATM is an important mediator of cell cycle checkpoint pathway in response to DNA double-strand 
breaks in cells (Ding et al., 2004). ATM is required for phosphorylation of BRCA1 in response to 
ionizing radiation-induced DSBs (Cortez et al., 1999, Gatei et al., 2000). BRCA1 is a nuclear 
protein with a cell cycle-regulated expression pattern (Somasundaram, 2003). It is 
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hyperphosphorylated in response to DSBs. BRCA1 can interact with DNA repair factors to form a 
BRCA1-associated genome surveillance complex (BASC) that contains proteins involved in 
mismatch repair (MSH2, MSH6, and MLH1), DSB repair (ATM and the MRE11/RAD50/NBS1 
(MRN) complex), DNA replication (RFC), and recombination (BLM) (Wang et al., 2000). 
Phosphorylated BRCA1 can recruit RAD51 recombinase to the sites of DNA damage and then 
activate RAD51-mediated homologous recombination repair of DSBs (Cousineau et al., 2005). In 
addition, BRCA1 is involved in NHEJ pathway through regulating MRN complex expression (Fu et 
al., 2003, Zhong et al., 1999).  Silencing of BRCA1, MYB, or TOPBP1 synergized with PARP 
inhibitors to increase prostate cancer cytotoxicity (Li et al., 2014). This cytotoxicity was resulted 
from DNA damage. MYB is involved in DNA damage repair through modulating MiR-143 in 
human nasopharyngeal carcinoma (Wang et al., 2015).  
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4 Research hypotheses, aims and significance 
The expression of MYB is positively associated with ER expression in human breast cancer. The 
role of MYB in breast cancer stem cells isolated from human ER+ breast cancer cells remains 
understudied. This thesis aims to provide a detailed view of MYB target genes in human ER+ breast 
cancer and to integrate the possible role of MYB in putative human breast cancer stem cells.  
4.1  Hypotheses   
I. MYB target genes are involved in cell proliferation, differentiation and apoptosis of 
human ER+ breast cancer cells.  
II. MYB and its target genes are involved in DNA damage response. 
III. Oestrogen regulates MYB expression in mammospheres derived from human ER+ breast 
cancer cells.  
IV. MYB knockdown influences the mammosphere-forming capacity of putative breast 
cancer stem cells. 
4.2 Aims 
4.2.1 Identify and validate MYB target genes in human ER+ breast cancer cells by using 
doxycycline (Dox)-inducible MYB shRNA and RNA-Seq gene expression profiling 
[Hypothesis I] [Chapter 3] 
4.2.2 Investigate the role of MYB and its target genes in DNA damage responses in human 
ER+ breast cancer cells [Hypothesis II] [Chapter 4] 
4.2.3 Grow mammospheres derived from human ER+ breast cancer cell lines and examine 
MYB expression of mammospheres [Hypothesis III] [Chapter 5] 
4.2.4 Test mammosphere-forming capacity of putative human ER+ breast cancer stem cells 
expressing inducible MYB shRNA [Hypothesis IV] [Chapter 5]  
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4.3 Significance 
This thesis will make three contributions of significance as follows:  
1) Understanding of how MYB and its target genes contribute to control cell proliferation 
and DNA damage response in human ER+ breast cancer  
2) These genes may be used to develop specific therapeutics;  
3) Understanding the potential role of MYB and its target genes in cancer stem cells 
derived from human ER+ breast cancer.  
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Chapter 2- Materials and Methods                           
2.1 Materials 
2.1.1 General chemicals and reagents 
• Acrylamide/ Bisacrylamide 19:1 solution – Amresco Inc. USA 
• Ammonium persulphate – Sigma-Aldrich, USA (A9164)  
• TEMED – BioRad, USA (161-0800) 
• 20% (w/v) sodium dodecyl sulfate (SDS) solution – BioRad, USA (161-0418) 
• Complete protease inhibitor cocktail – Roche Applied Sciences, Switzerland 
• Agarose – Amresco Inc. USA 
• DTT (dithiothreitol) - Fluka Chemie GmbH, Deisenhofen, Germany 
• 2-mercaptoethanol – Sigma-Aldrich, USA (M6250-100ML) 
• ECL detection kit – Pierce, Thermofisher Scientific, USA (Product # 32106) 
• Trizma base – Sigma-Aldrich, USA (T1503) 
• Quick Start™ Bradford dye reagent 1X – Bio-Rad, USA (500-0205) 
• Ethylenediaminetetra-acetic acid (EDTA) – Sigma-Aldrich, USA 
• Glycine – Ajax Finechem, Australia 
• Tween 20 – Ajax Finechem, Australia 
• Methanol – Ajax Finechem, Australia 
• Ethanol – Ajax Finechem, Australia 
• Tryptone – Oxoid Ltd, UK 
• BBL Yeast extract – BD, USA 
• Ampicillin – Sigma-Aldrich, USA 
• dNTPs – Fermentas Inc., USA 
• Dimethyl sulfoxide (DMSO) – Sigma-Aldrich, USA 
• Trypan Blue – Life Technologies, USA 
• Polybrene – Sigma-Aldrich, Castle Hill, NSW, Australia 
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2.1.2 Buffers and solutions 
2.1.2.1 Establishment of inducible MYB shRNA vectors 
• DNA purification (mini) Kit: Invitrogen, USA 
• DNA purification (Heidari Majd et al.) Kit: Invitrogen, USA 
• DNA gel extraction Kit: Invitrogen, USA 
• DNA 1kb Ladder purchased from Fermentas Inc., USA 
• DNA 100bp Ladder purchased from Fermentas Inc., USA 
• LB broth: 1% Bacto-tryptone (w/v), 0.5% yeast extract   
      (w/v), 1% NaCl (w/v), adjusted to pH 7.0 with NaOH 
• LB agar: Made by adding 2.0% Bacto-agar (w/v) to the LB broth 
2.1.2.2. Gene and protein expression 
• PureLink RNA Mini Kit: Invitrogen, USA 
• High capacity cDNA synthesis kit: # 4368814 Applied   
Biosystems, USA 
• SensiMix SYBR® & Fluorescein Kit: QT615-05  
Bioline, New Zealand 
• 	   	   	   TruSeq stranded total RNA library (with Ribo-­‐Zero GOLD) Pre kit:  
   Illumina, USA 
• Quick Start™ Bradford dye reagent: Biorad, USA 
• Prestained protein molecular weight standards from  
Fermentas Inc., USA, NEB, USA 
• 1x TAE: 40mM Tris, 20mM Acetic acid, 0.9mM EDTA orthophosphate, pH 7.2 
• 4x SDS-PAGE loading buffer: 125mM Tris, 20% glycerol  
(v/v), 4% SDS (w/v), 0.001% Bromophenol blue (w/v),  
      adjusted to pH 6.8 with HCl 
 47 
• TE Buffer: 10mM TrisHCl pH 7.5, 0.1mM EDTA 
• 2% SDS-PAGE lysis buffer: 50mM Tris.HCl pH 6.8, 2% SDS,  
10mM sodium fluoride (serine-threonine phosphatase inhibitor) 
• 10x Running Buffer for SDS-PAGE (Laemmli Buffer): 250mM Tris, 1.92M 
Glycine, 1% SDS 
• 10x Towbin's Protein Transfer Buffer: 250mM Tris, 1.92M Glycine, 0.37% SDS 
• 10x Tris buffered saline (TBS): 250mM Tris, 1.5M NaCl 
• Western Blot Stripping buffer: 50mM Tris.HCl pH6.8, 2%SDS, 100mM 
β-mercaptoethanol 
2.1.2.1 Cell culture 
• Dulbecco’s modified Eagle’s medium (DMEM): Life Technologies, USA 
• Fetal bovine serum (FBS): Thermo Scientific HyClone, Australia  
• L-glutamine and insulin: Sigma-Aldrich, Castle Hill, NSW, Australia 
• Non-essential amino acids and sodium pyruvate: Invitrogen, New Zealand 
• Human MammoCult™ basal medium and proliferation supplements: STEMCELL 
Technologies; cat# 05621 and 05622, USA 
• 1X phosphate-buffered saline (Chen et al.): 0.13 M sodium chloride (NaCl), 14mM 
di-sodium hydrogen rthophosphate (Na2HPO4) and 3.5mM sodium dihydrogen 
orthophosphate (NaH2PO4) 
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2.1.3 Cell lines 
  MCF-7 
  MCF-7 human breast cancer cells, a stable cell line derived by pleural effusion from human 
breast adenocarcinoma, were provided by Professor Greg Monteith’s laboratory in the School of 
Pharmacy, UQ. Normally, MCF-7 cells were cultured in DMEM (pH 7.4) containing Phenol Red 
and supplemented with 10% FBS, 2mM L-glutamine, insulin (50µg/mL), non-essential amino acids 
(0.1mM), and sodium pyruvate (1mM). Cells were grown at 37°C in a humidified incubator with an 
atmosphere of 95% air and 5% carbon dioxide (Drabsch et al., 2007)  
 
  HEK293T 
  Human embryonic kidney cell line (HEK 293T) (2 × 106) was cultured in DMEM containing 
10% FBS, 2mM L-glutamine and 1mM sodium pyruvate at 37°C in 25 cm2 flasks. 
 
2.1.4 List of lentiviral and retroviral plasmids for transfection of 293T cells  
Lentiviral plasmids 
• pMDLg/pRRE (Gag Pol) 
• pRSV (Koboldt et al.)   
• pMD.G (VSV-G) 
• pINDUCER11 vector 
• TransLenti Viral Packaging Mix 
Retroviral plasmids 
• pTRMPVIR vector 
• pEQ-PAM3 
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2.1.5 Enzymes 
• Restriction enzymes, including Xho I, EcoRI and Mlu I, were purchased from New England 
Biolabs, USA; 
• T4 DNA ligase purchased from Thermo Scientific, USA. 
• DNase I- Thermo Scientific, USA 
 
2.1.6 List of constructs used 
Lentiviral plasmids 
• pLV711MYB shRNA C4, C5 and nonsilencing control – Already present in the laboratory 
(Drabsch et al., 2007, Brown et al., 2010) 
• pGIPZ-MYBshRNA 378022, 378024 and 411110 were purchased from Open Biosystems. 
• pINDUCER11(miR-RUG) was obtained from Dr Hu’s laboratory (Meerbrey et al., 2011). 
• pINDUCER11MYBshRNA 378022, 378024 and 411110 were obtained by cloning 
pGIPZ-MYBshRNA into pINDUCER11(miR-RUG) vector by restriction digestion and 
ligation. 
Retroviral plasmds 
• pTRMPVIR MYBshRNA 721 and 2847 were obtained by cloning 
pT3G-TurboGFP-miRE.MYBshRNA into pTRMPVIR-miRE.Ren.713 vector by restriction 
digestion and ligation (Zuber et al., 2011). 
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2.1.7 List of primers used 
Table 2.1.7.1 Primers for real time-PCR use.  
Name Primer Sequence  
GAPDH  
 
Forward 
Reverse 
CGCTCTCTGCTCCTCCTGTT 
CCATGGTGTCTGAGCGATGT 
 
 
MYB  
 
Forward 
Reverse 
GCCAATTATCTCCCGAATCGA 
ACCAACGTTTCGGACCGTA 
	  
BCL2  
 
Forward 
Reverse 
TCCCTCGCTGCACAAATACTC 
ACGACCCGATGGCCATAGA 
	  
ER α  Forward 
Reverse 
AGCACCCTGAAGTCTCTGGA 
GATGTGGGAGAGGATGAGGA 
	  
 
 
Table 2.1.7.2 Primers for Sanger sequencing. 
 Name Primer Sequence  
pINDUCER11seq5-F  
 
Forward 
 
CACATACAGATCCAAGAAAC   
 
Amp-R-seq Forward 
 
ATAATACCGCGCCACATAGC 	  
DsRed1-C Forward 
 
AGCTGGACATCACCTCCCACAACG 	  
pLV711-GGGG-attB2 Forward GGGGACCACTTTGTACAAGAAA 	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Table 2.1.7.3 Primers for RNA-Seq validation by real time-PCR. 
 
Gene	  name	   Primer (Forward:5'->3') Primer (Reverse:5'->3') 
ALDH1A3 GATAAGCCCGACGTGGACAA ATACAGCCCTCCAGGTCGAT 
BAX CATGGGCTGGACATTGGACT AAAGTAGGAGAGGAGGCCGT 
CACNA1D ACAGGCGGGATTAAGGACAC CTGAGTCGGACCTTTTCACACT 
CCNT1 TGGTGGGAGTATGTTGACGC GCCCTCCAATTCCAAATGCG 
CDH3 GAGATTGGGTGGTTGCTCCA CCAAAGAGCTGTGGGGTACA 
CEP164 TCCACATCAGCCTCTGTAGATGA GGGGCTAATGAGGAACCCAA 
CHTOP TCAGACAAGCACTGGACGTG TGACATCCCGCCCCTAAGTA 
CLEC3A CAACATGGCTCAGCAGGCTT TTGGAGGGCGTTGATTTCGT 
COPS7B GTGGATTTCTGCATTGGCCG TCACGTTTTTCCCTCTCTGCT 
CSRNP2 CGGATCCTATTGTTAGCCGGAG ACTGATGAGCCCACATCCAC 
ESAM CTTCCAGCGTGGTACACCTT GGCCCCTAGATTTGCCTTGT 
FOXC1 TCACAGAGGATCGGCTTGAAC TCCTGCTTTGGGGTTCGATT 
GHR TGATCAGAGGCGAAGCTCGG CTCCAGGGTGCTCTGCTAAG 
ITGAV GTCTTTCTACCTCTGCCTCACA CGAGAAGAAACATCCGGCAC 
KDM2A GTGACGCAGCAGCATTGTTC AACCGTGGAGCTGGTTTCAT 
MAML3 CAGAGGAACCACACGCTGAT ACATGTGCGAAGGGAGAGTG 
TRIM13 CTAGCCGGAGTAGCCTCTAGT AGGCAAAACCCGTGGATCAT 
WBP11 AAACAGCGCATGATGGTTCG TTGGAAGGAGCATGTGGCAT 
ZBTB2 TGCACTAGTCTCTCCGCTCT CGGGCTGTATGTCAGTTGGT 
ZKSCAN8 CCGTGCCACAACTCCAAAAA GCTGAGACTGGTCGTCCT 
ZMYND8 TAAGGAGCAGGATGGACGGA TCTCGTTTTTGGCAAGCAGC 
ZNF436 CCCAGTGCTCGACTTCCATT CCATCTCGAGCACAAGGGTT 
ZNF721 TTTTGCCAGTGCAGGGGATA TCCCTTCTGCACTTTACACACG 
PTPRF TTTGATGATGGGGCAGGGTC TTCGCAGGGGCTGAGTAAC 
STK17A CCTGGTTGACACAGAGCAGT CCATTTGGCCAGAGGTCCAT 
RAD1 GCTGAAGTGCTCACGGCT GAGAGCCCTTCTCAGCAAAGT 
RAD51AP2 TCGCTGTCATGTCTCTCCCT TCCCAGACTTTTTCCGCCTC 
XRCC3 AGCCAGGCCTGTTAAACCAA GGCTGACTTGACTGAGGCAT 
XRCC6 TGCGTGGATTGTCGTCTTCT TGGATACACACTTGCTTCAAGG 
ESR1 TGGGAATGATGAAAGGGATACGA TCTCCACCATGCCCTCTACA 
BCL2L15 CTTCGGATGTTGGGTGACCA AGCTGGAATCCTGAGCACAC 
FANCA GAAGAGGCCTTCCTGCATGT TATCAGTTCCACGGGGTTGC 
FANCE CAGATGGACTTGCTGTGTGC AGGTCAGGGCAGTTGTAAGC 
E2F3 CCTTACAGCAGCAGGCAAAG TCTGGAGGGGCTTTCACAAC 
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Table 2.1.7.3 Primers for RNA-Seq validation by real time-PCR (continued). 
 
Gene	  
name	   Primer (Forward:5'->3') Primer (Reverse:5'->3') 
BMP4 TTGTCTCCCCGATGGGATTC TGAAGCCGGTAAAGATCCCG 
CCNB3 CCAAGGGAACACCAAAGGAGAT AGTCCACAAGAATGGCCCTC 
GDF9 TCTGGGGGAGAAGCTCAGAT GAACTTTGAAAAGCGCGGGA 
PLEKHA7 CGGGACACTTTACCTGAGCA TGCTGGACGGTCTTTGGTTT 
BRCA1 GATGGGACCTTGTGGAAGAA ACGACCAAACCAACACCAAT 
TOPBP1  TGCTTCATCGCTCCTACCTT ACCCACTAAATGCTCCCTCA 
18S rRNA GAGGTAGTGACGAAAAATAAC TTGCCCTCCAATGGATCCT 
β-tubulin  CTCTGAAGCTGACCACACCA GCCAGGCATAAAGAAATGGA 
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2.1.8 Antibodies 
Table 2.1.8 Antibodies for western blotting and immunostaining. 
Name Species Source Dilution 
Anti-MYB 1.1 Mouse Millipore, USA   1:500 
Anti-GAPDH 
 (v-18) 
Goat Santa Cruz 
Biotechnology, USA 
1:1000 
Anti-β-actin 
 
Mouse Santa Cruz 
Biotechnology, USA 
1:1000 
Anti-mouse IgG-HRP 
 (sc-2005) 
Goat Santa Cruz 
Biotechnology, USA  
1:5000 
Anti-goat IgG-HRP  
(sc-2020) 
Donkey Santa Cruz 
Biotechnology, USA 
1:5000 
Anti-BCL2 (C-2) Mouse Santa Cruz 
Biotechnology, USA 
1:1000 
Anti-human γ-H2AX Mouse Biolegend, USA 1:1000 
Alexa flour 594  
Anti-mouse IgG 
Goat Biolegend, USA 1:1000 
Anti-human RAD51 Rabbit Santa Cruz 
Biotechnology, USA 
1:1000 
Alexa flour 750  
Anti-rabbit IgG 
Donkey Biolegend, USA 1:1000 
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2.2 Methods 
2.2.1 Plasmids and bacteria   
2.2.1.1 Purification of plasmid DNA 
  Small-scale purification of plasmid DNA (less than 15µg) was carried out using the PureLink 
Quick Plasmid Miniprep Kit (Invitrogen Australia) kit in accordance with the manufacturer’s 
instructions. Midipreps (for 15-350µg plasmid DNA) were carried out using the Invitrogen 
midiprep kit (Invitrogen, USA) following manufacturer’s protocols. Concentration of DNA was 
determined by using the Nanodrop spectrophotometer (ND1000, Nanodrop technologies, USA) and 
the purity of the eluted plasmid was evaluated by the ratio of absorbance at 260 nm and 280 nm. 
 
2.2.1.2. Restriction enzyme digestion  
  These were normally conducted following the manufacturer’s instructions. Briefly, restriction 
enzyme digests were usually performed in a total volume of 20µL containing 10µg of plasmid DNA 
and usually a two to ten-fold excess of the enzyme (compared to DNA) with its appropriate buffer. 
The DNA/restriction enzyme mixture was incubated for at least 1.5 hours. The DNA was analysed 
alongside an appropriate molecular weight marker using 1% DNA agarose gel electrophoresis. The 
restriction digest gel analysis of the DNA was viewed on an ultra violet transilluminator and the 
images photographed using Polaroid film. 
 
2.2.1.3 Agarose gel electrophoresis 
  DNA was fractionated by electrophoresis in 1% agarose gels run for approximately 40 mins at 
100V. Gels were horizontally submerged in TAE buffer and DNA samples loaded with 2.5% Ficoll, 
0.1% lauryl sarkosyl, 0.025% bromophenol blue, and 0.025% xylene cyanol. 2µL of 10mg/mL of 
ethidium bromide solution was added to the agarose just before casting the gel to enable 
visualization on exposure to UV light. Gels were photographed by using AlphaImager HP system. 
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2.2.1.4 Isolation of DNA from agarose gels 
  Restriction enzyme digested DNA fragments were recovered from 1% agarose gels by using the 
Epi-UV plate illumination on the gel documenter (ProteinSimple, USA) and GeneRuler™ 1kb Plus 
DNA ladders and 100bp DNA ladders (NEB) to determine the correct position of the required 
fragment and then cutting it out with a scalpel blade. Isolation of DNA from the gel slice was 
performed using the PureLink® Quick Gel Extraction Kit (Invitrogen, USA) and the gel extraction 
protocol within. 
 
2.2.1.5 DNA ligation 
  Insert DNA was ligated into approximately 50ng linearized vector DNA in the presence of 1 unit 
of T4 DNA ligase (Thermo Scientific, USA) and ligation buffer (400mM Tris-HCl, 100mM MgCl2, 
100mM DTT, 5mM ATP) in a total volume of 20µL. The molar ratio of insert DNA over vector 
was 5:1. Ligation reaction was incubated at 22°C for 10 min.  
 
2.2.1.6 Bacterial cell transformation 
  α-Select Silver competent cells were used for transformation (Zane et al., 2010). α-Select Silver 
competent cells are directly comparable to E. coli DH5α cells. The genotype of α-Select Silver 
competent cells is F- deoR endA1 recA1 relA1 gyrA96 hsdR17 (rk -, mk +) supE44 thi-1 phoA 
Δ(lacZYA argF)U169 Φ80lacZΔM15λ-. Bacterial cell transformation was performed using the 
manufacturer’s instructions. Briefly, cell transformation was carried out by mixing low quantities 
(5ng) of DNA in 10µL of bacterial cell suspension and then incubated on ice for 30 minutes. After 
that, the contents of the tube were placed in 42°C water bath for around 30 seconds and then 
immediately replaced tubes on ice for 2 minutes.  The transformed cells were diluted to 1mL by 
addition of 990µL LB medium (2% Tryptone, 0.5% Yeast Extract, 0.4% glucose, 10mM NaCl, 
2.5mM KCl, 10mM MgCl2 & 10mM MgSO4) and then incubated them at 37°C for 60 min with fast 
shaking at 200 rpm.  Cell mix (100µL) was placed onto LB agar plates containing selection 
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antibiotics (100 µg/mL Ampicillin) and incubated overnight at 37°C. 
 
2.2.1.7 DNA sequencing 
   Plasmid sequencing was serviced by the Australian Genome Research Facility (AGRF). Briefly, 
sequencing reactions are performed using ABI Prism BigDye Terminator Sequencing reaction kits 
by using 200-500ng of double stranded plasmid DNA along with 1µL of BDT, 5X BDT buffer, 3.2 
pmol of appropriate primers and Milli Q water to make up to 20µL. The reactions were performed 
in a thermal cycler as follow: incubation at 96°C for 2 minutes, followed by 30 cycles of 96°C for 
10 seconds, 50°C for 5 seconds and 60°C for 4 minutes, with a final hold at 4ºC. 
  The clean-up of sequencing reactions was performed using the magnesium sulphate protocol 
whereby 75µL of 0.2mM MgSO4 was added to the reactions, incubated for a minimum of 15 
minutes at room temperature followed by centrifugation at top speed on a table top centrifuge for a 
minimum of 15 minutes. Supernatants were discarded and the pellet allowed air-drying for 20 
minutes after which they were sent off to AGRF, University of Queensland. Sequence analysis on 
return was performed using two software packages – Sequencher DNA software version 4.1.4 
(Gene Codes Corporation, USA) and DS gene (Discovery studios, USA). 
 
2.2.2 Gene and protein expression 
2.2.2.1. Real-time Quantitative PCR 
  Total RNA was extracted from cells by using the PureLink RNA Mini Kit (Invitrogen, USA) and 
following manufacturer’s instructions. The 1-2µg of total RNA was then subject to DNase I 
(Thermo Scientific, USA) digestion for 15 minutes at 37°C followed by inactivation at 65°C for 5 
minutes after adding 1µL of 25mM EDTA. The DNase I treated RNA was then used as a template 
to reverse-transcribe to cDNA using the high capacity cDNA synthesis kit (Applied Biosystems, 
USA) using manufacturer’s protocols. The prepared cDNA was then used as template for real-time 
quantitative PCR using SensiMix SYBR & Fluorescein Kit (Bioline, New Zealand) on the ABI7900 
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real-time PCR machine (Applied Biosystems, USA). Typical cycling is 95°C/10 min; 40 cycles of 
94°C/ 20 sec, 56 °C/20 sec, 72°C/30 sec; followed by 65 -99 °C for melt curve analysis. Data was 
analysed on the StepOne software v2.2.2 (Applied Biosystems, USA).  
 
2.2.2.2 RNA-Seq gene expression profile 
  1x105 cells were treated with or without doxycycline for 3 days to collect total RNA. Total RNA 
extraction was following by using the PureLink RNA Mini Kit (Invitrogen, USA) and 
manufacturer’s instructions. RNA libray was prepared by using TruSeq stranded total RNA library 
(with Ribo-­‐Zero GOLD) Pre kit and following manufacturer’s instructions. RNA sequencing was 
performed by Dr. Angelika Christ and colleagues at the IMB Sequencing Facility and data analysis 
was performed by the Queensland Facility for Advanced Bioinformatics. Briefly, RNA-Seq data 
was analysed by using Dox treatments, adjust p-value (P<0.05) and log2 fold change (log2>0.5 or 
log2<0.5) to investigate differential expression of genes.      
 
2.2.2.3 Protein extraction 
  For the preparation of whole cell protein extracts, 200,000 cells were seeded into T25 flasks and 
grown for 5 days. Prior to protein extraction, cells were harvest from flask and transferred to 1.5mL 
tubes. Subsequently, cells were washed with 1mL PBS and centrifuged at 2000rpm at 4°C for 5 
minutes. The supernatant was removed and the cell pellet were resuspended in 200µL of SDS lysis 
buffer (1% SDS, 10mM EDTA, 50mM Tris-HCl (pH to 8.1) and add protease inhibitors (fresh)) 
and incubated on ice for 15 minutes. Sonication was performed at 50mHz output for 10 seconds to 
lyse the cells and then placed on ice for 10mins, followed by centrifugation at 14000rpm for 30 
mins at 4°C. Supernatant was then transferred to a 1.5mL tube and stored at - 20°C until use when it 
was boiled with an appropriate volume of loading buffer prior to loading on an SDS-PAGE gel. 
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2.2.2.4 Estimation of protein concentration 
  The total protein concentration was quantified by performing Bradford assays with the Quick 
Start™ Bradford dye reagent (Biorad, USA). Five different concentrations of BSA (ranging from 
6.25µg/mL to 1mg/mL) were used as protein standards. Briefly, the 5µL of appropriate dilution of 
total protein lysate was added into each well of flat bottom 96 well plate. After that, 250µL of the 
dye reagent was added into each well and then incubated them at RT for 5 minutes. The protein 
concentrations were analysed by measuring absorbance at 595nm on a Bio-Rad UV 
spectrophotometer and compared to blank solutions of Bradford dye with 5µL diluted lysis buffer. 
 
2.2.2.5 SDS-PAGE preparation and electrophoresis 
  To obtain appropriate resolution of proteins, a stacking gel was poured over the top of the 
resolving gel. Either a 10 well or 15 well of comb was inserted into the stacking gel. The 10% 
acrylamide resolving gel was prepared by adding 7.5mL 40% acrylamide: bisacrylamide (29:1), 
7.5mL 1.5 M Tris-HCl pH 8.8, 150µL 20% SDS, Milli Q water was added to 30mL and finally 
polymerized by adding 300µL 10% ammonium persulfate (Domagala et al.) and 30µL TEMED to 
make up 30mL. The 5% stacking gels were prepared by adding 1.25mL 40% 
acrylamide:bisacrylamide (29:1), 1.25mL 1 M Tris-HCl pH 6.8, 50µL 20% SDS, Milli Q water 
added to 10mL and finally polymerized by adding 100µL 10% ammonium persulfate (Domagala et 
al.) and 10µL TEMED and make up to a total volume of 10mL. After loading of extracts, 
electrophoresis was run at 70 V until markers were in the resolving gel after which they were run at 
100 V for 40 mins. 
2.2.2.6 Protein transfer from gel to membrane 
  Before protein transfer to PVDF membrane, the stacking gel was removed from the resolving gel 
and then incubated in chilled 1x Towbin’s protein transfer buffer for 10 minutes to allow dispersion 
of the SDS from the gel. PVDF membrane was cut to the dimensions of the gel. Subsequently, 
PVDF membrane was activated by submerging in methanol for 10 seconds and then placed in 
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transfer buffer until needed.  
  Transfers were carried out by the wet-transfer protocol by placing the resolving gel and PVDF 
membrane in between wet filter paper and sponge pads into the transfer cassette and then placed in 
the transfer tank (Bio-Rad, USA) which was filled with chilled 1x transfer buffer and a frozen ice 
pack. 
  Protein transfer was usually carried out at constant voltage of 100 volts for 1hr. Once completed, 
the membrane was rinsed with TBS and soaked in methanol for 10 seconds, before being air dried 
at RT. 
 
2.2.2.7 Immunoblotting  
  Prior to antibody binding, the membrane was blocked in TBS containing 5% skim-milk powder 
for 1 hour. The primary antibody was diluted to the optimal dilution (as listed in Table 2.1.8) in 
TBS buffer with 2.5% skim-milk powder and incubated with the membrane at 4ºC overnight. After 
that, the membrane was washed thrice in TBS-0.1%Tween 20 (3 x 5 minutes) before incubating 
with the secondary antibody at 1 in 5000 dilution (RT, 1hr). Following a further three washes in 
TBS-0.1%Tween 20 (3 x 5 minutes), membrane was developed with the ECL substrate. Detection 
was carried out on the VersaDoc 5000 MP Imaging system (BioRad, USA). 
 
2.2.3 Cell culture 
2.2.3.1 Adherent cell culture 
   Cell lines were subcultured when reaching 80% confluence of T25 flask. Generally, cancer cells 
were washed with 5mL sterile 1X PBS for 5 seconds to remove traces of serum after removing old 
culture medium. After that, PBS solution was discarded and the cells were treated with 0.5mL 
0.25% (w/v) trypsin with 0.53mM EDTA for 5 minutes in 5% CO2 incubator to detach cells from 
T25 flask. Subsequently, 4mL culture medium was added to the flask to resuspend the cells and 
then 1mL aliquot of cell suspension was transferred into a new T25 flask and grown at 37°C in a 
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humidified incubator with an atmosphere of 95% air and 5% carbon dioxide. For routine cultures, 
the media were replenished every 2-3 days. For long term storage, cancer cells were harvested and 
resuspended in cell freezing solution plus 90% FBS and 10% DMSO and stored at -80°C or in 
liquid nitrogen tanks. 
 
2.2.3.2 Production of lentivirus 
Lentivirus 
  5 × 106 293T cells were plated in T75 flasks on the first day for transfections the following day. 
Lentivector, Gag/pol, RSV-Rev, and VSV-G plasmids were cotransfected at the ratios in table 
2.2.3.2.1. 53.7µL of Lipofectamine 2000 was mixed with 2mL of Opti-MEM medium. The DNA 
and the Lipofectamine 2000 mixture were combined and incubated at room temperature for 20 
minutes. While the DNA/Lipofectamine complex was incubating, 5mL of antibiotic free Opti-MEM 
medium was added into the T75 flask containing the preseeded 293T cells (being careful not to 
dislodge cells by hydraulic force). The DNA/Lipofectamine complex was carefully added to flasks 
and then incubated at 37°C for 6 hrs. After 6hrs, the Opti-MEM medium was replaced by normal 
and antibiotic free culture medium. The cells were allowed to grow for 72 hours before harvesting 
the viral supernatants. After that, the viral supernatant was spun down to remove any dead or loose 
293Ts at 1300rpm for 5 minutes. The viral supernatants (10mL) were filtered by 0.4µm filter before 
loading to a Vivaspin 20 column (Sartorius, 100kD cutoff), and spun at 3,000 g for 60 min, at 4°C 
on a swing bucket rotor. The viral supernatants were stored at -70ºC freezer until cell transduction. 
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Table 2.2.3.2.1: Ratios of lentiviral plasmids used for transfection of 293T cells. 
Plasmid Amount of DNA per 75 cm2 plate 
(µg) 
    
pLV711 vector   7.5         
pMDLg/pRRE (Gag Pol) 4.5     
pRSV (Koboldt et al.)   3.3     
pMD.G (VSV-G) 2.6     
total 17.9     
 
Plasmid Amount of DNA per 75 cm2 plate 
(µg) 
    
pINDUCER11 vector     9         
TransLenti Viral Packaging Mix 28.5      
total 37.5     
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2.2.3.3 Cell transduction with solution containing lentivirus 
  100,000 cells were plated in 6 well plate and grown overnight prior to lentiviral infection. In next 
day, the medium was removed and then 1mL of viral supernatant along with 5µg/mL of polybrene 
was added to the cells. After 72 hour infection, viral supernatant was replaced by normal culture 
medium and grown for a further 48hrs. GFP+ or Venus+ cells were sorted by using the MoFlo 
Astrios cell sorter (Beckman Coulter, USA). 
 
2.2.3.4 Cell proliferation assay 
2.2.3.4.1 Trypan Blue 
  10,000 cells were cultured at low density in 12-well plates and trypsinised at the timepoints. 
After neutralisation in harvest medium, the cells were washed with PBS twice and resuspended in 
1mL of PBS. Cell number was counted by using Cellometer Auto T4 Cell Counter (Thermo 
Scientific), as according to the manufacturer’s instructions. 
 
2.2.3.4.2 DAPI staining 
  1000 cells were seeded in 96 well plates and grown for 1, 3, 5 and 7 days. After treatment, cells 
were stained by using DAPI staining after cell fixation by 4% formaldehyde for 20 minutes.  
Briefly, cells were staining with DAPI (300nM) for 30mins and then washed with PBS twice. Cell 
number was counted by using ImageXpress Micro XLS system (at 10x magnification), as according 
to the manufacturer’s instructions. 
 
2.2.3.5 Mammosphere forming assay 
  50ml of complete human MammoCult™ Medium was prepared by adding 5mL of thawed 
MammoCult™ Proliferation Supplements to 45mL of MammoCult™ Basal Medium. Additional 
supplementation (4µg/mL heparin and 0.48µg/mL hydrocortisone) is required to obtain complete 
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MammoCult™ Medium for optimal growth of human mammospheres (Wolf et al., 2013).  
   1000 single cells expressing fluorescent protein were grown in suspension culture using 96 well 
ultralow attachment plates (Corning) and MammoCult Basal Medium and MammoCult 
Proliferation Supplement. Normally, mammospheres were collected by gentle centrifugation (350 x 
g for 5mins) after 7 day growth and dissociated enzymatically (10 minutes in 0.25% trypsin, 
0.53mM EDTA-4Na) and then pipetted mechanically. A single cell suspension was confirmed by 
using a haemocytometer and calculating the number of viable cells per ml using trypan blue. 1000 
single cells obtained from dissociation were replated into ultralow attachment plates and passaging 
for few generations after every 7 day growth.  
   The number of mammospheres which are greater than 50µm diameter was counted by 
ImageXpress Micro XLS system (at 10x fluorescent magnification) (Molecular Devices, US). 
Mammosphere forming efficiency (%) is calculated as follows: (number of mammospheres per 
well/number of cells seeded per well) x 100 (Shaw et al., 2012).  
 
2.2.3.6 RNA extraction from mammosphere-derived cells 
  20,000 single cells were grown in 24 well ultralow attachment plates to form mammospheres. 
After 7 day growth, mammosphere derived cells were harvested into 1.5mL tubes. Total RNA 
extraction was extracted from mammosphere-derived cells by using the PureLink RNA Mini Kit 
and following manufacturer’s instructions.  
 
2.2.3.7 Immunostaining 
  1000 cells were seeded in 96 well plates. These cells were cultured with Dox or without Dox for 
five days before exposure to actinomycin D (ACT D) or etoposide (ETO) for a further 24 hours. 
After treatment, cells were fixed by 4% formaldehyde for 20 mins and blocking with 3% 
BSA/PBST solution at 4C overnight. Briefly, cells were immunostained with anti-γ-H2AX mAb 
(Alexa Fluor 594; red) and/or anti-RAD51 pAb (Alexa Fluor 750; cyan) at 4C overnight. After that, 
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cells were counterstaining with DAPI (300nM) for 60mins and then washed with PBS twice. Cells 
were imaged by Olympus fluorescent microscopy (at 40x magnification), as according to the 
manufacturer’s instructions. 
2.2.3.8 Cytosolic and nuclear protein extraction 
  Preparation of cytosolic and nuclear extracts were described previously (Abmayr et al., 2006). 
Briefly, cells were lysed in hypotonic lysis buffer (10mM HEPES pH7.9, 1.5mM MgCl2, 10mM 
KCl, 1x cOmplete protease inhibitor cocktail) on ice for 15minutes. The suspended cells were 
centrifuged at 420 x g for 5 minutes. The packed cells were resuspended in a volume of 3x packed 
cell volume of hypotonic lysis buffer on ice 10 minutes. The suspension was homogenized by using 
a syringe with a 27G needle before centrifuging at 11,000 x g for 20 minutes. The supernatant was 
transferred to a fresh tube. This fraction is the cytoplasmic fraction. The sedimented crude nuclei 
were resuspended in 1/2x packed nuclear volume (pnv) of low salt buffer (20mM HEPES pH7.9, 
1.5mM MgCl2, 20mM KCl, 0.2mM EDTA, 25% glycerol, 1x cOmplete protease inhibitor cocktail). 
The recovered nuclei were added a volume of high-salt buffer (20mM HEPES pH7.9, 1.5mM 
MgCl2, 1.4 M KCl, 0.2mM EDTA, 0.2mM EDTA, 25% glycerol, 1x cOmplete protease inhibitor 
cocktail) equal to 1/2 pnv and shaking gently for 30 minutes. These nuclei were centrifuged at 
21,000 x g for 5 minutes. The supernatant was transferred into a new tube and stored at –70 °C. 
This fraction is the cytoplasmic fraction.   
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Chapter 3- Identification and validation of MYB target genes 
in human ER+ breast cancer 
3.1 Introduction 
     Over 70% of human breast cancers are oestrogen receptor positive (ER+) and express high 
levels of MYB (Guerin et al., 1988, Guerin et al., 1990). MYB expression is necessary for the 
proliferation of ER+ breast cancer cells in vitro (Drabsch et al., 2007) and for tumour development 
in vivo (Miao et al., 2011). MYB functions as a transcription factor to regulate many cellular genes 
that are associated with cell survival (such as BCL2), cell proliferation, differentiation, 
tumourigenesis and apoptosis in normal and cancer cells (Ramsay and Gonda, 2008).  To date, 
most known MYB target genes have been identified in hematopoietic cells. There is relatively little 
information about MYB target genes in human ER+ breast cancer. However, a previous study 
identified several MYB-regulated genes in human ER+ breast cancer via identification of MYB 
binding sites in the promoter of target genes and Q-PCR (Quintana et al., 2011). MYB binding sites 
are not only located in the target gene promoters but also located in other regions that are far from 
the promoter of target genes (Kintscher et al., 2004, Gundelach et al., 2007). Here, genes whose 
expression is directly or indirectly controlled by MYB are defined as MYB-regulated genes (as 
described in Chapter 1); genes that are directly regulated by MYB bound within the gene are 
defined as MYB target genes. Taken together, the aim of the studies presented in this chapter is to 
identify and validate MYB target genes in human ER+ breast cancer by combining inducible 
shRNA-mediated MYB knockdown with RNA-Seq gene expression profiling.  To achieve this aim, 
the first step was to generate and validate human ER+ breast cancer MCF-7 cell lines with efficient 
MYB knockdown. 
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3.2 Results 
3.2.1) Construction of pINDUCER11 MYB shRNA  
The pINDUCER lentiviral system is a doxycycline (Dox) inducible shRNA expression lentiviral 
system (Meerbrey et al., 2011). The Dox-inducible lentiviral vector (pINDUCER11) has two 
reporters (eGFP and RFP) (Figure 3.1(a)). This pINDUCER11 vector can express eGFP in the 
absence of Dox that can be used to track transduced cells. This vector also expresses RFP in the 
presence of Dox to allow tracking of shRNA-expressing cells. GIPZ lentiviral vectors (pGIPZ) 
encoding MYB shRNAs or a non-silenceing shRNA were purchased from Open Biosystems. The 
DNA fragments corresponding to the MYB or non-silencing shRNA in the pGIPZ were 
approximately 345bp (Figure 3.1(b)) following digestion with Mlu and Xho I restriction 
endonucleases; they were then ligated into Mlu and Xho I-cut pINDUCER11. The DNA fragment of 
MYB shRNA could be cut from ampicillin-resistant pINDUCER11 MYB shRNA colonies (Figure 
3.1(c)) and gave the correct sequence after DNA sequencing (data not shown).  
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Figure 3.1: Generation of pINDUCER11 MYB shRNA plasmids. (a) A diagram of 
pINDUCER11 (mir-RUG); (b) pGIPZ-MYB shRNA and pINDUCER11-miR11 (Mlu+Xho I double 
digestion) in 1% DNA agarose gel; (c) pINDUCER11 MYB shRNA (Mlu+Xho I double digestion) 
in 1% DNA agarose gel. The contrast and brightness of all pictures were enhanced. 
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3.2.2) Dox-inducible MYB shRNA lentiviral particle production  
  Dox-inducible MYB shRNA lentiviral particles were produced as described in Materials and 
Methods by using human embryonic kidney 293T cells with a Dox-inducible lentiviral vector and 
other lentiviral packing plasmids (Figure 3.2(a)). Figure 3.2(b) shows high intensity of GFP+ cells at 
48 hours after transfection.  
 
3.2.3) Lentiviral transduction of the human ER+ breast cancer cell line MCF-7  
  Dox-inducible MYB shRNA lentiviral particles were transduced into the human ER+ breast cancer 
cell line MCF-7 cells (Figure 3.3(a)). As illustrated in Figure 3.3(b), the GFP+ RFP- cells were 
visible on day five after lentivirus transduction and these cells - approximately 26% to 49% of the 
total - were sorted by flow cytometry in order to exclude cells expressing MYB shRNA before Dox 
induction (Figure 3.3(c)).  
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Figure 3.2: pINDUCER11 MYB shRNA lentivirus packaging in human embryonic kidney 
293T (HEK 293T) cells. (a) A diagram of lentivirus particle production (adapted from System 
Biosciences, Inc., 2016); (b) Fluorescent microscope of HEK 293T cells expression eGFP 
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Figure 3.3: Lentiviral transduction of human ER+ breast cancer cell line MCF-7 cells. (a) A 
diagram of lentivirus transduction; (b) Fluorescence microscope of MCF-7 cells expressing 
eGFP; (c) The eGFP+RFP- cells were sorted by flow cytometry for further work. 
  
 71 
3.2.4) Dox-inducible MYB shRNA synthesis in human ER+ breast cancer cell line MCF-7 cells  
      To induce MYB shRNA synthesis in the GFP+ RFP- human ER+ breast cancer cell line 
MCF-7 cells, cells were treated with 1µg/ml of Dox for 48hours. Figure 3.4(c) shows that high 
intensity of RFP expression in these cells when compared to the untreated cells in Figure 3.4(b). 
This suggests that MYB shRNA synthesis is likely to have commenced.  
 
3.2.5) MYB and BCL2 expression in human ER+ breast cancer cell line MCF-7 cells 
    Three pools of MCF-7 cells expressing MYB shRNA were generated (Figure 3.4). To examine 
whether these cells can knockdown MYB expression, cells were cultured in the absence or presence 
of Dox for five days to collect samples for Q-PCR and western blotting analysis. Here, two pools of 
MCF-7 cells expressing either MYB shRNA 378024 or MYB shRNA 411110 did not result in 
differential expression of MYB after Dox induction (data not shown). Thus, the following figures 
only showed the results for MYB shRNA 378022 (subsequently named MYB shRNA 1) cells. As 
illustrated in Figure 3.5(a), around 60 % inhibition of MYB mRNA expression was found in MCF-7 
cells transduced with the MYB shRNA 1 clone after exposure to Dox while Dox treatment had no 
impact on expression in the nonsilencing control (NS) or parental groups. A similar result was 
found in western blotting analysis (Figure 3.5(b)).  
    BCL2 is a well-known MYB target gene. To investigate whether BCL2 expression was 
influenced by MYB knockdown in cells expressing MYB shRNA 1, cells were grown in the absence 
or presence of Dox for five days. As illustrated in Figure 3.6, BCL2 mRNA expression and protein 
expression in MYB shRNA 1 clone were not reduced in the presence of Dox when compared to wild 
type and NS clones. This shows that MYB knockdown in the MYB shRNA1 MCF-7 cell line may 
not be sufficient to affect MYB target gene expression. 
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Figure 3.4: Doxycycline (Dox)-inducible MYB shRNA synthesis in the human ER+ breast 
cancer cell line MCF-7. (a) A diagram of Dox-induction mechanism; (b) without Dox 1µg/ml; 
(c) with Dox 1µg/ml  
 
 73 
(a) 	  
Pa
ren
tal
MY
B s
hR
NA
 1 NS
0.0
0.5
1.0
1.5
2.0
2.5
MCF-7 5days
Re
lat
ive
 M
YB
 m
RN
A 
lev
el -Dox
+Dox*
*
	  
(b)  
 
    (c) 
    
Pa
ren
tal
MY
B s
hR
NA
1 NS
0
50
100
150
MCF-7 5days
Re
lat
ive
 M
YB
 ex
pr
es
sio
n -Dox
+Dox*
*
*
 
Figure 3.5: MYB expression in MCF-7 parental cells or cells expressing Dox-inducible MYB 
shRNA or nonsilencing shRNA (NS). Cells were cultured in the absence or presence of Dox 
(5µg/ml) for five days. Total cell lysates were collected for (a) Q-PCR for MYB mRNA expression 
or (b) western blot analysis with MYB and GAPDH (as loading control) antibodies; (c) all data 
from panel (b) were normalised against GAPDH. The standard deviation is represented by error 
bars (n= 3; * indicates P<0.05).  
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Figure 3.6: BCL2 expression in MCF-7 parental cells or cells expressing Dox-inducible MYB 
shRNA or nonsilencing shRNA (NS).  (a) Q-PCR for BCL2 mRNA expression; (b) western 
blotting analysis with BCL2 and GAPDH (as loading control) antibodies; (c) all data from panel (b) 
were normalised against GAPDH. The standard deviation is represented by error bars (n= 2) 
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3.2.6) The effect of silencing MYB with the pINDUCER vector on cell proliferation of the 
human ER+ breast cancer cell line MCF-7  
    Previous studies from the Gonda laboratory demonstrated that silencing MYB slowed down 
cell proliferation of MCF-7 cells (Drabsch et al., 2007, Brown et al., 2010). Thus, cell proliferation 
was used as a second indicator for assessment of the effect of MYB knockdown in the MYB 
shRNA1 clone.  To examine this effect with the pINDUCER MYB shRNA vectors, parental cells 
and cells expressing MYB shRNA1 or nonsilencing shRNA were cultured in the absence or 
presence of Dox for a seven-day time course. As illustrated in Figure 3.7, there was no inhibition of 
cell proliferation of cells expressing MYB shRNA1 in the presence of Dox (dotted red line) when 
compared to the MYB shRNA1 group in the absence of Dox (solid red line).   
  This MYB shRNA1 MCF-7 cell line generated with the pINDUCEER vector showed inducible 
downregulation of MYB after Dox induction, but no consequent effects on MYB regulated gene 
expression and cell proliferation in contrast to our previous findings (Drabsch et al., 2007, 2010). 
Thus, this vector system and MYB shRNA1 cells might not be suitable for identification of MYB 
novel target genes. 
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Figure 3.7: The effect of suppressing MYB on cell proliferation of MCF-7 cells. Parental cells 
(black lines) or cells expressing NS shRNA (green lines) or MYB shRNA 1 (red lines) were cultured 
in the absence or presence of Dox for 1, 3, 5 or 7 days.  Cells were stained with DAPI and counted 
by Imagexpress fluorescent microscope. All data were normalised against day 1 cell number in each 
group. 
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3.2.7) Generation of human ER+ breast cancer MCF-7 cells expressing Dox-inducible MYB 
shRNA C4 or C5 
   Because the pINDUCER vectors with MYB shRNA1 were not sufficiently effective to suppress 
MYB expression in MCF-7 cells for identification of MYB target genes, stable cell lines expressing 
another Dox-inducible MYB shRNA lentiviral vector (pLV711; Drabsch et al., 2007, Brown et al., 
2010) were generated. This vector, which contained different MYB shRNA templates (C4 or C5), 
was transduced into MCF-7 cells. These cells were grown in the absence or presence of Dox for 
five days to collect total cell lysate for Western blotting. A pLV711-Luc-shRNA vector was 
transduced into MCF-7 cells as a nonsilencing control. Figures 3.8(a) and 3.8(b) (left panel) show 
that MYB expression in two MYB shRNA clones (C4 and C5) was reduced by approximately 80% 
after exposure to Dox, compared to parental and Luc shRNA groups administered an identical 
treatment. However, there was a problem with “leakiness” in these two MYB shRNA cells. In the 
absence of Dox induction, when compared to parental and Luc shRNA groups with an identical 
treatment, there was still a clear reduction in the level of MYB – approximately 50% and 20% 
respectively (Figure 3.8(b), left panel). Importantly, BCL2 expression was also reduced after MYB 
shRNA induction with Dox (Figure 3.8(a)), but only to a small extent in the absence of Dox (Figure 
3.8(b), right panel), which is in agreement with a previous report from the Gonda laboratory 
(Drabsch et al., 2010). 
   To further examine the physiological effect of silencing MYB in MYB shRNA C4 and C5 clones, 
MCF-7 cells expressing MYB shRNA or nonsilencing shRNA were cultured in the absence or 
presence of Dox for a seven day time course. As illustrated in Figure 3.9, approximately 20 to 30% 
inhibition (P<0.05) of cell proliferation was observed in the MYB shRNA C4 clone in the presence 
of Dox (dotted red line), compared to the MYB shRNA C4-Dox (solid red line), Luc shRNA-Dox 
(solid green line) and Luc shRNA+Dox (dotted green line) groups. Approximately 40 to 50% 
inhibition (P<0.05) of cell proliferation was found in the MYB shRNA C5 clone in the presence of 
Dox (dotted blue line), compared to the MYB shRNA C5-Dox (solid blue line), and Luc 
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shRNA±Dox groups.  
   These MYB shRNA MCF-7 cell lines generated with the pLV711 vector showed inducible 
downregulation of MYB after Dox induction and consequent effects on MYB regulated gene 
expression and cell proliferation. Thus, these cell lines should be suitable to use in identifying MYB 
novel target genes. 
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Figure 3.8: MYB and BCL2 expression in human ER+ breast cancer MCF-7 cells.  Parental 
cells were transduced with a Dox-inducible shRNA vector. They were cultured in the absence or 
presence of Dox (5µg/ml) for five days. Total cell lysates were collected for western blot analysis (a) 
with MYB, BCL2 and GAPDH (as loading control) antibodies; (b) all data from panel (a) were 
normalised against GAPDH. The left panel in (b) represents MYB expression; the right panel in (b) 
represents BCL2 expression. The standard deviation is represented by error bars (n= 3; * indicates 
P<0.05).  
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Figure 3.9: The effect of silencing MYB on cell proliferation of MCF-7 cells. Cells expressing 
Luc shRNA (as a nonsilencing control, green lines) or MYB shRNA (C4, red lines; C5, blue lines) 
were cultured in the absence or presence of Dox for 1, 3, 5 or 7 days. Cells were stained with DAPI 
and counted by Imagexpress fluorescent microscope. All data were normalised against day 1 cell 
number in each group (n= 4; * indicates P<0.05). 
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3.2.8) Transcriptome sequencing of MCF-7 cells expressing inducible MYB shRNA 
     RNA sequencing (RNA-Seq) is a powerful approach for comprehensive transcriptome 
analysis (Wang et al., 2009). The transcriptome is the full range of transcripts in a cell for a specific 
developmental stage or physiological condition (Wang et al., 2009). Understanding the 
transcriptome via RNA-Seq provides the ability to investigate gene fusion (Maher et al., 2009), 
identification of transcription start sites (Tsuchihara et al., 2009), the identification of the 5’ and 3’ 
ends of genes, new splicing variants, post-transcriptional modifications, classification of transcripts 
(including coding RNAs, non-coding RNAs and small RNAs) and changing expression levels of 
each gene during development and under different conditions (Wang et al., 2009).  
     RNA-Seq technology offers the following advantages compared to DNA microarrays for 
identifying differentially expressed genes. Firstly, RNA-Seq technology does not require species- or 
transcript-specific probes so that it avoids hybridization issues and offers unbiased detection of 
known and unknown transcripts. Secondly, RNA-Seq technology offers low background signal 
because cDNA fragments can be unambiguously mapped to unique regions of the genome (Wang et 
al., 2009). Consequently, it offers a greater dynamic range (over few thousand fold) than DNA 
microarray (one-hundredfold to a few-hundredfold) (Wang et al., 2009). Thirdly, RNA-Seq has 
been shown high accuracy for quantifying gene expression levels that can be validated by using 
Q-PCR (Nagalakshmi et al., 2008) and high level of reproducibility for technical and biological 
replicates (Mortazavi et al., 2008, Cloonan et al., 2008). Taking these advantages into account, 
RNA-Seq was used to identify MYB novel target genes in this Chapter.  
    Generally, the basic procedures of RNA-Seq are involved in the generation of a library of 
complementary DNA (cDNA) fragments with adaptors attached to one or both ends from a 
population of purified and fragmented mRNAs before direct sequencing of cDNAs using 
high-throughput DNA sequencing technologies followed by the mapping of the sequencing reads to 
the genome (Figure 3.10(a)). To obtain downregulation of MYB and consequent effects on MYB 
target genes, cells expressing MYB shRNA (C4 or C5) were cultured in the presence of Dox; the 
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transcriptomes of these cells were compared to that of the non-silencing control. Owing to the high 
cost of RNA-Seq, only Luc shRNA cells (represented as nonsilencing control) were cultured in the 
absence or presence of Dox to eliminate the effects of Dox induction in gene expression of cells. 
Figure 3.10(b) shows a diagram of the experimental design that was performed triplicate samples in 
each group for RNA-Seq.  
   Total RNA isolation from the MCF-7 cell lines was performed as described in Materials and 
Methods using commercial RNA extraction kits. The RNA quality of all samples was assessed by 
running Bioanalyzer electropherograms and determining the RNA Integrity Number (RIN) 
(Schroeder et al., 2006) that is calculated using the 28s/18s ratio, the region before the peaks, signal 
areas, and intensities (Figure 3.10(c)). As illustrated in Figure 3.10(d), all RNA samples were intact 
RNA (RIN>8) except for MYB shRNA C4+Dox-3 group that was partially degraded (RIN=6.7). 
These RNA samples were converted to cDNA libraries for RNA-Seq by Dr. Angelika Christ and 
colleagues at the IMB Sequencing Facility, UQ. Figure 3.10(e) show the size distribution of cDNA 
fragments generated with TruSeq RNA library Kit was ranging from approximately 200bp to 
1000bp, with an expected product at approximately 250 to 300bp. As illustrated in Figure 3.10(f), 
all samples were observed a peak among 200 to 300bp.  
   These data show acceptable quality of total RNA and cDNA libraries from all samples. Thus, 
these cDNA libraries should be suitable for RNA-Seq gene expression profiling. 
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(a)  
 
 
(b)  
 
 (c)  
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(e)  
 
 
 85 
(f)  
 
 
Figure 3.10: cDNA libraries preparation from MCF-7 cells for RNA-Seq. (a) A flowchart of 
RNA-Seq; (b) A schematic diagram of the experimental design used to identify candidate 
MYB-regulated genes by RNA-Seq; (c) An example of RNA quality ran by Bioanalyzer 
electropherograms. The RNA quality was determined by RIN. The number of RIN is 9.2, 6.2 or 3.2 
that represent a highly intact RNA sample, a partially degraded total RNA sample or a degraded 
total RNA sample individually; (d) Bioanalyzer electropherograms of 12 samples after RNA 
extraction represented total RNA quality that was determined by RIN values; (e) An example of the 
size distribution of a cDNA library ran by a Bioanalyzer electropherogram; (f) The size distribution 
of 12 cDNA libraries generated from MCF-7 MYB and NS shRNA lines. All samples were diluted 
to 1 in 40 before running Bioanalyzer electropherograms.  
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Table 3.1: The concentration of cDNA fragments from 150 bp to 400 bp in 12 samples. 
 
NS: Non-silencing control 
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3.2.9) Identification of potential MYB target genes in MCF-7 cells from RNA-Seq and ChIP 
datasets 
   There are many platforms for RNA-Seq use (Glenn, 2011, Liu et al., 2012). Here, the Illumina® 
systems, which typically generates 25 million reads per sample, was used to sequence all cDNA 
libraries. Library generation and sequencing were performed by Dr. Angelika Christ and colleagues 
at the IMB Sequencing Facility. As illustrated in Table 3.2, approximately 19 to 37 million input 
reads of each sample were identified. These data were further analysed by Dr. Stephen Rudd in the 
Queensland Facility for Advanced Bioinformatics (QFAB). After sequencing 12 RNA libraries, raw 
reads were subjected to quality control (QC) analysis using FastQC (Kroll et al., 2014). QC analysis 
involved the analysis of sequence quality, GC content, and k-mers (Kroll et al., 2014). For 
acceptable duplication, k-mer or GC content levels are less than outliers with 30 % disagreement 
(Conesa et al., 2016). Generally, read quality decreases towards the 3’ end of reads. If read quality 
was very low, bases were removed by using a software tool (Trimmomatic) (Bolger et al., 2014, 
Conesa et al., 2016). This software can also trim adaptor sequences, and eliminate poor-quality 
bases (Bolger et al., 2014). Briefly, the process of removal of adaptor sequences started with 
identification of adapter sequences. There were two approaches to detect adaptor sequences within 
the reads (Bolger et al., 2014). In simple mode, each read was scanned from the 5’ end to the 3’ end 
to determine whether any adapter sequences are present (Bolger et al., 2014). The ‘seed and extend’ 
approach (Li and Homer, 2010) was used to find initial matches between the adaptor sequences and 
the reads. Based on this initial match, a local alignment was performed. If the alignment score 
exceeded approximately 0.602, the aligned region plus the remainder after the alignment were 
removed (Bolger et al., 2014). After removal of adaptor sequences, to infer which transcripts are 
expressed, the rest of RNA-Seq reads were mapped to the human genome. The percentage of 
mapped reads is an important mapping quality parameter to understand the overall sequencing 
accuracy and of the presence of contaminating DNA (Mortazavi et al., 2008, Dobin et al., 2013, 
Conesa et al., 2016). The percentage of RNA-Seq reads to map onto the human genome between 
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70% and 90% is acceptable (Mortazavi et al., 2008, Dobin et al., 2013, Conesa et al., 2016). Briefly, 
approximately 15 to 27 million reads in each sample were mapped to the University of California, 
Santa Cruz (UCSC) human genome (Kent et al., 2002, Zhao and Zhang, 2015) (Table 3.2). Table 
3.2 shows approximately 71 to 81% uniquely mapped reads, 15 to 26% of reads that were mapped 
to multiple loci, 3 to 4% of reads that were unmapped because of too short cDNA fragments in each 
sample. To estimate transcript expression, the number of reads per kilobase of exon model per 
million reads (RPKM) is the most commonly within-sample normalization method (Mortazavi et al., 
2008, Zhao et al., 2015). The number of RPKM was calculated by using a computational software 
package called edge R (Robinson et al., 2010). Before that, principal component analysis (PCA) 
was used to check the reproducibility among replicates and to check whether Dox induction 
affected gene expression among replicates. 
    To investigate whether Dox induction affected gene expression in each sample of MCF-7 cells, 
principal components analysis (PCA), which is a method to determine and visualize 
sample–to–sample differences as distances, was used. The distances between replicates in each 
group were closer together; thus, the differences between replicates in each group were smaller. As 
illustrated in Figure 3.11(a), the distance between NS-Dox-1 and NS-Dox-2 samples (blue dots) 
was greater than the distance between NS-Dox-1 and NS-Dox-3 samples (blue dots). A similar 
result was also observed in within the MYB shRNA C4+Dox groups (pink dots) and in within the 
MYB shRNA C5+Dox groups (green dots) (Figure 3.11(a)). These could result from different 
cDNA concentration of triplicate samples in each group (Table 3.1). Furthermore, the NS-Dox 
groups (blue dots) and the NS+Dox groups (purple dots) were close. Moreover, the NS+Dox groups 
(purple dots) were far from the MYB shRNA C4+Dox (pink dots) or the MYB shRNA C5+Dox 
groups (green dots) (Figure 3.11(a)). In addition, no genes in the NS+Dox groups showed 
differential expression, compared to the NS-Dox groups (data not shown). These data show that a 
small difference in within groups, but much less effect of Dox induction on gene expression in the 
NS groups. MYB knockdown resulted in a substantial effect on gene expression of MYB shRNA (C4 
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and C5) groups, compared to the NS+Dox groups, as expected. Thus, the data from the NS+Dox 
and the two MYB shRNA+Dox groups were used to analyse differential gene expression in response 
to MYB knockdown.  
  Prior to categorizing differential expression of potential MYB target genes, approximately 5300 
genes were identified as common to the NS+Dox and two MYB shRNA+Dox groups (data not 
shown). Following analysis, the differential expression of genes was ranked by using a 
computational software package called edge R (Robinson et al., 2010) with two parameters: 
adjusted p-value (less than 0.05) and log2 fold change (greater than 0.5 or less than -0.5) (Feng et al., 
2012). As illustrated in Figure 3.11(b), 562 genes in the MYB shRNA C4+Dox group and 517 genes 
in the MYB shRNA C5+Dox group showed differential expression when compared to the NS+Dox 
group. After further analysis of differential expression of genes in the two MYB shRNA groups, 
some of the differentially-expressed genes were only present in either MYB shRNA C4 or MYB 
shRNA C5 groups (data not shown). To identify potential MYB target genes and to maximise the 
chances of obtaining robust results, 193 differentially-expressed genes that were in common 
between the two different MYB shRNAs (C4 and C5) (Figure 3.11(c)) were used for further analysis. 
This dataset was then integrated with two published chromatin immunoprecipitation (ChIP) coupled 
with promoter microarray (ChIP-Chip) datasets from breast cancer with two different anti-MYB 
antibodies (Quintana et al., 2011) to identify direct MYB target genes that have genomic MYB 
binding sites in the promoters. The 193 differentially-expressed genes that were in common 
between the two different MYB shRNAs was also integrated with a published ChIP-Seq dataset 
from adenoid cystic carcinoma (ACC) (Drier et al., 2016) to identify direct MYB target genes that 
are directly regulated by MYB bound within the gene. These published ChIP datasets were 
generated by using three different anti-MYB antibodies to identify genomic MYB binding sites in a 
gene because of known problems with MYB antibody specificity/effectiveness in ChIP studies 
(Figure 3.11(c)). After integration, 145 potentially direct MYB target genes were identified from the 
193 genes in terms of having genomic MYB binding sites (Figure 3.11(c)). Finally, 25 potentially 
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direct MYB target genes (i.e. 13 potential MYB active genes and 10 potential MYB repressed genes 
and 2 genes that have MYB binding sites) were selected for the next stage of analysis based on 
involvement in cell survival, cell adhesion, DNA damage responses, transcriptional regulation, 
proliferation or apoptosis. In addition, 13 genes that showed differential expression after MYB 
knockdown but no genomic MYB binding sites from the two ChIP studies mentioned were also 
selected. These were included because MYB can indirectly regulate target gene expression as 
described in Chapter 1, and because they were of biological interest (e.g. XRCC3 is involved in 
NHEJ pathway to repair DNA damage), and they also may actually have MBS in MCF7 cells that 
are not in the promoters and not in ACC, and because ChIP studies that were performed in different 
cells may not accurately reflect which genes have MBS in MCF-7 cells.   
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Table 3.2: List of input and uniquely mapped read numbers from sequencing the 12 samples using 
Illumina® NextSeq system.  
 
   NS: Non-silencing control 
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 (a)  
 
 
(b) 
 
Adj.P < 0.05 
logFC > 0.5  
and  
logFC < -0.5 
MYB shRNA C4+Dox vs. NS+Dox 1101 562 
MYB shRNA C5+Dox vs. NS+Dox 1070 517 
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(c) 
 
Figure 3.11: Expression profiling analysis of MYB regulated genes in MCF-7 cells. (a) Principal 
components analysis was performed by the computer software called plotPCA. PCA1 separated 
samples and accounted for 18% of the variance and resulted in separation between the Luc shRNA 
(represented as NS) and the two MYB shRNA groups. PCA2 accounted for 13% of the variance and 
resulted in separation between the MYB shRNA C4 and the MYB shRNA C5 cells. Blue dots 
represent the NS-Dox groups. Purple dots represent the NS+Dox groups. Pink dots represent the 
MYB shRNA C4+Dox groups. Green dots represent the MYB shRNA C5+Dox groups; (b) 
Differential gene expression was analysed by using two parameters (adjusted P value and log2Fold 
Change). 1101 genes in the MYB shRNA C4+Dox group and 1070 genes in the MYB shRNA 
C5+Dox group showed significance (adjusted P<0.05) when compared to the NS+Dox group. 562 
genes from 1011 genes in the MYB shRNA C4+Dox group and 517 genes from 1070 genes in the 
MYB shRNA C5+Dox group showed differential gene expression when compared to the NS+Dox 
group; (c) The identification process of MYB regulated genes and integration with three different 
MYB ChIP datasets: MYB ChIP1 generated by using anti-MYB 1.1 antibody, MYB ChIP2 
generated by using anti-MYB 1493 antibody and MYB ChIP-Seq generated by using anti-MYB 
A304-136A 
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3.2.10) Validation of MYB target genes in MCF-7 cells 
    The 38 genes selected as described above were then subjected to further validation by Q-PCR 
(Table 3.3). Because the MYB shRNA C5 clone showed less leakiness but still good MYB 
knockdown (Figure 3.8(b), left panel), it was used for the validation of differential expression of 
MYB target genes in MCF-7 cells. Five known MYB target genes (BCL2, BRCA1, CCNE1, CXCR4 
and TOPBP1) were used as positive controls. As illustrated in Table 3.3, there were 23 potential 
MYB activated genes, 13 potential MYB repressed genes and two MYB target genes from 38 
potential MYB target genes. After Q-PCR analysis, 15 genes in the MYB shRNA C5+Dox group 
including BCL2, BRCA1, TOPBP1 and MYB showed significance of differential expression (P<0.05) 
when compared to the Luc shRNA+Dox and MYB shRNA C5-Dox groups (Figure 3.12(a)). 
However, only eight MYB activated genes (COPS7B, E2F3, ESR1, ITGAV, RAD1, XRCC3, XRCC6 
and ZMYND8), one MYB repressed genes (such as GHR) and two MYB target genes (BAX and 
CDH3) in the MYB shRNA C5 cell line were validated in terms of downregulation or upregulation 
of MYB target genes after MYB knockdown when compared to both the Luc shRNA+Dox and MYB 
shRNA C5-Dox groups (Figures 3.12(a), 3.12(b) and 3.12(c)). However, when only compared to 
the Luc shRNA+Dox group, an additional 12 genes in the MYB shRNA C5+Dox group, including 
the remaining two positive controls, showed significant differential expression (P<0.05) (Figure 
3.12(b)). Thus, using the broader criteria, 27 potential and known target genes were validated by 
Q-PCR (also see Discussion). 
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Table 3.3: List of MYB target genes that were selected for validation by Q-PCR. 
Gene name MYB-regulated gene (A/R/N)
a
 ChIP (Y/N)
b
 Validated in MCF-7 cells
a,c
 Validated in MCF-7 cells
a,d
 
ALDH1A3 A Y N A 
BAX N Y (ONLY ACC ChIP) N N 
BCL2L15 A N N N 
BMP4 A N N N 
CACNA1D A Y N A 
CCNB3 A N N N 
CCNT1 R Y N A 
CDH3 N Y (ONLY ACC ChIP) N N 
CEP164 R Y A A 
CHTOP R Y N N 
CLEC3A A Y N N 
COPS7B A Y A A 
CSRNP2 A Y N A 
E2F3 A N A A 
ESAM R Y N N 
ESR1 A N A A 
FANCA A N N N 
FANCE R N N N 
FOXC1 R Y N N 
GDF9 R N N A 
GHR R Y R R 
ITGAV A Y A A 
KDM2A A Y N A 
MAML3 R Y N A 
PLEKHA7 R N N A 
PTPRF A Y N N 
RAD1 A N A A 
RAD51AP2 A N N A 
STK17A A Y N N 
TRIM13 A Y N N 
WBP11 R Y A A 
XRCC3 A N A A 
XRCC6 A N A A 
ZBTB2 A Y N N 
ZKSCAN8 R Y N N 
ZMYND8 A Y A A 
ZNF436 R Y N N 
ZNF721 A Y N A !  
a The capital letters (A, R, or N) in the column of MYB-regulated genes or validated in MCF-7 cells represent a MYB 
activated gene, a MYB repressed gene or none of them individually.   
b The capital letter Y in the ChIP column indicates MYB binding sites were identified in one of three published ChIP 
datasets (Quintana et al., 2011, Drier et al., 2016); N indicates no MYB binding site was identified in these datasets. 
c The column of validated in MCF-7 cells represents a MYB target gene in the MYB shRNA C5 cells was validated 
when compared to the NS+Dox and the MYB shRNA+Dox groups.  
d The column of validated in MCF-7 cells represents a MYB target gene in the MYB shRNA C5 cells was validated 
when compared to the NS+Dox group.  
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Figure 3.12: Validation of MYB regulated genes by quantitative real time PCR in the MYB 
shRNA C5 cells. Potential MYB target genes from Table 3.3 were validated by Q-PCR. All Q-PCR 
results are shown in (a), (b) and (c) in gene names, followed by five positive controls. Panel (a) 
represents MYB target genes in the MYB shRNA+Dox group showed significant differential 
expression  (P<0.05) when compared to the MYB shRNA-Dox and the NS+Dox groups; Panel (b) 
represents MYB target genes in the MYB shRNA+Dox group showed significant differential 
expression  (P<0.05) when only compared to the NS+Dox group; Panel (c) represents MYB target 
genes in the MYB shRNA+Dox group that showed no significant differential expression (P>0.05) 
when compared to the MYB shRNA-Dox and the NS+Dox groups. All data are normalised against 
18S rRNA mRNA. The standard deviation is represented by error bars (n=3; * indicates P<0.05). 
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3.2.11) Pathway analyses 
     The 145 differentially expressed genes with MYB-binding sites between the Luc 
shRNA+Dox (as a nonsilencing control) and the two MYB shRNA+Dox datasets were used to 
generate two individual gene lists (MYB activated genes and MYB repressed genes) with Log2FC 
(less than 0.5 or higher than 0.5) and significant p-values (P<0.05). These two gene lists were used 
to identify particular pathways by using GeneGO bioinformatics software and thus to correlate 
MYB target genes with biological functions. As illustrated in Figure 3.13(a), genes that play a role 
in the regulation of cell adhesion, TGF-β mediated regulation of cell proliferation and cytoskeleton 
remodelling were enriched (P<0.05) in the set of potential MYB activated genes. Potential MYB 
repressed genes showed enrichment (P<0.05) among genes that play a role in the regulation of 
ESR1 action on cytoskeleton remodelling and cell migration, regulation of G-protein signalling 
(M-RAS, R-RAS, TC21, Rho A, S1P2 receptor, G-protein α 12), and regulation of cell 
development (Figure 3.13(b)). Figure 3.13(c) shows that two potential MYB target genes (ESR1 and 
GHR) are involved in breast cancer signalling pathways. Although pathway analyses provide an 
idea of the possible role of differentially regulated genes, further functional experiments are 
required to provide more evidence.  
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(a) Potential MYB activated genes 
 
 
 100 
(b) Potential MYB repressed genes 
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(c)  
 
Figure 3.13: Gene GO analysis of potential MYB target genes in human ER+ breast cancer 
cells. (a) Potential MYB activated genes showing an enrichment in the listed pathways; (b) 
Potential MYB repressed genes showing an enrichment in the listed pathways; (c) a general schema 
of breast cancer showing MYB target genes (ESR1 and GHR, red square) that are involved in breast 
cancer signalling pathways  
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3.3 Discussion 
   The first part of this chapter described my attempts to establish human ER+ breast cancer cells 
expressing MYB shRNA. These cells were utilized to identify and validate MYB target genes by 
combining Dox-inducible RNA interference with RNA-Seq gene expression profiling. RNA 
interference has been applied for a tool of gene modification to study the roles and functions of a 
specific and interesting gene. Silencing a specific gene by transferring small interfering RNA 
(siRNA) or short hairpin RNA (shRNA) into target cells is simpler and faster than gene knockout 
that is mediated by homologous recombination (Elbashir et al., 2001, Brummelkamp et al., 2002).  
   However, delivery of siRNA oligonucleotides to target cells to silence a specific gene may be 
limited by transfection efficiencies. The transduction of shRNA into mammalian cells through 
infection with lentiviral vectors allows integrating shRNA into host genome. This strategy provides 
stable and long-term targeted gene silencing. Unfortunately, some standard shRNA vectors 
constitutively inhibit targeted gene expression after introduction. If the shRNA is targeted at a gene 
that is essential for cell survival and cell growth, the possibility of obtaining a stable cell line is low. 
Hence, inducible shRNA vectors may be more suitable for silencing targeted genes expression 
because such systems can provide temporal and reversible control of the targeted gene expression 
(Szulc et al., 2006, Matsukura et al., 2003).      
   However, there are still problems in achieving effective and regulated shRNA-mediated gene 
knockdown. For example, the leakiness of short hairpin activity in the uninduced state is a problem 
of some inducible shRNA systems (Aagaard et al., 2007, Pluta et al., 2007). To avoid this problem, 
the pINDUCER lentiviral system for inducible RNA interference in vitro and in vivo was developed 
(Meerbrey et al., 2011). This pINDUCER lentiviral vector can minimize basal expression of 
shRNAs in polyclonal populations because it can present different colours in the absence or the 
presence of Dox (Figure 3.1(a)). In the absence of Dox, cells only express GFP that helps to track 
transduced cells. In the presence of Dox, cells express RFP that tracks the shRNA-expressing cells. 
   To date, the CRISPR (clustered regularly interspaced short palindromic repeats) interference 
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(CRISPRi) system has been developed for an alternative way of gene silencing (Heintze et al., 2013, 
Qi et al., 2013). The CRISPRi system is based on the CRISPR/Cas9 system that is a general 
bacterial genetic immune mechanism to detect and degrade exogenous sequences from invading 
bacteriophages (Barrangou et al., 2007, Horvath and Barrangou, 2010). The CRISPR/Cas9 system 
use the single guide RNAs (sgRNAs) to target and cleave foreign DNA elements in a 
sequence-specific manner (Deltcheva et al., 2011, Jinek et al., 2013). The essential components of 
the CRISPR/Cas9 system are the CRISPR-associated (Cas) endonuclease, the trans-acting RNA 
(tracrRNA), and CRISPR RNA (crRNA) (Deltcheva et al., 2011, Jinek et al., 2013). The CRISPRi 
system employs a catalytically dead Cas9 (dCas9) lacking endonuclease activity to generate a DNA 
recognition complex that can specifically interfere with transcriptional elongation, RNA polymerase 
binding or transcription factor binding (Jinek et al., 2012, Jinek et al., 2013, Qi et al., 2013). The 
CRISPRi system is more specific to knockdown target genes (Gilbert et al., 2013) and usually 
achieving at least 90% downregulation of target genes with minimal off-target effects when 
compared to RNAi system (Gilbert et al., 2014). Thus, the CRISPRi system can be as a 
complementary method to knockdown MYB. 
   In this chapter, I established one stable cell line with pINDUCER vector and two stable cell 
lines with the pLV711 vector each of which expressed different MYB shRNAs for RNA interference. 
Figure 3.5 shows that 60% inhibition of MYB expression in cells expressing MYB shRNA1 from 
pINDUCER was obtained in the presence of Dox when compared to the absence of Dox. However, 
there was no effect on BCL2 expression or cell proliferation of MCF-7 cells expressing MYB 
shRNA1 in the presence of Dox (Figures 3.6 and 3.7). In contrast, Figure 3.8 shows approximately 
80% inhibition of MYB expression in cells expressing MYB shRNA C4 or C5 after Dox induction. 
Furthermore, this resulted in BCL2 downregulation (Figure 3.8(a)) and approximately 40% to 50% 
inhibition of cell proliferation of MCF-7 cells (Figure 3.9). These data suggest that the differential 
effects on BCL2 expression and cell proliferation seen with the three MYB shRNA cell lines, 
generated from two different vectors, are likely to result from the level of MYB expression in the 
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presence of Dox. 
   Previous studies indicated that MYB knockdown inhibits cell proliferation and leads to cell cycle 
arrest at the late G1 or early S phase (Drabsch et al., 2007) via downregulation of cyclin B1 
expression (Okada et al., 2002, Nakata et al., 2007) and cyclin E1 (Malaterre et al., 2007, Cheasley 
et al., 2015). MYB overexpression promotes cell cycle progression and cell proliferation through 
upregulation of cyclins (A1, D1 and E1) (Srivastava et al., 2012). My data in Figures 3.8(b) shows 
80% inhibition of MYB expression in cells expressing MYB shRNA (C4 or C5) after Dox induction. 
This led to approximately 40% to 50% inhibition of cell proliferation of MCF-7 cells (Figure 3.9). 
Thus, it is possible that MYB knockdown may suppress cell proliferation of MCF-7 cells via 
downregulation of key cyclins (A1, B1, D1 and E1). 
   The second part of the work described in this Chapter was to identify MYB target genes by 
combining RNA-Seq gene expression profiles with three published ChIP datasets. My data in PCA 
analysis (Figure 3.11(a)) and the analysis of differential gene expression (data not shown) show no 
differences between the NS−Dox and the NS+Dox groups, but obvious differences between the 
NS+Dox group and the two MYB shRNA (C4 or C5)+Dox groups. This implies that there was no 
effect of Dox itself on gene expression of cells, and that changes of gene expression only resulted 
from MYB knockdown. Figure 3.11(b) shows that approximately 500 genes that had the significant 
differential gene expression between the NS+Dox groups and the two MYB shRNA+Dox groups 
were found. After further analysis of differential expression of genes in the two MYB shRNA 
groups, some of the differentially-expressed genes only appeared in one of the two MYB shRNA 
groups (data not shown). Thus, to obtain robust results, common genes from the two MYB 
shRNA+Dox versus NS+Dox groups were used for identification of MYB target genes.  
    Previous studies indicated that BCL2 is a known MYB target gene in myeloid cells (Frampton 
et al., 1996, Zhao et al., 2011) and breast cancer (Drabsch et al., 2010). Figure 3.8 shows that 
silencing MYB resulted in decreased BCL2 expression in cells expressing MYB shRNA C4 or C5. 
However, when analysed the data from RNA-Seq gene expression profiles, BCL2 did not show 
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differential expression. This may result from low average reads per kilobase of transcript per 
million mapped reads (RPKM) values. Previous studies indicated that genes with an average RPKM 
value across samples between 0.125 and 1 were considered to be expressed at low levels (Hackett et 
al., 2012, Seyednasrollah et al., 2015). The average RPKM value of BCL2 across samples in 
RNA-Seq data from my experiments was approximately 0.333. It is unclear why BCL2 was 
apparently expressed at such low levels in my RNA-Seq data. 
   Table 3.3 shows only 9 MYB target genes were confirmed as being differentially expressed by 
Q-PCR, out of the 38 potential MYB target genes that were selected for this analysis. This low rate 
of PCR validation of RNA-Seq differentially expressed genes may result from shRNA leakiness in 
the MYB shRNA C5 cells before Dox induction which would subsequently result in downregulation 
of some of 38 potential MYB target genes  (such as CSRNP2 and ZNF721) in the absence of Dox 
(Figure 3.12(b)). 
   My data in Figure 3.11(b) shows that approximately 500 genes showed differential expression 
between the NS+Dox groups and the two MYB shRNA+Dox groups. However, only 73 genes (such 
as ESR1 and GHR) were identified as direct MYB target genes (Figure 3.11(c)), but no known 
MYB target genes (such as BCL2; (Drabsch et al., 2010)) in breast cancer. This low ratio of 
identification of MYB target genes in breast cancer may be due to the two published ChIP-on-ChIP 
data containing MYB binding sites in the promoter region of the target gene (Quintana et al., 2011). 
MYB can function as an enhancer factor to regulate target gene expression (Kintscher et al., 2004, 
Gundelach et al., 2007); i.e. these MYB binding sites were not located in the promoter of the target 
genes (Wilczek et al., 2009, Zhao et al., 2011). Previous studies reported that chromatin 
immunoprecipitation followed by sequencing (ChIP-Seq) could identify enhancer factor binding 
sites in the non-promoter regions (Jothi et al., 2008, Visel et al., 2009). Thus, ChIP–Seq in ER+ 
breast cancer can be applied to integrate with RNA-Seq data for improvements in reliably 
identifying MYB target genes. 
    As described in Chapter 1, almost half of all human breast cancers are ER+ and highly express 
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MYB. MYB promoted breast cancer proliferation (Drabsch et al., 2007), invasion and metastasis 
(Knopfova et al., 2012, Li et al., 2016). Metastatic breast cancers in the bone (Ogba et al., 2014, 
Savci-Heijink et al., 2016) and lymph nodes (Harrell et al., 2006, Ogba et al., 2014) expressed ER. 
My data in Figure 3.13 shows that potential MYB target genes (e.g. ESR1 and GHR) are involved in 
many biological functions including cell proliferation, cell adhesion, cytoskeleton remodelling and 
cell migration. These functions are important in breast cancer development and metastasis. 
Metastatic breast cancers that can result in secondary tumours are the main problem in breast cancer 
therapy following surgery to remove primary tumours (Ahmad, 2013). Thus, targeting MYB and its 
target genes may lead to improvements in breast cancer therapy. This will require further studies. 
For example, it would be of interest to investigate whether the combination of MYB knockdown and 
ESR1 in ER+ breast cancer by RNAi would affect proliferation and migration in vitro and in vivo. 
    In conclusion, although this chapter only identified 145 potentially direct MYB target genes 
containing genomic MYB binding sites and only validated 38 genes of these, I noticed that several 
MYB target genes that are involved in DNA damage repair pathways (e.g. BRCA1, TOPBP1, 
XRCC3 and XRCC6) were identified. As described in Chapter 1, breast cancer is intimately related 
to accumulation of DNA damage and DNA repair defects (e.g. BRCA1) (Cressman et al., 1999, 
Cipollini et al., 2004). Recently, two studies observed that MYB was involved in DNA damage 
response in prostate cancer (Li et al., 2014) and nasopharyngeal cancer (Wang et al., 2015). 
However, the role of MYB and its target genes in DNA damage responses in human ER+ breast 
cancer is still understudied. Thus, the following chapter investigates the role of MYB in DNA 
damage responses. 
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Chapter 4- MYB is involved in the DNA damage response in 
human ER+ breast cancer cells 
4.1 Introduction 
  Previous studies from our laboratory found that shRNA-mediated MYB knockdown greatly 
sensitised breast cancer cells to chemically-induced apoptosis by down-regulating BCL2 (a MYB 
target gene) (Drabsch et al., 2010). Furthermore, several published studies (Taha et al., 2004; 
Thomadaki et al., 2006) indicated that actinomycin D (ACT D) and etoposide (ETO) treatment 
could induce DNA damage in human ER+ breast cancer (MCF-7) cells. Moreover, silencing MYB 
increased DNA damage-induced cell death in castration-resistant prostate cancer cells by 
downregulating DNA damage response genes (Li et al., 2014). In addition, downregulated MYB 
expression increased radiation-induced DNA damage in nasopharyngeal carcinoma (Wang et al., 
2015). However, there is very little information on MYB function in the DNA damage response of 
ER+ breast cancer cells. Therefore, the aim of the work in this chapter was to investigate whether 
silencing MYB affected the DNA damage repair and then resulted in cell death in MCF-7 cells.  
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4.2 Results 
4.2.1) Silencing MYB increases cell sensitivity to DNA-damaging agents in MCF-7 cells  
   To examine whether MYB silencing sensitized MCF-7 cells to DNA-damaging agents, cells 
expressing Luc shRNA or Dox-inducible MYB shRNA (C5) with the pLV711 vector were treated 
with or without Dox for five days before exposure to ACT D or ETO for a further 24 hours. As 
illustrated in Figures 4.1(a) and 4.1(b), silencing MYB alone did not result in cell death, in 
agreement with Drabsch et al. (2010), while ACT D treatment resulted in approximately 40% 
cytotoxicity toward parental cells and the MYB shRNA cells in the absence of Dox (Figure 4.1(a)). 
However, cell death in the MYB shRNA group was increased approximately two-fold after the 
combination of ACT D and Dox induction, compared to ACT D only group. A similar phenomenon 
was found in the MYB shRNA cells after exposure to the combination of ETO treatment and Dox 
induction, compared to ETO alone in both the Luc shRNA and the MYB shRNA-Dox groups 
(Figure 4.1(b)). These results suggest that silencing MYB sensitises MCF-7 cells to DNA-damaging 
agents. 
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Figure 4.1: Cytotoxicity of DNA damaging agents (ACT D and ETO) in MCF-7 cells. Parental 
cells and cells expressing Luc shRNA or MYB shRNA were cultured in the absence or presence of 
Dox for five days before exposure to ACT D (a) or ETO (b) with or without Dox for a further 24hrs. 
Cells were stained with PI and analysed by FACS for cell death (n=4; * indicates P<0.05).  
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4.2.2) Silencing MYB enhances the inhibitory effect of ETO on the growth of MCF-7 cells 
   Previous studies indicated that ETO treatment induced DNA damage and resulted in growth 
inhibition of human ER+ breast cancer MCF-7 cells that could be due to effects on proliferation, 
viability or both (Sinha et al., 1988, Zhang et al., 2004, Bidwell and Raucher, 2006). Proliferating 
cells are often presumed to repair DNA damage quickly (Bielas and Heddle, 2000). As described in 
Chapter 1 and 3, several MYB target genes (e.g. BRCA1 and TOPBP1) are involved in response to 
repair DNA damage. To investigate whether MYB silencing enhances ETO-induced DNA damage 
and subsequently enhances the effects of ETO on cell growth, cells expressing Luc shRNA or MYB 
shRNA were treated with or without ETO in the absence or presence of Dox for 24 hours before 
washing out the ETO. These treatments were aimed to induce DNA damage over the first 24 hours 
of the study that potentially allows DNA repair without further DNA damage. Subsequently, these 
cells were continuously cultured in the absence or presence of Dox for a further five days (Figure 
4.2(a)). These treatments were aimed to affect some MYB targets-mediated DNA repair (in 
response to ETO induced DNA damage) over the further five days of the study only. If ETO-induce 
DNA damage can be repaired, cells will survive and grow. The number of cells will increase. As 
illustrated in Figure 4.2(c), MYB silencing slowed down cell growth of the MYB 
shRNA+Dox+DMSO group (blue dotted line), compared to the MYB shRNA–Dox+DMSO group 
(blue solid line) as reported previously (Drabsch et al., 2007). When cells were treated with ETO in 
the absence of Dox, inhibition of cell growth of the Luc shRNA and the MYB shRNA cells was 
observed (green, red, magenta and brown solid lines in Figures 4.2(b) and 4.2(c)), Furthermore, 
when cells were treated with the combination of ETO and Dox, a dramatic inhibition of cell growth 
was seen in the MYB shRNA+Dox+ETO cells (magenta and brown dashed lines), compared to the 
MYB shRNA–Dox+ETO (Figure 4.2(c)), the Luc shRNA–Dox+ETO (green and red solid lines in 
Figure 4.2(b)) and the Luc shRNA+Dox+ETO groups (green and red dashed lines in Figure 4.2(b)). 
These results suggest that silencing MYB enhances the effect of ETO-induced DNA damage and 
subsequently inhibits cell growth of MCF-7 cells. 
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Figure 4.2: Effect of silencing MYB on cell proliferation of MCF-7 cells. (a) A diagram 
illustrating the experimental design. (b) Cells expressing Luc shRNA or MYB shRNA were cultured 
in the absence or presence of Dox for five days before exposure to ETO with or without Dox for a 
further 24 hours. After washing out ETO on day 1, cells were continually cultured in the absence or 
presence of Dox for 5 days. Luciferase or GFP positive cells were counted at daily intervals. DMSO 
was added at 0.25% which was the same concentration resulting from ETO addition.  
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4.2.3) Silencing MYB promotes DNA damage-induced cell death through downregulation of 
BCL2 expression  
    Previous studies showed that ETO-induced DNA damage triggers apoptosis through the 
downregulation of BCL2 and upregulation of pro-apoptotic BCL2 family proteins such as BAX 
(Milosevic et al., 2003, Thomadaki et al., 2006). BCL2 is a MYB target gene in breast cancer 
(Drabsch et al., 2010) and in myeloid cells (Frampton et al., 1996, Zhao et al., 2011). To test 
whether MYB silencing results in BCL2 downregulation in order to promote DNA damage-induced 
cell death, cells were treated with ETO in the absence or presence of Dox for 24 hours to collect cell 
lysates for western blotting analysis. As illustrated in Figures 4.3(a) and 4.3(b), BCL2 expression in 
the MYB shRNA cells was reduced following exposure to Dox+DMSO treatment for 24 hours when 
compared to the MYB shRNA–Dox+DMSO group, in agreement with Drabsch et al. (2010). 
Furthermore, BCL2 expression in the MYB shRNA cells was significantly reduced (P<0.05) 
following exposure to the combination of ETO and Dox for 24 hours when compared to ETO only 
in the MYB shRNA cells and the Luc shRNA cells (as NS control) (Figure 4.3(b)). These data imply 
that silencing MYB enhances BCL2 downregulation in order to promote DNA damage-induced cell 
death. 
 
 
 
 
 
 
 
 
 113 
 (a)  
 
 
(b) 
              
-D
ox
+D
MS
O
-D
ox
+E
TO
+D
ox
+D
MS
O
+D
ox
+E
TO
0.0
0.5
1.0
1.5
2.0
 
R
el
at
iv
e 
B
C
L2
 e
xp
re
ss
io
n
( o
f  
β
-a
ct
in
)
Luc shRNA
MYB shRNA
*
*
* *
 
Figure 4.3: The effect of BCL2 expression in ETO-induced cell death in MCF-7 cells 
expressing Luc shRNA (as a nonsilencing control) or Dox-inducible MYB shRNA. Cells were 
cultured in the absence or presence of Dox for five days before exposure to ETO with or without 
Dox for a further 24 hours to collect total cell lysates. Total cell lysates were analysed via western 
blot (a) using an anti-BCL-2 pAb, an anti-MYB mAb, and an anti-β-actin mAb (as loading control). 
All data (b) were normalised against β-actin. The standard deviation is represented by error bars (n= 
3; * indicates P<0.05). 
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4.2.4) Silencing MYB increases ETO-induced DNA damage 
   The variant histone H2AX is a key factor in the response to DNA damage. It can be 
phosphorylated on serine residue 139 and recruited to the site of damaged DNA (Rogakou et al., 
1998). Phosphorylated H2AX is also called γ-H2AX (Rogakou et al., 1998). To explore the 
mechanism underlying ETO induced cytotoxicity, γ-H2AX signal was assessed by western blotting 
analysis. As illustrated in Figure 4.4(a) (right panel), MYB silencing in the MYB shRNA cells did 
not induce γ-H2AX. However, 24 hours of combined ETO and Dox administration (right panel in 
Figure 4.4 (a)) led to increased γ-H2AX signal in the MYB shRNA cells when compared to ETO 
alone (left panel in Figure 4.4(a)); this was not observed in parental and non-silencing (Luc shRNA) 
cells (Figure 4.4(b)). Next, to further understand the effect of silencing MYB on ETO induced 
γ-H2AX signal, cells were treated with –Dox+ETO or +Dox+ETO for different times (3hrs, 6hrs 
and 24hrs) to collect cell lysates for western blotting analysis (Figures 4.5(a) and 4.5(b)). As 
summarised in Figure 4.5(c), an approximately 2-fold increase of γ-H2AX signal (P<0.05) was 
found in the MYB shRNA cells treated with the combination of ETO and Dox for three hours, 
compared to ETO alone, DMSO alone or +Dox+DMSO in the Luc shRNA and the MYB shRNA 
groups. This difference in the MYB shRNA cells was lost at 6 hours treatment (P>0.05), but 
reappeared at 24-hours treatment (P<0.05) (blue dashes and solid lines in Figure 4.5(c)). Figure 
4.5(c) also shows higher γ-H2AX signal in the MYB shRNA cells after exposure to either ETO 
alone or combination of ETO and Dox for six hours, compared to same treatment in the Luc shRNA 
cells. This result was observed in three independent experiments (P<0.05) and could result from 
shRNA leakiness of the MYB shRNA cells in the absence of Dox induction. In addition, Figure 
4.5(c) shows that the maximal signal of γ-H2AX occurred after six hours treatment and was reduced 
at 24 hours treatment. These data suggest that MCF-7 cells may start repairing DNA damage over 
this period (6 to 24 hours) and that reduced levels of MYB may delay the DNA repair.   
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Figure 4.4: γ-H2AX signal in MCF-7 parental cells and cells expressing Luc shRNA or 
Dox-inducible MYB shRNA. Cells were cultured in the absence or presence of Dox for five days 
before exposure to ETO in the absence or presence of Dox for a further 24 hours. These cells were 
used to collect total cell lysates. Total cell lysates were analysed via western blot (a) with γ-H2AX 
and GAPDH antibodies. (b) The left panel represents that cells were exposed to –Dox 
only, –Dox+DMSO or –Dox+ETO treatment; the right panel represents that cells were exposed to 
+Dox only, +Dox+DMSO or +Dox+ETO treatment. All data (b) were normalised against GAPDH 
expression of wild type cells. The standard deviation is represented by error bars (n= 3; * indicates 
P<0.05).  
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Figure 4.5: γ-H2AX signal in MCF-7 cells expressing Luc shRNA or Dox-inducible MYB 
shRNA. Cells expressing Luc shRNA (a) or MYB shRNA (b) were cultured in the absence or 
presence of Dox before exposure to ETO with or without Dox for a further time series to collect 
total cell lysates. Total cell lysates were collected for western blot analysis (a and b) with γ-H2AX 
and β-actin antibodies; all data (c) were normalised against β-actin control (n=3; * indicates 
P<0.05). 
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4.2.5) Downregulation of MYB increased ETO-induced γ-H2AX focus formation 
    γ-H2AX focus formation is another assay for DNA damage, such as DNA double strand breaks; 
these are marked by microscopically visible γ-H2AX foci (Rogakou et al., 1999, Banath et al., 
2010). To further confirm that MYB knockdown promoted ETO-induced DNA damage, 
immunofluorescent staining with γ-H2AX antibodies and DAPI (to mark nuclei) was performed 
(Figures 4.6(a) and 4.6(b)). Because an average of approximately ten γ-H2AX foci per cell were 
present in DMSO-treated cells (the vehicle for ETO), a cell that contained more than ten γ-H2AX 
foci was defined as γ-H2AX positive. As illustrated in Figure 4.6(c), approximately 20% of cells 
were γ-H2AX positive in the MCF-7 Luc shRNA and MYB shRNA groups after exposure to 10 µM 
ETO in the absence of Dox for 24 hours. However, approximately 60% of cells were γ-H2AX 
positive in the MYB shRNA group after exposure to the combination of ETO and Dox, showing that 
MYB knockdown exacerbated DNA damage induced by ETO. 
   To further confirm that silencing MYB increased γ-H2AX focus formation in response to DNA 
damage, cells were treated with four other DNA-damaging agents (mitomycin C, cisplatin, 
doxorubicin and hydroxyurea) for three hours. As illustrated in Figure 4.7, an increase of 
approximately 1.5 to 2 fold in γ-H2AX positive cells was found in all four MYB shRNA groups 
after exposure to the combination of Dox and DNA-damaging agents, compared to MYB 
shRNA–Dox and Luc shRNA±Dox groups treated with DNA-damaging agents. These data support 
the proposition that MYB may play an important role in protection against DNA damage. 
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Figure 4.6: The effect of MYB silencing on ETO-induced γ-H2AX focus formation in MCF-7 
cells. Cells expressing Luc shRNA (a) or Dox-inducible MYB shRNA (b) were cultured in the 
absence or presence of Dox for five days before exposure to ETO with or without Dox for a further 
24 hours. They were then stained for γ-H2AX (Alexa Flour® 594; red) and nuclear DNA (DAPI; 
blue) and visualised by fluorescent microscopy (x40); (c) Approximately 300 cells in three different 
fields of fluorescent microscopy were counted. A cell that contained more than ten γ-H2AX foci 
was defined as γ-H2AX positive. The standard deviation is represented by error bars (n= 3; * 
indicates P<0.05). 
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Figure 4.7: The effect of MYB silencing on four DNA-damaging agent-induced γ-H2AX focus 
formation in MCF-7 cells. Cells expressing Luc shRNA or Dox-inducible MYB shRNA were 
cultured in the absence or presence of Dox for five days before exposure to DNA-damaging agents 
((a) Mitomycin C; (b) Cisplatin; (c) Doxorubicin and (d) Hydroxyurea) with or without Dox for a 
further three hours. They were then stained for γ-H2AX (Alexa Flour® 594; red) and nuclear DNA 
(DAPI; blue) and visualised by fluorescent microscopy (x40). Approximately 300 cells in three 
different fields of fluorescent microscopy were counted. Data shows mean ± S.E.M. A cell that 
contained more than ten γ-H2AX foci was defined as γ-H2AX positive (n= 2). 
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4.2.6) Silencing MYB affects RAD51 focus formation in the nucleus  
   RAD51 is a key factor in the homologous-recombination-mediated repair of DSB (Zeidler et al., 
2005). The repair of DNA damage involves the accumulation of RAD51 at the site of DNA damage 
in the nucleus (Gildemeister et al., 2009). To test whether silencing MYB affects RAD51 
colocalization with γ-H2AX in the nucleus, cells were subjected to in situ subcellular fractionation 
to remove cytoplasmic material before staining with anti-γ-H2AX mAb (Alexa Fluor® 594; red), 
anti-RAD51 pAb (Alexa Fluor® 750; cyan) and DAPI. This was followed by confocal fluorescence 
microscopy. As illustrated in Figure 4.8(a), when cells expressing Luc shRNA or MYB shRNA were 
exposed to ETO in the absence of Dox, increased γ-H2AX foci were observed, compared 
to –Dox+DMSO treatment. A similar result was also observed in +Dox+ETO treatment in the Luc 
shRNA or the MYB shRNA cells when compared to +Dox+DMSO treatment. Furthermore, 
increased numbers of γ-H2AX foci were observed in the MYB shRNA +Dox+ETO group when 
compared to the Luc shRNA +Dox+ETO group, as expected from the results shown above.  
Moreover, Figure 4.8(a) also shows increased RAD51 foci in the Luc shRNA or the MYB shRNA 
cells after exposure to ETO alone in the absence of Dox when compared to –Dox+DMSO treatment. 
However, when the MYB shRNA cells were treated with Dox and ETO, the number of RAD51 foci 
in the nucleus was dramatically reduced when compared to MYB shRNA–Dox+ETO group and Luc 
shRNA±Dox+ETO groups (Figure 4.8(a)). Because the background numbers of γ-H2AX and 
RAD51 foci in cells that were treated with DMSO were approximately 10 (as above) and 5 foci per 
cell, respectively, a cell that contained more than these numbers of foci was defined as γ-H2AX or 
RAD51 positive. Figure 4.8(b) (left panel) shows that approximately 5 to 10% of cells were 
γ-H2AX positive in Luc shRNA and MYB shRNA groups after exposure to DMSO alone in the 
absence or presence of Dox. Furthermore, ETO treatment of Luc shRNA±Dox and MYB 
shRNA–Dox cells resulted in approximately 40% γ-H2AX positive cells (Figure 4.8(b), left panel). 
Moreover, an increase of approximately 1.5 to 2 fold in γ-H2AX positive cells was found in the 
MYB shRNA+Dox+ETO group when compared to the MYB shRNA–Dox+ETO and Luc 
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shRNA±Dox+ETO groups (Figure 4.8(b), left panel), as expected from the results shown above. 
Figure 4.8(b) (right panel) also shows that approximately 10% of cells were RAD51 positive in Luc 
shRNA and MYB shRNA groups after exposure to DMSO alone in the absence or presence of Dox. 
Furthermore, approximately 30 % RAD51-positive cells were observed in Luc shRNA±Dox+ETO 
and MYB shRNA–Dox+ETO groups (Figure 4.8(b), right panel). However, an average decrease of 
approximately 5 fold in RAD51 positive cells was found in the MYB shRNA+Dox+ETO group 
when compared to MYB shRNA–Dox+ETO and Luc shRNA±Dox+ETO groups (Figure 4.8(b), 
right panel). These data show that MYB appears to play an important role in RAD51 focus 
formation in response to DNA damage. 
   Previous studies indicated that maximal γ-H2AX signal was detectable after approximately 3 
hours of ETO exposure (Friedmann et al., 2004, Muslimovic et al., 2009). Furthermore, in my data, 
the population of γ-H2AX focus-positive cells (approximately 70%) in the MYB shRNA cells with 
+Dox+ETO 3hrs treatment (Figure 4.8(b), left panel) is greater than in the MYB shRNA cells with 
+Dox+ETO 24hrs treatment (approximately 50%) (Figure 4.6(c)). Thus, cells with ±Dox+ETO 3hrs 
treatment were used to further study whether MYB knockdown affect RAD51 expression. Quintana 
et al. (2011) reported that RAD51 is a MYB-regulated gene. To further investigate whether MYB 
silencing affects RAD51 expression in response to ETO-induced DNA damage, cells were treated 
with ETO in absence or presence of Dox for three hours. Total RAD51 protein expression was 
assessed by western blotting analysis. Figure 4.9(a) shows that MYB silencing in the MYB shRNA 
cells increased γ-H2AX protein, compared to the Luc shRNA cells (Figure 4.9(a)), as expected from 
the results shown above. However, MYB silencing in the MYB shRNA cells did not change total 
RAD51 expression after 3 hours’ treatments (Figures 4.9(a) and 4.9(b)). These data imply that MYB 
does not directly regulate RAD51 expression that is important for RAD51 focus formation in 
response to DNA damage.  
   Previous studies showed that RAD51 is transported from the cytosol into the nucleus in 
response to DNA damage in mammalian cells (Raderschall et al., 1999, Gildemeister et al., 2009).  
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To investigate whether MYB silencing affects cytosolic and nuclear RAD51 expression, cell 
expressing Luc shRNA or MYB shRNA were cultured in the absence or presence of Dox for five 
days before exposure to ETO plus or minus Dox for a further three hours to collect cell lysates. 
These cell lysates were isolated into the cytosolic and the nuclear extract as described in Material 
and Methods. The cytosolic and the nuclear RAD51 expressions were analysed by western blotting 
with anti-RAD51 pAb. Figures 4.10(a) and 4.10(b) show that ETO treatment only or silencing MYB 
only in the MYB shRNA cells did not change cytosolic and nuclear RAD51 expression at three 
hours of treatment, compared to the Luc shRNA cells. However, when the MYB shRNA cells were 
treated with the combination of Dox+ETO for three hours, the nuclear RAD51 expression in the 
MYB shRNA cells was significantly (P<0.05) reduced by approximately 50%; this result was not 
observed in the Luc shRNA cells with same treatment (Figures 4.10(a) and 4.10(b), right panel). 
These data suggest that MYB plays an important role in cellular redistribution of RAD51 in 
response to DNA damage. 
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Figure 4.8: The effect of γ-H2AX foci and RAD51 foci in MCF-7 cells expressing Luc shRNA 
or Dox-inducible MYB shRNA. (a) Cells were cultured in the absence or presence of Dox for 5 
days before exposure to ETO plus or minus Dox for a further 3 hours. Cells were immunostained 
using anti-γ-H2AX mAb (red) and anti-RAD51 pAb (cyan). Subsequently, the cells were 
counterstained with DAPI for nuclear DNA (blue) and evaluated by confocal microscopy (x60). 
The formation of white foci in each merged image is indicative of γ-H2AX/RAD51 colocalization; 
(b) Approximately 300 cells in three different fields of confocal microscopy were counted. A cell 
that contained more than ten γ-H2AX foci or five RAD51 foci was defined as γ-H2AX positive or 
RAD51 positive, respectively. The standard deviation is represented by error bars (n= 3; * indicated 
P<0.05). 
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Figure 4.9: RAD51 expression in MCF-7 cells expressing Luc shRNA or Dox-inducible MYB 
shRNA. Cells were cultured in the absence or presence of Dox for 5 days before exposure to ETO 
plus or minus Dox for a further 3 hours. These cells were used to collect total cell lysates. 8% of 
total cell lysates were analysed via western blot (a) using an anti-γ-H2AX mAb, an anti-RAD51 
pAb, an anti-MYB mAb, and an anti-β-actin mAb (as loading control). All data (b) were normalised 
against β-actin (n=3; P>0.05). 
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Figure 4.10: The effect of cytosolic and nuclear RAD51 expression in MCF-7 cells expressing 
Luc shRNA or Dox-inducible MYB shRNA. Cells were cultured in the absence or presence of 
Dox for five days before exposure to ETO plus or minus Dox for a further three hours. These cells 
were used to collect total cell lysates. Total cell lysates were isolated into the cytosolic extract and 
the nuclear extract. 10% of the cytosolic extract and 50% of the nuclear extract were analysed via 
western blot (a) using an anti-RAD51, an anti-β-actin (as loading control for cytosolic extract) and 
an anti-PCNA antibodies (as loading control for nuclear extract). The left panel represents the 
cytosolic extract; the right panel represents the nuclear extract. All data (b) were normalised against 
an anti-β-actin (as a cytosolic loading control) or an anti-PCNA (as a nuclear loading control) (n=3; 
P<0.05). 
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4.2.7) Silencing MYB downregulates DNA damage response genes expression in response to 
ETO-induced DNA damage  
     As described in Chapter 1, MYB can influence gene regulation via direct mechanisms. 
Previous studies indicated that several genes (BRCA1, CEP164 and TOPBP1) that were involved in 
DNA repair were MYB target genes (Quintana et al., 2011, Drier et al., 2016). Furthermore, both 
BRCA1 (Cousineau et al., 2005) and TOPBP1 (Moudry et al., 2016) regulate RAD51 function in 
response to DNA damage. To investigate whether silencing MYB affects expression of selected 
DNA damage response genes in response to ETO-induced DNA damage, quantitative real-time 
PCR analysis of expression of BRCA1, CEP164 and TOPBP1 was performed. As illustrated in 
Figures 4.11(a), 4.11(c) and 4.11(f), BRCA1, CEP164 and TOPBP1 expression in MCF-7 cells was 
increased in both Luc shRNA and MYB shRNA cells after exposure to ETO for 24 hours in the 
absence of Dox, compared to DMSO controls. However, expression of BRCA1, CEP164 and 
TOPBP1 in the MYB shRNA+Dox group exposed to either a DMSO or ETO treatment was reduced, 
compared to Luc shRNA cells with the same treatments (Figures 4.11(a), 4.11(c) and 4.11(f)). In 
addition, as described in Chapter 3, RAD51AP2, which encodes a protein that interacts with RAD51 
(Kovalenko et al., 2006), was identified as a MYB-regulated gene from my RNA-Seq data. To 
investigate whether silencing MYB affect RAD51AP2 expression in response to ETO-induced DNA 
damage, quantitative real-time PCR analysis of RAD51AP2 mRNA expression was carried out. As 
illustrated in Figure 4.11(e), RAD51AP2 expression in MCF-7 cells was increased in both Luc 
shRNA and MYB shRNA cells after exposure to ETO for 24 hours in the absence of Dox, compared 
to DMSO treatment. However, RAD51AP2 expression in the MYB shRNA+Dox group, together 
with either DMSO or ETO treatment, was reduced compared to the similarly-treated Luc shRNA 
cells (Figure 4.11(e)). These data suggest that MYB may play an important role in the direct 
regulation of several DNA damage response genes in response to ETO-induced DNA damage. 
    As described in Chapter 1, MYB can also influence gene regulation via indirect mechanisms.  
Previous studies indicated BRCA1 interacts with PALB2 and BRCA2, which are not known MYB 
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target genes, to form a BRCA complex (Sy et al., 2009) before recruiting RAD51 to form RAD51 
foci at the site of DNA damage (Lord and Ashworth, 2007). To investigate whether silencing MYB 
affects BRCA2 and PALB2 expression in response to ETO-induced DNA damage, quantitative 
real-time PCR analysis of BRCA2 and PALB2 mRNA expression was performed. As illustrated in 
Figure 4.11(b), BRCA2 expression in the Luc shRNA cells did not change significantly (P>0.05) 
after exposure to ETO, compared to DMSO treatment, in agreement with a previous finding 
(Andres et al., 1998). Furthermore, BRCA2 expression in the MYB shRNA cells was increased after 
exposure to ETO in the absence of Dox treatment (Figure 4.11(b)). However, when compared to the 
Luc shRNA+DMSO group, BRCA2 expression in the MYB shRNA cells was not increased (P>0.05) 
after exposure to ETO (Figure 4.11(b)). Furthermore, BRCA2 expression in the MYB shRNA+Dox 
group, together with either DMSO or ETO treatment, was reduced when compared to the MYB 
shRNA–Dox+ETO group or to the Luc shRNA cells (Figure 4.11(b)). Thus, it was still unclear 
whether etoposide could increase BRCA2 mRNA expression in MCF-7 cells and whether silencing 
MYB affected BRCA2 expression. 
    In addition, Figure 4.11(d) shows that PALB2 expression in MCF-7 cells was increased in both 
Luc shRNA and MYB shRNA cells after exposure to ETO in the absence of Dox, compared 
to –Dox+DMSO treatment. However, PALB2 expression in the MYB shRNA+Dox group, together 
with either DMSO or ETO treatment, was reduced when compared to the Luc shRNA cells with 
either DMSO or ETO treatment (Figure 4.11(d)). These data suggest that MYB may play a role in 
ETO-induced PALB2 expression in MCF-7 cells and silencing MYB affect PALB2 expression in 
response to ETO-induced DNA damage.  
   Figure 4.11(b) shows a low level of BRCA2 expression in the MYB shRNA cells 
with –Dox+DMSO treatment, compared to the Luc shRNA cells under the same conditions. 
Similarly, Figure 4.11(d) shows generally lower PALB2 mRNA expression in the MYB 
shRNA-Dox+DMSO group compared to the Luc shRNA-Dox+DMSO group. These differences 
between the Luc shRNA cells and the MYB shRNA cells were also observed in the –Dox+ETO 
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treatments. These differences may result from leakiness of MYB shRNA expression in the absence 
of Dox induction, as I found in Chapter 3. 
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Figure 4.11: Quantitative real-time PCR analysis of DNA damage response genes mRNA 
expression in MCF-7 cells. Cells expressing Dox-inducible MYB shRNA or Luc shRNA were 
cultured as described in Figure 4.1 to collect total RNA following ETO or DMSO treatment for 
quantification of BRCA1 (a), BRCA2 (b), CEP164 (c), PALB2 (d), RAD51AP2 (e) and TOPBP1 (f) 
mRNA expression. The data are normalised in each case to the mRNA level in control (Luc 
shRNA-Dox+DMSO cells) (n=4, * indicates P<0.05). 
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4.3 Discussion 
    The purpose of the studies in this chapter was to investigate the role of MYB in the response to 
chemically-induced DNA damage. DNA damage by ACT D and ETO resulted in cell death in 
human ER+ breast cancer MCF-7 cells. In this chapter, it was found that knockdown of MYB 
enhanced cell death of MCF-7 cells after exposure to ACT D or ETO. This increased cytotoxicity 
may result from increasing DNA damage, down-regulation of BCL2 expression, the effects on DNA 
damage response genes such as BRCA1 and TOPBP1 or a combination of these effects. 
     ACT D (trade name: Cosmegen®) and ETO (trade name: VP-16) are common 
DNA-damaging agents (Grimm et al., 1980, Cocconi et al., 1991, Wood et al., 2006, DeVita and 
Chu, 2008). Crawford and Bowen (2002) found that 24 hour exposure to ~800nM ACT D resulted 
in approximately 30% death of MCF-7 cells. Similarly, my data in Figure 4.1(a) shows that 24 
hours exposure to 100nM ACT D in the absence of silencing MYB resulted in around 40% death of 
MCF-7 cells. However, MYB knockdown resulted in 80% of cell death of MCF-7 cells in the 
presence of 100nM ACT D for 24 hours. In addition, my data in Figure 4.1(b) shows that 24 hours 
exposure to 10µM ETO in the absence of silencing MYB resulted in approximately 15 % death of 
MCF-7 cells. However, silencing MYB increased cell death to approximately 30%. These data 
suggest that targeting MYB in combination with DNA-damaging agents may be worth exploring for 
the treatment of breast cancer.   
   Based on morphological change, cell death can be classified into four main groups including 
necrosis, apoptosis, autophagy and mitotic catastrophe (Kroemer et al., 2009, Galluzzi et al., 2012). 
Previous studies from this laboratory found that silencing MYB greatly sensitised breast cancer cells 
to chemically-induced apoptosis by down-regulating BCL2 (Drabsch et al., 2010). My data in 
Figure 4.3 also shows that obvious BCL2 down-regulation MCF-7 cells upon silencing MYB. 
Therefore, the death of MCF-7 cells after exposure to the combination of ETO and silencing MYB is 
likely to be due at least in part to BCL2 downregulation.  
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   ETO is a topoisomerase II α (topo IIα) inhibitor. Walker and Nitiss (2002) reported that 
inhibition of topo IIα resulted in the formation of DNA double-strand breaks and subsequent cell 
death. γ-H2AX is a common marker for DNA double strand breaks (Rogakou et al., 1998), and 
ETO can induce the formation of γ-H2AX foci (Li et al., 2015). My data in Figures 4.4, 4.5 and 4.6 
show that silencing MYB increased the γ-H2AX signal and foci formation in the presence of ETO in 
MCF-7 cells. Furthermore, Figure 4.5 also shows that silencing MYB resulted in an approximately 
2-fold increase of the γ-H2AX signal at three-hours treatment. This difference was lost at 6 hours 
treatment when the γ-H2AX signal was maximal, but reappeared at 24 hours treatment. In addition, 
the maximal γ-H2AX signal was occurred at six hours treatment and was reduced at 24 hours 
treatment. Therefore, it appears that silencing MYB increases ETO induced-DNA damage and may 
delay the repair of such DNA damage in MCF-7 cells. 
    Previous studies indicated that MYB knockdown results in a block of progression from the 
G1/S and G2/M phases (Gewirtz et al., 1989, Drabsch et al., 2007). This G1/S and G2/M cell cycle 
arrest is mediated through downregulation of cyclin E1 during G1/S transition (Ohtsubo et al., 1995, 
Malaterre et al., 2007, Cheasley et al., 2015) and cyclin B1 during G2/M transition (Nakata et al., 
2007). Furthermore, five DNA damaging agents (ETO, cisplatin, doxorubicin, mitomycin C and 
hydroxyurea) cause S phase delay and G2/M phase arrest (Smith et al., 1994, Ling et al., 1996, 
Johnson et al., 1999, Kang et al., 2001, Nam et al., 2010).  Moreover, under cell cycle arrest, cells 
are more sensitive to DNA damaging agents (e.g cisplatin) (Mueller et al., 2006). This may result 
from downregulation of key proteins (e.g. TOPBP1 and ATM) in response to DNA damage during 
cell cycle arrest (Mueller et al., 2006, Jeon et al., 2007, Mjelle et al., 2015). As illustrated in Figures 
4.6 and 4.7, an increase of γ-H2AX positive cells was found in all four MYB shRNA groups after 
exposure to the combination of Dox and DNA damaging agents, compared to MYB shRNA–Dox 
and Luc shRNA±Dox groups treated with DNA damaging agents. Therefore, it is possible that MYB 
knockdown may accelerate the effect of DNA damaging agent-induced S and G2/M cell cycle arrest 
in the MYB shRNA cells, compared to MYB shRNA-Dox+ETO and Luc shRNA±Dox+ETO groups.  
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     Previous studies indicated that DNA interstrand crosslinking agents (e.g. mitomycin C (Dusre 
et al., 1989) and cisplatin (Saleh et al., 2012)), topoisomerase II α (topo IIα) inhibitors (e.g. 
doxorubincin (Ross and Bradley, 1981, Nitiss, 2009) and ETO (Nitiss, 2009)), and replication fork 
blocking agents (e.g. hydroxyurea (Ward and Chen, 2001)) can induce DNA double strand breaks. 
Figure 4.7 shows that silencing MYB increased the number of γ-H2AX foci positive cells after 
exposure to all of theses DNA damaging agents (mitomycin C, cisplatin, doxorubicin or 
hydroxyurea), while Figure 4.5 implies that silencing MYB increases ETO induced-DNA damage 
through delaying the repair of such DNA damage. Therefore, there is a possibility that silencing 
MYB increases the number of DNA double strand breaks induced by DNA-damaging agents 
through delaying DNA repair in MCF-7 cells. 
    DNA double-strand breaks are dangerous lesions that can threaten genome stability. Thus, the 
repair of DNA double strand breaks is an important cellular mechanism to ensure genomic stability. 
The cellular response to DNA double strand breaks comprises two main pathways, namely HR and 
NHEJ (Helleday et al., 2007). In HR, RAD51 is a key protein in the response to DNA double-strand 
breaks (Mladenov et al., 2006). My data in Figure 4.8 shows that silencing MYB in the MYB shRNA 
cells reduced the formation of RAD51 foci after exposure to Dox+ETO treatment. RAD 51 can 
translocate from the cytosol to the site of DNA damage in the nucleus to form DNA-repair foci 
(Tarsounas et al., 2004). Furthermore, the formation of ETO-induced RAD51 foci was abolished in 
the absence of RAD51C in vivo (Rodrigue et al., 2006) and lack of RAD51C in the nucleus resulted 
in the degradation of nuclear RAD51 (Bennett and Knight, 2005, Gildemeister et al., 2009). 
Moreover, RAD51C is a MYB-regulated gene (Quintana et al., 2011, Drier et al., 2016). My data in 
Figures 4.9 and 4.10 show that silencing MYB in the MYB shRNA cells did not detectably change 
the total amount of RAD51 or cytosolic RAD51 expression, but reduced nuclear RAD51 expression 
after exposure to +Dox+ETO treatment. There are two possibilities to explain this apparent 
discrepancy. Firstly, the amount of RAD51 in the cytosol is much greater than the nucleus. Only 
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10% of the cytosolic extract was used to examine cytosolic RAD51, compared to 50% of the 
nuclear extract to examine nuclear RAD51 expression. In the untreated samples, the intensity of the 
cytosolic and nuclear RAD51 was roughly equal that means RAD51 in the cytosol was 5 fold more 
than the nucleus. Thus, a change in the amount of nuclear RAD51 may not show up as a change in 
the cytosol, because the proportionate change may be five times less. Secondly, there is a possibility 
that silencing MYB may result in the downregulation of RAD51C expression that subsequently 
resulted in the low level of RAD51C in the nucleus. The low level of RAD51C may result in the 
nuclear RAD51 degradation, and affect nuclear RAD51 localisation and consequently result in the 
failure of RAD51 focus formation in response to ETO-induced DNA damage.  
     My data in Figure 4.10(a)(right panel) shows that there is a small amount of nuclear RAD51 
in the MYB shRNA cells after +Dox+ETO treatment, but Figure 4.8(a) shows that silencing MYB 
resulted in no RAD51 foci in the nucleus of the MYB shRNA cells after +Dox+ETO treatment. 
Previous studies reported that phosphorylation of nuclear RAD51 is required for RAD51 focus 
formation (Moudry et al., 2016, Liu and Smolka, 2016). Thus, a possible explanation is silencing 
MYB may interfere with nuclear RAD51 phosphorylation through downregulating expression of 
target genes that encoding DNA repair proteins such as TOPBP1 that are involved in 
phosphorylation of RAD51, subsequently leading to the loss of RAD51 foci.  
     A previous study indicated that BRCA1 regulates RAD51 recruitment in response to DNA 
double strand breaks during the HR process (Cousineau et al., 2005). Furthermore, CEP164 
phosphorylated RPA (Sivasubramaniam et al., 2008) and phosphorylated RPA can bind to DNA 
before recruiting RAD51 to DNA damage sites (Fanning et al., 2006, Krejci et al., 2012). Moreover, 
BRCA1, CEP164 and TOPBP1 are MYB target genes (Quintana et al., 2011, Drier et al., 2016) that 
are involved in DNA repair. My data in Figures 4.11(a), 4.11(c) and 4.11(f) show that ETO 
treatment increased BRCA1, CEP164 and TOPBP1 mRNA expression in both Luc shRNA cells and 
MYB shRNA cells, in agreement with previous studies (Brodie and Henderson, 2010, Shin et al., 
2013, Liu et al., 2012). However, silencing MYB reduced BRCA1, CEP164 and TOPBP1 mRNA 
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expression in MYB shRNA cells after exposure to ETO. A similar result was found for RAD51AP2 
(a potential MYB target from RNA-Seq dataset) mRNA expression (Figure 4.11(e)). Thus, 
silencing MYB affects BRCA1, CEP164, RAD51AP2 and TOPBP1 mRNA expression and is likely 
to consequently reduce the level of BRCA1, CEP164, RAD51AP2 and TOPBP1 proteins, all of 
which are involved in RAD51 focus formation in response to ETO-induced DNA damage 
(Cousineau et al., 2005, Kovalenko et al., 2006, Sivasubramaniam et al., 2008, Moudry et al., 
2016). 
    As described in Chapter 1, many chemotherapeutic agents induce DNA damage to kill cancer 
cells. If the DNA damaged lesions are successfully repaired, cancer cells will escape from cell 
death. Thus, targeting DNA damage response (e.g. RAD51 expression (Hine et al., 2008) or RAD51 
focus formation (Budke et al., 2012)) in cancer therapy has studied for many years (Hosoya and 
Miyagawa, 2014, Ward et al., 2015, Gavande et al., 2016). However, the use of DNA damaging 
agents (e.g. ETO and cisplatin) is limited by dose-limiting toxicities as well as the development of 
drug resistance (reviewed by Cheung-Ong groups (2013)). In this Chapter, I found that silencing 
MYB increased the effects of low doses of DNA damaging agents through interfering with RAD51 
focus formation. Thus, the combination of silencing MYB and DNA damaging agents may be 
potentially valuable for the improvement of breast cancer therapy.  
   In conclusion, my data highlight the potential roles of MYB in the DNA damage response in 
breast cancer. Silencing MYB increased ETO-induced DNA damage, reduced BCL2 expression, and 
suppressed RAD51 focus formation. The failure of RAD51 focus formation may result from 
downregulation of expression of important DNA damage response genes (e.g. BRCA1 and 
TOPBP1). DNA damage response genes examined in this Chapter can encode proteins that are 
involved in RAD51 focus formation. RAD51 foci are still composed of many other proteins (e.g. 
RPA (Tarsounas et al., 2003) and RDA52 (Wray et al., 2008, Krejci et al., 2012) that help RAD51 
to bind to DNA). Phosphorylation of RAD51 is required for the loading of RAD51 at the DNA 
damage sites before RAD51 focus formation (Moudry et al., 2016, Liu and Smolka, 2016). It is still 
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unclear the role of MYB in the RAD51 focus formation. It will be of interest to investigate whether 
MYB knockdown affects RAD51 focus formation through affecting the DNA repair proteins 
expression (e.g. RPA and RAD52) or RAD51 phosphorylation. This can be achieved by using 
combination of MYB knockdown and DNA repair proteins inhibitors (e.g. RPA inhibitors, RAD52 
inhibitors and PLK-1 inhibitors). 
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Chapter 5- The effect of MYB knockdown in mammosphere- 
derived cells 
5.1.Introduction  
   A tumour consists of different types of tissue components such as phenotypically heterogeneous 
cancer cells and stromal cells (Bergers and Benjamin, 2003). A model of tumour development has 
been proposed to explain the origin of tumours in terms of the heterogeneity of cancer cells 
(Visvader, 2011). As described in Chapter 1, the cancer stem cell (CSC) hypothesis states that 
heterogeneous cells in new tumours may arise from only a small population of undifferentiated cells, 
transit amplifying cells or the maturation arrest of immature stem cells (Al-Hajj and Clarke, 2004, 
Al-Hajj et al., 2004). Evidence to support the CSC hypothesis was first reported in haematological 
malignancies that only a tiny population of cancer cells was able to form new tumours (Lapidot et 
al., 1994, Bonnet and Dick, 1997, Sutherland et al., 1996). Putative CSC populations that have 
stem-like properties (self-renewal and differentiation) and that enable the regeneration of new 
tumours have been identified in many epithelial cancers: the breast (Al-Hajj et al., 2003), prostate 
(Collins et al., 2005), pancreas (Li et al., 2007), colon (O'Brien et al., 2007), ovaries (Gao et al., 
2010) and brain (Singh et al., 2004). For example, CD44+CD24-/low cells that were isolated from 
patients with breast cancer and that were serially transplanted into the mammary fat pads of 
nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice can regenerate the original 
tumours (Al-Hajj et al., 2003, Mani et al., 2008). These cells also expressed the putative stem cell 
marker OCT-4 (Ponti et al., 2005).  
    A previous study indicated that a cancer stem cell-related gene (NANOG) was a MYB target 
gene in human ER+ breast cancer MCF-7 cells (Quintana et al., 2011). However, the identification 
and functional analysis of putative mammary cancer stem cells has been hindered by the absence of 
suitable in vitro assays for testing key stem cell properties (e.g. self-renewal). The 
mammosphere-forming assay is a surrogate assay that examines whether cancer cells are able to 
self-renew and to be passaged several times (Dontu et al., 2003). Previous studies demonstrated that 
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ER+ breast cancer cell lines such as MCF-7 cells were able to form mammospheres and 
subpopulation of mammosphere-derived cells could be passaged in culture (Morrison et al., 2012, 
Smart et al., 2013). Other studies indicated that silencing MYB in sphere-derived cells of 
nasopharyngeal cancer cells (Wang et al., 2015) or pancreatic cancer cells (Farhana et al., 2013) 
affected sphere-forming capacities that were assessed by measuring the number of spheres and the 
size of spheres. However, there is little information about the role of MYB in spheres derived from 
ER+ breast cancer stem cells. Therefore, the aim of this chapter was to investigate potential role of 
MYB in human ER+ breast cancer stem cells using the mammosphere assay. 
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5.2.Results  
5.2.1) Oestrogen-induced cell proliferation and MYB mRNA expression 
    Previous studies indicated that oestrogen promoted cell proliferation (Lykkesfeldt and Briand, 
1986, Drabsch et al., 2007) and mammopshere formation in ER+ breast cancer cells (Sun et al., 
2014). To test whether human ER+ breast cancer (MCF-7) cells were able to form spheres in the 
presence of oestrogen, it was necessary to first confirm that MCF-7 cells were behaving as truly 
oestrogen responsive cells. Normal FBS contains some oestrogen activity, but this can be removed 
by charcoal-stripping (Cao et al., 2009). Thus, charcoal-stripped FBS in phenol red-free medium 
(Note: phenol red has weak estrogenic activity (Wesierska-Gadek et al., 2006)) was used to culture 
MCF-7 cells to ensure the total absence of oestrogen. Figure 5.1(a) shows that the number of 
MCF-7 cells increased by at least two-fold when treated with either phenol red free medium + 
stripped FBS + β-oestradiol (group B), phenol red medium + non-stripped FBS (group D) or phenol 
red medium + non-stripped FBS+ β-oestradiol (group E), compared to phenol red free medium + 
stripped FBS (group A). When cells in phenol red free medium + stripped FBS were treated with 
100nM fulvestrant (an oestrogen receptor antagonist; group C), the cell number was decreased 
(Figure 5.1(a)). Furthermore, the MYB expression of MCF-7 cells was increased by treating with 
either phenol red free medium + stripped FBS + β-oestradiol (group B in Figure 5.1(b)) or phenol 
red medium+ non-stripped FBS (group D in Figure 5.1(b)). When cells (groups C and F in Figure 
5.1(b)) were treated with fulvestrant, the MYB expression was decreased. These data imply that the 
MCF-7 cells in the Gonda laboratory responded positively to oestrogen and thus were suitable to be 
used to perform mammosphere culture experiments and other studies requiring oestrogen response.  
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Figure 5.1: Oestrogen-induced cell proliferation and MYB mRNA expression in the human 
ER+ breast cancer cell line (MCF-7). (a) β-oestradiol induced cell proliferation of MCF-7 cells. 
Cells were treated with either phenol red free medium + stripped FBS only (group A), phenol red 
free medium + stripped FBS + β-oestradiol (group B), phenol red free medium + stripped FBS + 
100 nM fulvestrant (group C), phenol red medium + non-stripped FBS (group D), phenol red 
medium + non-stripped FBS + 10 nM β-oestradiol (group E) or phenol red medium + non-stripped 
FBS + 100nM fulvestrant (group F) for 72 hours. The cell number was calculated using an 
automated cell counter (Cellometer® Auto T4). All data were normalised against the phenol red 
free medium + stripped FBS group. The standard deviation is represented by error bars (n= 3). The 
asterisk denotes a significant difference between the two samples (Student’s t-test, P<0.05); (b) 
Q-PCR of MYB mRNA expression in MCF-7 cells. Cells were treated with the same groups in 
panel (a). All Q-PCR data were normalised against GAPDH controls. The standard deviation is 
represented by error bars (n=3). The asterisk denotes a significant difference between the two 
samples (P<0.05).  
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5.2.2) Mammosphere culture of human ER+ breast cancer cell line MCF-7  
    Previous studies indicated that MCF-7 cells were able to form mammospheres in the presence 
of oestrogen containing medium (Sun et al., 2014). To confirm that the MCF-7 cells in our 
laboratory were able form mammosphere in the presence of oestrogen containing medium, cells 
were cultured in phenol red-containing human MammoCultTM medium without FBS and 
β-oestradiol in ultra-low attachment. Sufficient oestrogen activity was provided by the phenol red. 
Figure 5.2(a) shows the protocol I used to culture and passage mammosphere-derived cells. As 
illustrated in Figure 5.2(b), the human ER+ breast cancer MCF-7 cells were able to form 
mammospheres after 5 days of growth in the presence of phenol red-containing medium. These 
mammospheres were able to be passaged for three time generations. To further measure the number 
and size of mammospheres by fluorescent microscopy, MCF-7 parental cells were transduced with 
a GFP-expressing lentiviral vector. These cells could be analysed by using the ImageXpress® 
high-content imaging fluorescent microscope (Figure 5.2(c)). Cellular structures greater than 50µm 
diameter were defined as mammospheres (Dontu et al., 2003). 
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(a)                                  (b) 
       
(c) 
 
Figure 5.2: Sphere formation assay in mammosphere cultures of MCF-7 cells. (a) a diagram of 
mammosphere culture workflow shows how to culture and passage mammosphere-derived cells 
(red and blue balls). Briefly, single cells were culture in an ultra-low attachment plate for five days 
to form mammospheres. These mammospheres were dissociated enzymatically into single cells and 
replated in a new ultra-low attachment plate before growing them for further five days; (b) 1000 
single cells were plated in each well of a 96-well ultra-low attachment plate in the presence of 
phenol red medium without FBS. Depicted images show one field per well. The formation of 
mammospheres was observed after five days’ culture. Mammospheres were dissociated 
enzymatically and then 1000 single cells were replated in a new well of a 96-well plate. The capital 
letter P represents a passage. P0 cells on Day 0 represents single cells dissociated from adherent 
cells. P1 to P3 cells on Day 0 represent single cells dissociated from mammospheres. (c) The 
number of spheres in each well was counted using an ImageXpress® fluorescent microscope 
(10X/0.3 NA). These are images from the ImageXpress® fluorescent microscope. The left panel 
shows a whole well that contains 68 images. The right panel represents that one of these 68 images 
shows a mammosphere in a whole well. A particle in sized over than 50 µm was defined as a 
mammosphere (Dontu et al., 2003). Scale bars = 100 µm. 
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5.2.3) MYB expression in mammosphere-derived MCF-7 cells  
    Previous studies indicated that oestrogen promoted mammopshere formation (Sun et al., 2014) 
and regulated MYB expression in ER+ breast cancer cells (Drabsch et al., 2007). To investigate MYB 
expression in mammospheres, MCF-7 cells were cultured in phenol red-containing medium without 
FBS in an ultra-low attachment plate for five days to allow formation of mammospheres. These 
mammosphere-derived cells were passaged three times and used to collect total RNA for 
quantification of MYB mRNA expression by Q-PCR at each passage. As illustrated in Figure 5.3, 
MYB expression in P0 sphere-derived cells was reduced approximately 94% compared to adherent 
cells. However, MYB expression in P2 spheres increased approximately three-fold, compared to P0 
spheres (P<0.05). These data show that levels of MYB in mammospheres are much lower than in 
adherent cells; possible mechanisms will be discussed later.  
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Figure 5.3: Quantitative real-time PCR analysis of MYB mRNA expression in mammosphere 
derived MCF-7 cells. MCF-7 cells were cultured for five days to allow formation of 
mammospheres. These mammosphere-derived cells were passaged three times and total RNA was 
collected at each passage for quantitation of MYB mRNA expression by Q-PCR. P0, P1 and P2 
indicate the first generation mammosphere culture and the subsequent two passages, respectively. 
RNA was also collected from an adherent MCF-7 cell culture. GAPDH was as an internal control 
for Q-PCR. All data were normalised in each case to the MYB mRNA level in P0 sphere cells (n=3; 
* indicated P<0.05). 
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5.2.4) The effects of silencing MYB on mammosphere-forming capacity of MCF-7 cells 
   Previous studies indicated that silencing MYB reduced the number of spheres derived from 
nasopharyngeal cancer cells (Wang et al., 2015) and the size of spheres derived from pancreatic 
cancer cells (Farhana et al., 2013). The number and size of spheres are two parameters used for 
assessment of mammosphere-forming capacity (Dontu et al., 2003, Smart et al., 2013). MYB 
knockdown also suppressed proliferation of MCF-7 cells in adherent cultures (Drabsch et al., 2007). 
Thus, to investigate whether silencing MYB affected the mammosphere-forming ability of MCF-7 
cells, cells expressing Dox-inducible MYB shRNA or Luc shRNA (as a nonsilencing control), as 
described in Chapter 3, were cultured in the absence or presence of Dox for five days to allow 
sphere formation. These spheres were dissociated enzymatically and then passaged for three further 
generations, and the number of spheres counted (as described above) at each passage. As illustrated 
in Figure 5.4(a), the number of spheres in the MYB shRNA group was not reduced in the presence 
of Dox at P0, compared to MYB shRNA-Dox and Luc shRNA±Dox groups. MYB mRNA 
expression in mammosphere-derived cells expressing MYB shRNA was reduced in the presence of 
Dox when compared to the MYB shRNA-Dox group and the Luc shRNA±Dox groups (data not 
shown). A similar result was also found at each subsequent generation (Figures 5.4(b), 5.4(c) and 
5.4(d)). To investigate whether silencing MYB affected the size of mammospheres, they were 
divided into four categories in terms of sphere diameter (Shriver et al., 2015) at the P0, P1 and P2 
generations, and the numbers of spheres in each category was counted. As illustrated in Figure 
5.5(a), the number of spheres from 51 to 100 µm diameter in P0, P1 and P2 generations of MYB 
shRNA group was not reduced in the presence of Dox, compared to MYB shRNA-Dox and Luc 
shRNA±Dox groups. A similar result was also found in the 101 to 150 µm, 151-200 µm and >200 
µm groups (Figures 5.5(b), 5.5(c) and 5.5(d)). To further investigate whether silencing MYB 
affected the number of cells in a sphere, single cells were cultured in the absence or presence of 
Dox for five days to allow sphere formation. These spheres were enzymatically dissociated into 
single cells and counted as described in Materials and Methods after each generation. As illustrated 
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in Figure 5.6(a), the number of single cells per sphere in the P0 generation of the MYB shRNA 
group was not reduced in the presence of Dox, compared to MYB shRNA-Dox and Luc 
shRNA±Dox groups. A similar result was also found in the P1 generation (Figure 5.6(b)). However, 
the number of single cells per sphere in the P2 generation of the MYB shRNA group was reduced in 
the presence of Dox, compared to MYB shRNA-Dox and Luc shRNA±Dox groups (Figure 5.6(c)). 
Taken together, these data suggest that silencing MYB expression does not affect 
mammosphere-forming ability of MCF-7 cells in terms of number or size of spheres, but may affect 
the average number of single cells in a mammosphere. However the variability in Figure 5.5 and 
particularly Figure 5.6 makes this latter inference unreliable. 
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Figure 5.4: The number of mammospheres derived from MCF-7 cells expressing inducible 
MYB shRNA or Luc shRNA. 1000 single cells expressing Luc shRNA or MYB shRNA were 
cultured in the serum free + phenol red medium in the absence or presence of Dox for five days to 
allow formation of mammospheres. These mammosphere-derived cells were passaged four time 
generations. The number of spheres in a well was counted by ImageXpress® fluorescent 
microscope. The capital letter P represents a passage. (a) P0 spheres represent the first generation of 
mammospheres;  (b) P1 spheres represent the second generation of mammospheres; (c) P2 spheres 
represent the third generation of mammospheres and (d) P3 spheres represent the fourth generation 
of mammospheres. Duplicate samples within each group were examined twice (n=2). 
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Figure 5.5: The size of mammospheres derived from MCF-7 cells in five-day cultures. 1000 
single cells expressing Luc shRNA or MYB shRNA were cultured in the serum free + phenol red 
medium in the absence or presence of Dox for five days to allow formation of mammospheres. 
These mammosphere-derived cells were passaged three time generations. The size of spheres in a 
well was counted by ImageXpress® fluorescent microscope. The capital letter P represents a 
passage. P0 spheres represent the first generation of mammospheres. P1 spheres represent the 
second generation of mammospheres. P2 spheres represent the third generation of mammospheres. 
P0, P1 and P2 generations of mammospheres were divided into four groups according to the 
diameter of spheres: (a) 51-100µm; (b) 101-150µm; (c) 151-200µm and (d) >200µm and the 
percentage of the total number of spheres in each size range is shown. Duplicate samples within 
each group were examined twice.  
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Figure 5.6: The number of single cells per sphere in five-day mammosphere cultures. 1000 
single cells expressing Luc shRNA or MYB shRNA were cultured in the absence or presence of Dox 
for five days to allow mammospheres formation. These mammosphere-derived cells were passaged 
for three further times. After sphere counting, the spheres were dissociated into single cells and 
manually counted with trypan blue staining. The capital letter P represents a passage. (a) P0 spheres 
represent the first generation of mammospheres;  (b) P1 spheres represent the second generation of 
mammospheres; (c) P2 spheres represent the third generation of mammospheres. Duplicate samples 
within each group were examined twice. 
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5.3 Discussion 
  In this chapter, I examined the potential role of MYB in mammospheres derived from ER+ breast 
cancer MCF-7 cells. MYB mRNA expression was highly expressed in adherent MCF-7 cells (Figure 
5.3), as previously reported, but was dramatically reduced in the P0, P1 and P2 generations of 
mammospheres (Figure 5.3). There are a number of potential explanations for these observations. 
MYB expression can be regulated by transcriptional and post-transcriptional mechanisms as 
described in Chapter 1. For example, MYB transcription can be regulated by elongation control 
(Drabsch et al., 2007, Ramsay and Gonda, 2008). Previous studies from the Gonda laboratory 
indicated that MYB expression is regulated by oestrogen/ER (Drabsch et al., 2007); ligand-bound 
oestrogen receptor α (ERα) cooperated with P-TEFb (CyclinT1 and CDK9) to overcome MYB 
transcriptional pausing in MCF-7 cells (Drabsch et al., 2007, Mitra et al., 2012).  Furthermore, ER 
expression (Kok et al., 2009) and ERα expression (Guttilla et al., 2012) in mammosphere-derived 
MCF-7 cells were downregulated. MYB mRNA expression in P0 mammopshere derived cells was 
not increased after exposure to phenol red-containing human MammoCultTM medium 
+β-oestradiol for 5 days when compared to the phenol red-containing human MammoCultTM 
medium only group (data not shown). This means that sufficient oestrogen activity was provided by 
the phenol red. My data in Figure 5.1(b) shows that MYB expression was regulated by oestrogen 
activity, not serum. It is noticed that the low oestrogenic and serum-free environment may not a 
factor that results in low MYB expression in mammosphere-dervied cells. Thus, these studies 
provide one possible explanation, i.e. that the low level of ER expression in mammosphere-derived 
cells may not be sufficient to completely overcome MYB transcriptional pausing, resulting in low 
levels of MYB expression. In addition, a previous study reported that mammopshere culture of 
MCF-7 cells induced an epithelial-to-mesenchymal transition (EMT) and mesenchymal MCF-7 
cells highly expressed ZEB1 and two other EMT markers (SLUG and SNAL-1) (Guttilla et al., 2012). 
Furthermore, a previous study indicated that the ZEB1 transcription factor directly suppressed MYB 
expression in mesenschymal MCF-7 cells (Hugo et al., 2013). Thus, these studies provide the 
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second possibility that mammosphere-derived cells may highly express ZEB1, which subsequently 
results in a low level of MYB.   
    Previous studies reported that miR-200 family (miR-200a, miR-200b, miR-200c, miR-141, 
and miR-429) could downregulate ZEB1 expression (Korpal et al., 2008, Manavalan et al., 2013); 
suppression of ZEB1 expression promoted cell proliferation (Hugo et al., 2013) in adherent cultures. 
Furthermore, MYB activated the expression of the miR-200 family in adherent cultures (Pieraccioli 
et al., 2013). Moreover, previous studies from the Gonda laboratory indicated that MYB promoted 
cell proliferation and suppressed apoptosis and differentiation (Drabsch et al., 2007, Drabsch et al., 
2010). My data in Figure 5.3 shows high level of MYB in adherent cells. Thus, it is possible that 
high level of MYB of MCF-7 cells in adherent state may upregulate miR-200 family expression and 
subsequently downregulate ZEB1 that promotes cell proliferation. This will require further 
investigation. In addition, a previous study from the Gonda laboratory indicated that silencing MYB 
inhibited growth of MCF-7 cells (Drabsch et al., 2007) in adherent cultures. Furthermore, silencing 
MYB reduced the number of spheres derived from nasopharyngeal cancer cells (Wang et al., 2015) 
and the size of spheres derived from pancreatic cancer cells (Farhana et al., 2013). In contrast, in 
this chapter, it was observed that silencing MYB did not reduce the number or the size of spheres 
derived from MCF-7 cells at any passage (Figures 5.4 and 5.5). Owing to approximately less than 
10% MYB expression in mammoshpere-derived cells (Figure 5.3), this may result in no effect of the 
number or the size of spheres after silencing MYB. 
     Previous studies indicated that breast cancer cell lines such as MCF-7 cells contain a small 
population of cells that expressed several stem cell markers including ALDH1 (Gong et al., 2010), 
OCT4 and SOX2 (Ponti et al., 2005, Chen et al., 2012). The mammosphere-forming assay is a 
surrogate assay that reflects some stem cell properties. As described in Chapter 1, a subpopulation 
of MCF-7 cells was able to form mammospheres that could be passaged in culture (Borgna et al., 
2012). My data in Figure 5.2 confirms that MCF-7 cells were able to form mammospheres. These 
mammosphere-derived cells could be passaged in culture. Thus, my data supports that MCF-7 cells 
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have a subpopulation of breast cancer cells with stem cell properties. Previous studies reported that 
CD44+/ESA+ colorectal CSCs highly expressed ALDH1 and MYB (Dylla et al., 2008), and MYB 
knockdown reduced CD44+/ALDH+ CSCs enrichment and suppressed tumoursphere formation in 
nasopharyngeal carcinoma (Wang et al., 2015). Furthermore, MYB knockdown suppressed 
tumoursphere formation in CD133+ liver CSCs (Zhang et al., 2012) and in CD44+/CD24+ pancreatic 
CSCs (Farhana et al., 2013). In contrast, my data shows that mammosphere-derived cells expressed 
very low level of MYB (Figure 5.3), and MYB knockdown did not affect mammosphere-forming 
ability (Figures 5.4 and 5.5). Taken together, these data imply that MYB may not play an important 
role in breast cancer stem cells and in mammosphere formation by MCF-7 cells. However, previous 
studies reported that MYB was required for mammary cells transformation and tumour formation 
(Miao et al., 2011), and was a key regulator for stem cell fate in many tissues (e.g. colonic crypts 
and adult brain) (reviewed by (Ramsay and Gonda, 2008, Zhou and Ness, 2011)). Other studies 
reported that normal stem cells, when grown in an aberrant microenvironment, could transform to 
CSCs and these CSCs could generate tumours (Fujimori et al., 2012, Yan et al., 2014, Nishi et al., 
2014). Thus, whether MYB plays a role in cell transformation of breast stem cells into breast CSCs 
requires further studies. For example, MYB knockdown in breast stem cells can be performed to 
examine the change in population of CD44+/CD24+ cells and CD44+/CD24- cells (as a 
subpopulation of breast cancer stem cells) and tumour formation. 
    Previous studies reported that mammopshere culture of MCF-7 cells induced an 
epithelial-to-mesenchymal transition (EMT) and mammosphere-derived cells express 
mesenschymal markers (e.g. vimentin) (Guttilla et al., 2012). MYB expression was suppressed in 
MCF-7 cells that had undergone EMT (Hugo et al., 2013). Overexpression of MYB in mesenchymal 
cells resulted in the reversion of EMT (Hugo et al., 2013). My data in Figure 5.3 shows that MYB 
expression was suppressed when epithelial cells were growing in mammosphere cultures. These 
studies imply that MYB may play a role in preventing EMT. However, other studies reported that 
MYB upregulation actually induced EMT in the ER+ breast cancer cells (Cesi et al., 2011), in 
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prostate cancer (Srivastava et al., 2012) and in the avian neural crest (Karafiat et al., 2005). Thus, 
the role of MYB in EMT is controversial and requires further studies.  
    As described in Chapter 1, the ER+ breast cancer with epithelial phenotype highly expresses 
MYB. MYB can promote cell proliferation and suppress apoptosis and differentiation in adherent 
cultures (Drabsch et al., 2007, Drabsch et al., 2010). My data in Figure 5.3 shows that MYB 
expression was suppressed when MCF-7 cells with epithelial phenotype were growing in 
mammosphere cultures. Previous studies reported that mammopshere culture of MCF-7 cells 
induced an epithelial-to-mesenchymal transition (EMT) (Guttilla et al., 2012) and MYB expression 
was suppressed MYB expression in mesenschymal MCF-7 cells (Hugo et al., 2013). Overexpression 
of MYB in mesenchymal cells resulted in the reversion of EMT (Hugo et al., 2013).  These studies 
imply that MYB may play a role in preventing EMT. However, other studies reported that MYB 
upregulation actually induced EMT in the ER+ breast cancer cells (Cesi et al., 2011), in prostate 
cancer (Srivastava et al., 2012) and in the avian neural crest (Karafiat et al., 2005). Thus, the role of 
MYB in EMT is controversial and requires further studies. 
     In conclusion, this chapter demonstrated that MYB expression in mammosphere-derived cells 
was dramatically downregulated when compared to adherent cells. This may result from low level 
of ER expression, high level of ZEB1 expression or both that control MYB expression in 
mammosphere-derived cells. This requires further investigation. For example, mRNA expression of 
ER or ZEB1 in mammosphere-derived cells will be carried out by Q-PCR. After that, ER 
overexpression or ZEB1 knockdown in mammosphere-derived cells could be performed to evaluate 
whether MYB expression is affected.  
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Chapter 6- General discussion, significance, future directions and final 
conclusion 
    Breast cancer is among the top three diagnosed cancers in the world. Breast cancer can be 
divided into five subtypes according to gene expression profile (Rivenbark et al., 2013). 
Approximately 64% of breast cancers are oestrogen receptor positive (ER+). Cells possessing this 
trait express the MYB oncogene, which encodes a transcription factor (MYB) that regulates many 
cellular genes including genes associated with cell proliferation, differentiation and apoptosis. To 
date, most MYB target genes have been identified and characterized in hematopoietic cells while 
MYB and its target genes are still understudied in breast cancer. 
 
6.1 Summary of findings 
     The key findings presented in this thesis are: 
6.1.1 MYB target genes are associated with the regulation of cell proliferation, differentiation, 
cytoskeleton remodelling and cell migration, and cell development.  
     This thesis began by generation of ER+ breast cancer cell lines expressing doxycycline 
(Dox)-inducible MYB shRNA to knockdown MYB. After testing MYB shRNA cell lines with 
different shRNA vectors, cell lines generated with the pLV711 vector showed inducible 
downregulation of MYB after Dox induction and consequent effects on MYB regulated gene 
expression and cell proliferation. Thus, MYB shRNA cell lines with pLV711 vector were decided to 
use for identification of MYB regulated genes by using RNA-Seq gene expression profiling. 
Potential MYB target genes were then identified by integrating these results with three published 
ChIP datasets (Quintana et al., 2011, Drier et al., 2016). Approximately 500 genes showed 
differential expression between each of the two MYB shRNA groups, compared to non-silencing 
control (Luc shRNA) cells. After integration with published chromatin immunoprecipitation 
datasets, 145 potentially direct MYB target genes (e.g. ESR1 and GHR) that are involved in many 
biological functions as described above were identified. However, the rate of validation of MYB 
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target genes by Q-PCR was poor, implying that the identification of MYB regulated genes using 
RNA-Seq gene expression profiling may not have worked properly.    
 
6.1.2 MYB and its target genes are involved in the DNA damage response in ER+ breast 
cancer.  
     Accumulation of DNA damage and DNA repair defects such as BRCA1 (Cressman et al., 
1999, Cipollini et al., 2004), BRCA2 (Walsh et al., 2006) or PALB2 (Bowman-Colin et al., 2013) 
are intimately related to breast cancer. Several DNA damage response genes were identified as 
MYB target genes by ChIP studies (Quintana et al., 2011). The role of MYB and its target genes in 
the DNA damage responses of ER+ breast cancer cells is poorly understood. However, two studies 
indicated that silencing MYB increased radiation-induced DNA damage in nasopharyngeal 
carcinoma (Wang et al., 2015) and DNA damage-induced cell death in castration-resistant prostate 
cancer cells (Li et al., 2014). Thus, the second objective of this thesis was to investigate the role of 
MYB and its target genes in DNA damage responses in human ER+ breast cancer cells. Chapter 4 of 
this thesis demonstrated that silencing MYB sensitized ER+ breast cancer cells to DNA damaging 
agents. Here, my findings in Chapter 4 show that the effect of MYB knockdown sensitized cells to 
DNA damaging agents may result from BCL2 downregulation, increased DNA damage, reduced 
RAD51 focus formation, downregulation of nuclear RAD51 expression, an effect on DNA damage 
response genes, or a combination of the aforementioned effects. These data imply that MYB plays 
important roles in DNA damage response in ER+ breast cancer.  
 
6.1.3 MYB does not play a role in mammosphere formation of ER+ breast cancer. 
      Breast cancer may result from a small population of cancer cells with stem cell properties 
(Gangopadhyay et al., 2013) i.e. cancer stem cells (CSCs) (Bonnet and Dick, 1997, Al-Hajj and 
Clarke, 2004). The ER+ breast cancer MCF-7 cells contain a small population of cells that 
expressed several stem cell markers including OCT4 and SOX2 (Ponti et al., 2005, Chen et al., 
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2012). A previous study indicated that a cancer stem cell-related gene (NANOG) was identified as a 
MYB target gene in ER+ breast cancer (Quintana et al., 2011). Mammosphere culture is an in vitro 
surrogate assay to examine cancer stem cell properties such as self-renewal. Although MYB has 
been studied in breast cancer in vitro (Drabsch et al., 2007, Fang et al., 2009, Iddawela et al., 2012) 
and tumour formation in vivo (Miao et al., 2011), very little is known on the roles of MYB in CSCs 
of the ER+ breast cancer. Therefore, the aim of Chapter 5 of this thesis was to examine the potential 
role of MYB in human ER+ breast cancer stem cells. Here, my data in Figure 5.3 shows that much 
low level of MYB mRNA expression were found in mammosphere-derived cells, compared to 
MCF-7 cells in the adherent state. Furthermore, silencing MYB did not affect 
mammosphere-forming ability of MCF-7 cells. Theses findings imply that MYB may not play a role 
in breast cancer stem cells and mammosphere formation by MCF-7 cells.  
 
6.2 Significance of findings 
This thesis made two contribution of significance of key findings as follows:  
1) This thesis provides understanding of how MYB and its target genes are involved in many 
biological functions including cell proliferation, DNA damage response, and cell migration in ER+ 
breast cancer. MYB and its target genes play important roles in breast cancer development and 
metastasis that are problems of breast cancer therapy. Chapter 4 of this thesis have identified the 
combination of silencing MYB with DNA damage agents as a potentially effective combination 
therapy for ER+ breast cancer that not only increases DNA damage but also supresses or delays 
DNA repair. Further development will require the identification of more appropriate DNA 
damaging agents for clinical use and of a feasible approach for supressing MYB expression in breast 
cancer.  
2) This thesis also provides understanding the role of MYB in mammosphere-derived cells that have 
a small population of CSCs in ER+ breast cancer. Chapter 5 of this thesis provides evidence to 
support that MYB does not play a role in CSCs derived from ER+ breast cancer.  
 157 
6.3 Future Directions 
   Collectively, the results presented in this thesis have illuminated some of the previously 
unexplored areas regarding the role of MYB and its target genes in ER+ breast cancer cells. 
However, the results also raise some key unanswered questions. Thus, several directions of future 
research can be continued to carry on from this work. Firstly, chromatin immunoprecipitation 
followed by sequencing (ChIP–Seq) in ER+ breast cancer should be applied to integrate with 
RNA-Seq data for improvements in reliably identifying MYB target genes. As discussed in Chapter 
3 of this thesis, MYB binding sites may appear in the region that is far from the promoter of MYB 
target genes; these can be identified by ChIP-Seq but not by the ChIP-Chip method used previously 
(Quintana et al., 2011). Secondly, silencing MYB target genes by RNAi in ER+ breast cancer 
should be use to investigate whether biological functions of MYB target genes are affected. For 
example, silencing ITGAV, MYB or both in ER+ breast cancer may affect cell adhesion and 
migration (Sims et al., 2000). 
   As described in Chapter 4 of this thesis, silencing MYB increased DNA damage induced by six 
different reagents in ER+ breast cancer cells. These results demonstrated that MYB is involved in the 
homologous recombination-mediated responses to ETO-induced DNA damage, because MYB 
knockdown strongly suppressed RAD51 focus formation. It is still unclear how MYB knockdown 
affects RAD51 focus formation in responses to ETO-induced DNA damage. A previous study 
reported that TOPBP1 regulated PLK1-mediated phosphorylation of RAD51 that is required for 
RAD51 focus formation (Moudry et al., 2016). Thus, a third direction of future research should 
focus on the relationship between MYB and TOPBP1 expression in the regulation of RAD51 
phosphorylation. This can be archived by using combination of silencing MYB and TOPBP1 with 
anti-phosphorylated RAD51 antibody to investigate the effect of RAD51 phosphorylation. In 
addition, the role of MYB in other DNA repair pathways such as NHEJ (Hosoya and Miyagawa, 
2014) in responses to DNA damaging agents (Diggle et al., 2005, Basu and Krishnamurthy, 2010) 
remains unclear. Thus, a fourth direction of future research should focus on the role of MYB in the 
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NHEJ pathway in response to DNA damaging agents e.g. cisplatin (Diggle et al., 2005). It would 
also be of interest to interrogate epistatic relationship between MYB and DNA repair genes in NHEJ 
pathway by using combination of MYB knockdown and PARP inhibitors that induce single strand 
nicks (Metzger et al., 2013). 
    The results in Chapter 5 of this thesis confirmed that MCF-7 cells could form mammaospheres. 
MYB mRNA is, as was already known, highly expressed in adherent MCF-7 cells, but I found that it 
was dramatically reduced in several generations of mammospheres. It is still unclear why MYB 
expression was much low in mammosphere-derived cells. Previous studies indicated that 
mammosphere formation induced EMT and ZEB1 directly suppressed MYB expression in 
mesenschymal MCF-7 cells (Hugo et al., 2013). Thus, the fifth direction of future research should 
focus on the role of ZEB1 in mammosphere-derived cells in ER+ breast cancer. It would also be of 
interest to interrogate the relationship between MYB and ZEB1 in mammosphere-derived cells from 
ER+ breast cancer by using RNAi-mediated ZEB1 knockdown.  
 
6.4 Final conclusion 
      When this project first began, there was very little known about the roles of MYB and its 
target genes in ER+ breast cancer and cancer stem cells. The data presented in this thesis provide a 
foundation for studies on the role of MYB and its target genes (e.g. ERS1 and GHR) in breast cancer 
development and migration, and DNA damage response (e.g. MYB knockdown increased γ-H2AX 
expression and suppressed RAD51 focus formation), and mammosphere formation of ER+ breast 
cancer. As described in Chapter 1, apart from the surgery and radiation therapy, patients with ER+ 
positive breast cancer typically receive endocrine therapy (e.g. aromatase inhibitors and selective 
oestrogen-receptor response modulators) to prevent recurrence of the cancer [reviewed in (Rugo et 
al., 2016)]. Previous studies indicated oestrogen/ER complex regulates MYB expression (Drabsch et 
al., 2007). As a transcription factor, MYB plays an important role in tumourigenesis [reviewed in 
(Ramsay and Gonda, 2008)]. Thus, targeting MYB may be a potential strategy in ER+ breast cancer 
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therapy [reviewed in (Ramsay and Gonda, 2008, Gonda and Ramsay, 2015)].  
  Targeting MYB can be carried out by either MYB antisense oligodeoxynucleotides (ODN) 
(Gewirtz, 1993, Luger et al., 2002), a DNA vaccine (Williams et al., 2008, Cross et al., 2015), or 
siRNA/shRNA therapeutics for ER+ breast cancer therapy (Miao et al., 2011, Drabsch et al., 2007, 
Drabsch et al., 2010). 
  Clinical studies reported that oral etoposide monotherapy is effective to reduce tumour size in 
metastatic breast cancer patients (Neskovic-Konstantinovic et al., 1996, Yuan et al., 2012, 
Valabrega et al., 2015) and these patients survived for more than 16 months (Yuan et al., 2012). My 
in vitro findings in Chapter 4 indicated that the combination of MYB knock down and DNA 
damaging agents (e.g. etoposide) may be a potential strategy for ER+ breast cancer therapy. This 
requires further in vivo and clinical studies. 
   Inhibiting the interaction between MYB and its co-regulators may be the alternative approach 
for ER+ breast cancer therapy [reviewed in (Ramsay and Gonda, 2008, Gonda and Ramsay, 2015)]. 
For example, MYB interacts with CBP/P300 to regulate its target genes (Dai et al., 1996, Parker et 
al., 1999). Naphthol AS-E phosphate blocks the interaction between MYB and CBP/P300 in vitro 
(Kasper et al., 2013, Uttarkar et al., 2015). This requires further in vivo and clinical studies. 
   Targeting MYB regulated genes (e.g. BCL2) may be possible for ER+ breast cancer therapy 
[reviewed in (Ramsay and Gonda, 2008, Gonda and Ramsay, 2015)]. For example, a Phase II study 
of G3139 (a BCL2 antisense oligonucleotide) reported that G3139 in combination with 
dexamethasone and thalidomide decreases BCL2 expression in relapsed multiple myeloma patients 
and overall survival time of these patients is 12 months. My data in Chapter 3 and 4 show that some 
of potentially direct MYB target genes (e.g. BRCA1 and TOPBP1) may be valuable candidates for 
the improvement of breast cancer therapy.  
      In summary, MYB and its targets may be valuable approaches to develop novel treatments 
for ER+/MYB+ breast cancer. 
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